CLDF Title
Home | Contact Us | Bookmark
 
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
 
HCV-Single Disease Content  
Webcasts
     
HCV: Highlights from EASL 2013   Educational Webcast
HCV: Highlights from EASL 2013   Educational Webcast
HCV: Highlights from EASL 2013   Educational Webcast
HCV Case Study: Optimizing Outcomes with Current Therapies   Educational Webcast
HCV Case Study: Treat Now or Wait for New Therapies   CME Webcast
Emerging Therapies for HCV: Highlights from AASLD 2012   CME Webcast
Current CDC Guidelines on HCV Testing   Educational Webcast
Hepatitis C: Emerging Therapies   CME Webcast
2011 Update on HCV   Educational Webcast
CME eNewsletter
     
  Newsletter  
     
  Credit Designation  
  1.0 AMA PRA  
  Category 1 Credit(s)™  
  Download  
     
  ACHS  
  Jointly sponsored by The Annenberg Center for Health Sciences and the Chronic Liver Disease Foundation.

This activity supported by:
Janssen Therapeutics
Vertex Pharmaceuticals		  
     
 
 
Hepatitis C Emerging Therapy Update: Reports From the Liver Meeting 2012
 
Target Audience
This activity has been designed to meet the educational needs of hepatologists, gastroenterologists, physician assistants, and nurse practitioners involved in the care of patients with chronic liver disease.
 
Statement of Need/Program Overview
To provide important clinical data on issues related to the management of HCV.
 
Educational Objectives
Upon completion of this activity, participants should be better able to:
• To assess the efficacy and safety of new antiviral agents currently under development for the treatment of chronic hepatitis C
• To recognize the advantages offered by the new antiviral agents currently under development for the treatment of chronic hepatitis C when compared to current therapy with boceprevir or telaprevir + PegIFN + RBV
 
Accreditation Statement
Please see page 1 of the newsletter for full accreditation statement.
 
 
 
Dynamic CME Resource Library
     
Hepatitis C: Emerging Therapies   Educational eNewsletter
Slide Library
HCV 2011 Slides
Current Breakthroughs in the Management of Hepatitis C
 
HCV Slide Archive
Hepatology 2010 Slides
Current Perspectives on Chronic Liver Disease
 
 
Abstract Library
  1. Risk factors for recurrence after curative resection of hepatitis C-related hepatocellular carcinoma in patients without postoperative interferon therapy
    Yamashita YI, Shirabe K, Toshima T, Tsuijita E, Takeishi K, Harimoto N, Ikegami T, Yoshizumi T, Ikeda T, Soejima Y, Maehara Y. Hepatol Res. 2013 Mar 27. doi: 10.1111/hepr.12091. [Epub ahead of print]


  2. Hepatitis C virus therapy update 2013
    Casey LC, Lee WM. Curr Opin Gastroenterol. 2013 May;29(3):243-9. doi: 10.1097/MOG.0b013e32835ff972.


  3. Telaprevir-related dermatitis
    Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS. JAMA Dermatol. 2013 Feb;149(2):152-8.


  4. In vitro detection of hepatitis C virus in platelets from uninfected individuals exposed to the virus
    Padovani JL, Corvino SM, Drexler JF, Silva GF, Pardini MI, Grotto RM. Rev Soc Bras Med Trop. 2013 Apr 2:0. [Epub ahead of print]


  5. The role of natural killer cells in hepatitis C infection
    Howell J, Visvanathan K. Antivir Ther. 2013 Apr 4. doi: 10.3851/IMP2565. [Epub ahead of print]


  6. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin
    Huang CF, Yeh ML, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, Wang LY, Huang JF, Juo SH, Lin YC, Dai CY, Chuang WL, Yu ML. J Gastroenterol Hepatol. 2013 Apr 5. doi: 10.1111/jgh.12211. [Epub ahead of print]


  7. Interferon-lambda polymorphisms and hepatitis C virus clearance revisited
    Lupberger J, Felmlee DJ, Baumert TF. Hepatology. 2013 Apr 8. doi: 10.1002/hep.26443. [Epub ahead of print]


  8. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients
    Jiménez-Sousa MA, Berenguer J, Rallón N, Guzmán-Fulgencio M, López JC, Soriano V, Fernández-Rodríguez A, Cosín J, Restrepo C, García-Álvarez M, Miralles P, Benito JM, Resino S. J Viral Hepat. 2013 May;20(5):358-66. doi: 10.1111/jvh.12041. Epub 2012 Dec 20.


  9. Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results
    Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B, Gane E, Schuchmann M, Lohse AW, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Nehmiz G, Kukolj G, Böcher WO, Mensa FJ. Antivir Ther. 2013 Apr 4. doi: 10.3851/IMP2567. [Epub ahead of print]


  10. Hepatocyte destruction with enhanced collagen synthesis: characteristic feature of chronic hepatitis C patients on haemodialysis
    Ue M, Ikebe N, Munekage K, Ochi T, Hirose A, Kataoka H, Fujimoto S, Kikuchi K, Okuhara Y, Ono M, Saibara T. J Viral Hepat. 2013 May;20(5):350-7. doi: 10.1111/jvh.12031. Epub 2012 Dec 11.


  11. The role of the hepatitis viruses in cholangiocarcinoma
    Ralphs S, Khan SA. J Viral Hepat. 2013 May;20(5):297-305. doi: 10.1111/jvh.12093.


  12. Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma
    Costantini S, Capone F, Maio P, Guerriero E, Colonna G, Izzo F, Castello G. Oncol Rep. 2013 Jun;29(6):2163-8. doi: 10.3892/or.2013.2378. Epub 2013 Apr 3.


  13. ?-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C
    Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N. Hepatology. 2013 Apr 8. doi: 10.1002/hep.26442. [Epub ahead of print]


  14. Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug-Drug Interactions
    Kiang TK, Wilby KJ, Ensom MH. Clin Pharmacokinet. 2013 Apr 4. [Epub ahead of print]


  15. Hepatitis C virus adaptation to T-cell immune pressure
    Plauzolles A, Lucas M, Gaudieri S. ScientificWorldJournal. 2013;2013:673240. doi: 10.1155/2013/673240. Epub 2013 Mar 11.


  16. Hepatitis C and recurrent treatment-resistant acute ischemic stroke
    Saxsena A, Tarsia J, Dunn C, Aysenne A, Shah B, Moore DF. Proc (Bayl Univ Med Cent). 2013 Apr;26(2):182-4.


  17. HCV RNA viral load assessments in the era of direct-acting antivirals
    Cobb B, Pockros PJ, Vilchez RA, Vierling JM. Am J Gastroenterol. 2013 Apr;108(4):471-5. doi: 10.1038/ajg.2012.248.


  18. Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review
    Modabbernia A, Poustchi H, Malekzadeh R. Hepat Mon. 2013 Jan;13(1):e8340. doi: 10.5812/hepatmon.8340. Epub 2013 Jan 7.


  19. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response
    Neukam K, Barreiro P, Rivero-Juárez A, Caruz A, Mira JA, Camacho A, Macías J, Rivero A, Soriano V, Pineda JA. J Infect. 2013 Mar 28. pii: S0163-4453(13)00066-2. doi: 10.1016/j.jinf.2013.03.010. [Epub ahead of print]


  20. Survival after surgery for hepatocellular carcinoma in relation to presence or absence of viral infection
    Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Am J Surg. 2013 Mar 30. pii: S0002-9610(13)00132-3. doi: 10.1016/j.amjsurg.2012.08.011. [Epub ahead of print]


  21. Genome-wide analysis of host mRNA translation during hepatitis C virus infection
    Colman H, Le Berre-Scoul C, Hernandez C, Pierredon S, Bihouée A, Houlgatte R, Vagner S, Rosenberg AR, Féray C. J Virol. 2013 Apr 3. [Epub ahead of print]


  22. Management of the Extrahepatic Symptoms of Chronic Hepatitis C: Feasibility of a Randomized Controlled Trial of Exercise
    McKenna O, Cunningham C, Gissane C, Blake C. Am J Phys Med Rehabil. 2013 Apr 2. [Epub ahead of print]


  23. Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study
    Nishiguchi S, Enomoto H, Aizawa N, Nishikawa H, Osaki Y, Tsuda Y, Higuchi K, Okazaki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, Kudo M. J Gastroenterol. 2013 Mar 30. [Epub ahead of print]


  24. Systematic review: Asian patients with chronic hepatitis C infection
    Nguyen LH, Nguyen MH. Aliment Pharmacol Ther. 2013 May;37(10):921-36. doi: 10.1111/apt.12300. Epub 2013 Apr 5.


  25. Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review
    Bota S, Sporea I, Sirli R, Popescu A, Neghin? AM, D?nil? M, Str?in M. World J Hepatol. 2013 Mar 27;5(3):120-6. doi: 10.4254/wjh.v5.i3.120.


  26. SIGMA-1 RECEPTOR REGULATES EARLY STEPS OF VIRAL RNA REPLICATION AT THE ONSET OF HEPATITIS C VIRUS INFECTION
    Friesland M, Mingorance L, Chung J, Chisari FV, Gastaminza P. J Virol. 2013 Mar 27. [Epub ahead of print]


  27. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States
    Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. PLoS One. 2013;8(3):e58975. doi: 10.1371/journal.pone.0058975. Epub 2013 Mar 22.


  28. Treatment of HCV infection by targeting microRNA
    Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. N Engl J Med. 2013 May 2;368(18):1685-94. doi: 10.1056/NEJMoa1209026. Epub 2013 Mar 27.


  29. Development and evaluation of an internet and personal health record training program for low-income patients with HIV or hepatitis C
    McInnes DK, Solomon JL, Shimada SL, Petrakis BA, Bokhour BG, Asch SM, Nazi KM, Houston TK, Gifford AL. Med Care. 2013 Mar;51(3 Suppl 1):S62-6. doi: 10.1097/MLR.0b013e31827808bf.


  30. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management
    Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. J Hepatol. 2013 Mar 27. pii: S0168-8278(13)00197-9. doi: 10.1016/j.jhep.2013.03.018. [Epub ahead of print]


  31. Role of Interleukin-28B Polymorphism as a Predictor of Sustained Virological Response in Patients with Chronic Hepatitis C Treated with Triple Therapy: A Systematic Review and Meta-Analysis
    Bota S, Sporea I, Sirli R, Neghin? AM, Popescu A, Str?in M. Clin Drug Investig. 2013 May;33(5):325-31. doi: 10.1007/s40261-013-0074-0.


  32. Combination therapy of natural human interferon-beta and ribavirin for chronic hepatitis C patients with injection drug use
    Morikawa H, Kozuka R, Fujii H, Iwai S, Enomoto M, Tamori A, Saito S, Kawada N. Hepatol Res. 2013 Mar 27. doi: 10.1111/hepr.12066. [Epub ahead of print]


  33. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature
    Salk A, Stobaugh DJ, Deepak P, Ehrenpreis ED. Ann Pharmacother. 2013 Apr;47(4):537-42. doi: 10.1345/aph.1R526. Epub 2013 Mar 27.


  34. Telaprevir: Changing the standard of care of chronic hepatitis C
    Rajani AK, Ravindra BK, Dkhar SA. J Postgrad Med. 2013 Jan-Mar;59(1):42-7. doi: 10.4103/0022-3859.109493.


  35. Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus
    Tayel SS, Helmy AA, Ahmed R, Esmat G, Hamdi N, Abdelaziz AI. Arch Virol. 2013 Mar 23. [Epub ahead of print]


  36. Incident Hepatitis C Virus Infection in Men Who Have Sex With Men: A Prospective Cohort Analysis, 1984-2011
    Witt MD, Seaberg EC, Darilay A, Young S, Badri S, Rinaldo CR, Jacobson LP, Detels R, Thio CL. Clin Infect Dis. 2013 Apr 22. [Epub ahead of print]


  37. Prediction of efficacy to pegylated interferon-?-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks
    Wada Y, Tamai H, Uno A, Kawashima A, Shingaki N, Mori Y, Moribata K, Miyata K, Higashi K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M. Hepatol Res. 2013 Feb 25. doi: 10.1111/hepr.12101. [Epub ahead of print]


  38. Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients
    Huang CF, Dai CY, Yeh ML, Huang JF, Huang CI, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Lin YC, Yu ML. PLoS One. 2013;8(3):e58882. doi: 10.1371/journal.pone.0058882. Epub 2013 Mar 19.


  39. The Diagnostic Accuracy of Fibroscan for Cirrhosis is Influenced by Liver Morphometry in HCV Patients with a Sustained Virological Response
    D'Ambrosio R, Aghemo A, Fraquelli M, Grazia Rumi M, Francesca Donato M, Paradis V, Bedossa P, Colombo M. J Hepatol. 2013 Mar 22. pii: S0168-8278(13)00191-8. doi: 10.1016/j.jhep.2013.03.013. [Epub ahead of print]


  40. Pharmacokinetic Evaluation of the Interaction Between the HCV Protease Inhibitor Boceprevir and the HMG-CoA Reductase Inhibitors Atorvastatin and Pravastatin
    Hulskotte E, Feng HP, Xuan F, Gupta S, van Zutven M, O'Mara E, Wagner J, Butterton J. Antimicrob Agents Chemother. 2013 Mar 25. [Epub ahead of print]


  41. Patterns of Interferon-alpha Induced Thyroid Dysfunction Vary with Ethnicity, Sex, Smoking Status and Pre-Treatment TSH in an International Cohort of Patients Treated for Hepatitis C
    Mammen JS, Ghazarian SR, Rosen A, Ladenson PW. Thyroid. 2013 Mar 21. [Epub ahead of print]


  42. A health technology assessment of transient elastography in adult liver disease
    Steadman R, Myers RP, Leggett L, Lorenzetti D, Noseworthy T, Rose S, Sutherland L, Clement F. Can J Gastroenterol. 2013 Mar;27(3):149-58.


  43. A novel strategy to inhibit the reproduction and translation of hepatitis C virus
    Duan A, Ning L, Li C, Hou Y, Yang N, Sun L, Li G. Sci China Life Sci. 2013 Apr;56(4):293-7. doi: 10.1007/s11427-013-4468-2. Epub 2013 Mar 20.


  44. Hepatitis C virus-induced mitochondrial dysfunctions
    Brault C, Levy PL, Bartosch B. Viruses. 2013 Mar 21;5(3):954-80. doi: 10.3390/v5030954.


  45. Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin
    Webster DP, Wojcikiewicz T, Keller M, Castelnovo D, Mistry H, Gilleece Y, Tibble J, Fisher M. Int J STD AIDS. 2013 Mar 20. [Epub ahead of print]


  46. Simultaneous detection of hepatitis c virus antigen and antibodies in dried blood spots
    Brandão CP, Marques BL, Marques VA, Villela-Nogueira CA, Do Ó KM, de Paula MT, Lewis-Ximenez LL, Lampe E, Sá Ferreira JA, Villar LM. J Clin Virol. 2013 Mar 18. pii: S1386-6532(13)00075-9. doi: 10.1016/j.jcv.2013.02.014. [Epub ahead of print]


  47. Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
    Rong L, Guedj J, Dahari H, Coffield DJ Jr, Levi M, Smith P, Perelson AS. PLoS Comput Biol. 2013 Mar;9(3):e1002959. doi: 10.1371/journal.pcbi.1002959. Epub 2013 Mar 14.


  48. Serum aspartate aminotransferase levels and previous histopathological findings enable reduction of protocol liver biopsies after liver transplantation for hepatitis C
    Tanaka T, Therapondos G, Selzner N, Renner EL, Lilly LB. Can J Gastroenterol. 2013 Mar;27(3):131-6.


  49. Management of Hepatitis C Virus Infection in Heavy Drinkers
    Costentin CE, Trabut JB, Mallet V, Darbeda S, Thépot V, Nalpas B, Badin de Montjoye B, Lavielle B, Vallet-Pichard A, Sogni P, Pol S. Alcohol Alcohol. 2013 Mar 21. [Epub ahead of print]


  50. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial
    Deterding K, Grüner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Malek N, Großhennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H; for The Hep-Net Acute HCV-III Study Group. Lancet Infect Dis. 2013 Mar 21. pii: S1473-3099(13)70059-8. doi: 10.1016/S1473-3099(13)70059-8. [Epub ahead of print]


  51. Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection
    Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. J Clin Oncol. 2013 Mar 18. [Epub ahead of print]


  52. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir
    McPhee F, Hernandez D, Yu F, Ueland J, Monikowski A, Carifa A, Falk P, Wang C, Fridell R, Eley T, Zhou N, Gardiner D. Hepatology. 2013 Mar 15. doi: 10.1002/hep.26388. [Epub ahead of print]


  53. The incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis
    Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, Rich JD, van den Bergh BJ, Degenhardt L. Hepatology. 2013 Mar 15. doi: 10.1002/hep.26387. [Epub ahead of print]


  54. Recurrent hepatitis C and non-alcoholic fatty liver disease in transplanted patients: a review
    Testino G, Sumberaz A, Leone S, Borro P. Minerva Med. 2013 Apr;104(2):225-32.


  55. Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation
    Ueda Y, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K, Fujimoto Y, Miyagawa-Hayashino A, Haga H, Marusawa H, Teramukai S, Uemoto S, Chiba T. PLoS One. 2013;8(3):e58380. doi: 10.1371/journal.pone.0058380. Epub 2013 Mar 7.


  56. Sustained Virological Response following Chronic Hepatitis C treatment is associated with improvement in Insulin Resistance (Insulin Resistance in Hepatitis C)
    Chan CH, Hansen RD, Gilliver RS, Jones BE. Intern Med J. 2013 Mar 19. doi: 10.1111/imj.12136. [Epub ahead of print]


  57. Prevalence and predictors of hepatitis B virus co-infection in a united states cohort of hepatitis C virus-infected patients
    Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Hepatology. 2013 Mar 16. doi: 10.1002/hep.26400. [Epub ahead of print]


  58. Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection
    El-Kamary SS, Mohamed MM, El-Raziky M, Shardell MD, Shaker OG, Elakel WA, Esmat G. Liver Int. 2013 Feb 15. doi: 10.1111/liv.12139. [Epub ahead of print]


  59. Birth Cohort Screening for Chronic Hepatitis During Colonoscopy Appointments
    Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Am J Gastroenterol. 2013 Mar 19. doi: 10.1038/ajg.2013.50. [Epub ahead of print]


  60. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know
    Kim YH, Kim do Y. Oncology. 2013;84 Suppl 1:34-9. doi: 10.1159/000345887. Epub 2013 Feb 20.


  61. Hepatitis C virus vaccines - Progress and perspectives
    Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S. Microb Pathog. 2013 Mar 7. pii: S0882-4010(13)00025-9. doi: 10.1016/j.micpath.2013.02.005. [Epub ahead of print]


  62. Transient elastography in hepatitis C virus-infected patients with beta-thalassemia for assessment of fibrosis
    Poustchi H, Eslami M, Ostovaneh MR, Modabbernia A, Saeedian FS, Taslimi S, George J, Malekzadeh R, Zamani F. Hepatol Res. 2013 Feb 7. doi: 10.1111/hepr.12088. [Epub ahead of print]


  63. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
    Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Lancet Infect Dis. 2013 Mar 14. pii: S1473-3099(13)70033-1. doi: 10.1016/S1473-3099(13)70033-1. [Epub ahead of print]


  64. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
    Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, Demicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Lancet. 2013 Mar 14. pii: S0140-6736(13)60247-0. doi: 10.1016/S0140-6736(13)60247-0. [Epub ahead of print]


  65. A Comparison of Modified Directly Observed Therapy to Standard Care for Chronic Hepatitis C
    Cioe PA, Stein MD, Promrat K, Friedmann PD. J Community Health. 2013 Mar 8. [Epub ahead of print]


  66. IL-28B (IFN-?3) and IFN-? synergistically inhibit HCV replication
    Shindo H, Maekawa S, Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. J Viral Hepat. 2013 Apr;20(4):281-9. doi: 10.1111/j.1365-2893.2012.01649.x. Epub 2012 Aug 7.


  67. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study
    Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, Monti M, Petrarca A, Ranieri J, Urraro T, Triboli E, Laffi G, Zignego AL. J Viral Hepat. 2013 Apr;20(4):e107-14. doi: 10.1111/jvh.12017. Epub 2012 Dec 4.


  68. 'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype-3a infection and do not predict sustained virological response after 24 weeks of therapy
    Bucci C, von Delft A, Cristian A, Flemming VM, Harrison A, Halliday J, Collier J, Manganis C, Klenerman P, Irving W, Barnes E. J Gen Virol. 2013 Mar 13. [Epub ahead of print]


  69. Impairment of health-related quality of life in patients with chronic hepatitis C is associated with insulin resistance
    Kuwashiro T, Mizuta T, Kawaguchi Y, Iwane S, Takahashi H, Oza N, Oeda S, Isoda H, Eguchi Y, Ozaki I, Anzai K, Fujimoto K. J Gastroenterol. 2013 Mar 16. [Epub ahead of print]


  70. Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience
    Dumitra S, Alabbad SI, Barkun JS, Dumitra TC, Coutsinos D, Metrakos PP, Hassanain M, Paraskevas S, Chaudhury P, Tchervenkov JI. HPB (Oxford). 2013 Mar 14. doi: 10.1111/hpb.12041. [Epub ahead of print]


  71. Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
    Ross RS, Stambouli O, Grüner N, Marcus U, Cai W, Zhang W, Zimmermann R, Roggendorf M. Virol J. 2013 Mar 5;10:72. doi: 10.1186/1743-422X-10-72.


  72. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know
    Kim YH, Kim do Y. Oncology. 2013;84 Suppl 1:34-9. doi: 10.1159/000345887. Epub 2013 Feb 20.


  73. Hepatitis C virus vaccines - Progress and perspectives
    Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S. Microb Pathog. 2013 Mar 7. pii: S0882-4010(13)00025-9. doi: 10.1016/j.micpath.2013.02.005. [Epub ahead of print]


  74. Transient elastography in hepatitis C virus-infected patients with beta-thalassemia for assessment of fibrosis
    Poustchi H, Eslami M, Ostovaneh MR, Modabbernia A, Saeedian FS, Taslimi S, George J, Malekzadeh R, Zamani F. Hepatol Res. 2013 Feb 7. doi: 10.1111/hepr.12088. [Epub ahead of print]


  75. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
    Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Lancet Infect Dis. 2013 Mar 14. pii: S1473-3099(13)70033-1. doi: 10.1016/S1473-3099(13)70033-1. [Epub ahead of print]


  76. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
    Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, Demicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Lancet. 2013 Mar 14. pii: S0140-6736(13)60247-0. doi: 10.1016/S0140-6736(13)60247-0. [Epub ahead of print]


  77. A Comparison of Modified Directly Observed Therapy to Standard Care for Chronic Hepatitis C
    Cioe PA, Stein MD, Promrat K, Friedmann PD. J Community Health. 2013 Mar 8. [Epub ahead of print]


  78. IL-28B (IFN-?3) and IFN-? synergistically inhibit HCV replication
    Shindo H, Maekawa S, Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. J Viral Hepat. 2013 Apr;20(4):281-9. doi: 10.1111/j.1365-2893.2012.01649.x. Epub 2012 Aug 7.


  79. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study
    Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, Monti M, Petrarca A, Ranieri J, Urraro T, Triboli E, Laffi G, Zignego AL. J Viral Hepat. 2013 Apr;20(4):e107-14. doi: 10.1111/jvh.12017. Epub 2012 Dec 4.


  80. 'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype-3a infection and do not predict sustained virological response after 24 weeks of therapy
    Bucci C, von Delft A, Cristian A, Flemming VM, Harrison A, Halliday J, Collier J, Manganis C, Klenerman P, Irving W, Barnes E. J Gen Virol. 2013 Mar 13. [Epub ahead of print]


  81. Impairment of health-related quality of life in patients with chronic hepatitis C is associated with insulin resistance
    Kuwashiro T, Mizuta T, Kawaguchi Y, Iwane S, Takahashi H, Oza N, Oeda S, Isoda H, Eguchi Y, Ozaki I, Anzai K, Fujimoto K. J Gastroenterol. 2013 Mar 16. [Epub ahead of print]


  82. Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience
    Dumitra S, Alabbad SI, Barkun JS, Dumitra TC, Coutsinos D, Metrakos PP, Hassanain M, Paraskevas S, Chaudhury P, Tchervenkov JI. HPB (Oxford). 2013 Mar 14. doi: 10.1111/hpb.12041. [Epub ahead of print]


  83. Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
    Ross RS, Stambouli O, Grüner N, Marcus U, Cai W, Zhang W, Zimmermann R, Roggendorf M. Virol J. 2013 Mar 5;10:72. doi: 10.1186/1743-422X-10-72.


  84. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force
    Cottrell EB, Chou R, Wasson N, Rahman B, Guise JM. Ann Intern Med. 2013 Jan 15;158(2):109-13.


  85. Diabetes and Infections-Hepatitis C: Is There Type 2 Diabetes Excess in Hepatitis C Infection?
    Naing C, Mak JW, Wai N, Maung M. Curr Diab Rep. 2013 Mar 7. [Epub ahead of print]


  86. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients
    Macías J, Rivero A, Cifuentes C, Camacho A, Neukam K, Rivero-Juárez A, Mira JA, Torre-Cisneros J, Gómez-Mateos J, Pineda JA. Enferm Infecc Microbiol Clin. 2013 Feb 28. pii: S0213-005X(12)00443-0. doi: 10.1016/j.eimc.2012.12.004. [Epub ahead of print]


  87. The predictive value of steatosis in hepatitis C virus infection
    Adinolfi LE, Restivo L, Marrone A. Expert Rev Gastroenterol Hepatol. 2013 Mar;7(3):205-13. doi: 10.1586/egh.13.7.


  88. The Hepatitis C Self-Management Program: Sustainability of Primary Outcomes at 1 Year
    Groessl EJ, Ho SB, Asch SM, Stepnowsky CJ, Laurent D, Gifford AL. Health Educ Behav. 2013 Feb 27. [Epub ahead of print]


  89. Perspectives of a self-selected sample of former patients on the long-term health outcomes of interferon-based hepatitis C treatments: an exploratory study
    Hopwood M.


  90. The origin of hepatitis C virus
    Simmonds P. Curr Top Microbiol Immunol. 2013;369:1-15. doi: 10.1007/978-3-642-27340-7_1.


  91. A high MELD score, combined with the presence of hepatitis C, is associated with a poor prognosis in living donor liver transplantation
    Ikegami T, Shirabe K, Yoshiya S, Yoshizumi T, Yamashita YI, Harimoto N, Toshima T, Uchiyama H, Soejima Y, Maehara Y. Surg Today. 2013 Feb 23. [Epub ahead of print]


  92. Antiviral Activity of Boceprevir Monotherapy in Treatment-Naive Subjects With Chronic Hepatitis C Genotype 2/3
    Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, Gupta S, Hughes E, Chase R, Lahser F, Barnard RJ, Howe AY, Howe JA. J Hepatol. 2013 Feb 27. pii: S0168-8278(13)00140-2. doi: 10.1016/j.jhep.2013.02.018. [Epub ahead of print]


  93. Profile of alisporivir and its potential in the treatment of hepatitis C
    Gallay PA, Lin K. Drug Des Devel Ther. 2013;7:105-15. doi: 10.2147/DDDT.S30946. Epub 2013 Feb 15.


  94. Risk of Pancreatic Cancer in Relation to ABO Blood Group and Hepatitis C Virus Infection in Korea: A Case-Control Study
    Woo SM, Joo J, Lee WJ, Park SJ, Han SS, Kim TH, Koh YH, Kim HB, Hong EK. J Korean Med Sci. 2013 Feb;28(2):247-51. doi: 10.3346/jkms.2013.28.2.247. Epub 2013 Jan 29.


  95. Therapy for HCV Infection Increases Survival of Patients with Pre-Treatment Anemia
    Mohanty A, Erqou S, McGinnis KA, Vanasse G, Freiberg MS, Sherman KE, Butt AA. Clin Gastroenterol Hepatol. 2013 Jan 31. pii: S1542-3565(13)00166-3. doi: 10.1016/j.cgh.2013.01.023. [Epub ahead of print]


  96. A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots
    Shepherd SJ, Kean J, Hutchinson SJ, Cameron SO, Goldberg DJ, Carman WF, Gunson RN, Aitken C. J Clin Virol. 2013 Jan 28. pii: S1386-6532(13)00005-X. doi: 10.1016/j.jcv.2013.01.002. [Epub ahead of print]


  97. High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C
    Petta S, Handberg A, Marchesini G, Cammà C, Di Marco V, Cabibi D, Macaluso FS, Craxì A. J Viral Hepat. 2013 Mar;20(3):174-82. doi: 10.1111/j.1365-2893.2012.01641.x. Epub 2012 Jul 9.


  98. Serum fibrinogen alpha C-chain 5.9 kDa fragment (FIC 5.9) as a biomarker for early detection of hepatic fibrosis related to hepatitis C virus
    Sogawa K, Noda K, Umemura H, Seimiya M, Kuga T, Tomonaga T, Nishimura M, Kanai F, Imazeki F, Takizawa H, Yoneda M, Nakajima A, Tsutsumi M, Yokosuka O, Nomura F. Proteomics Clin Appl. 2013 Feb 4. doi: 10.1002/prca.201200094. [Epub ahead of print]


  99. The Association of IL28B Polymorphism and Graft Survival in Patients with Hepatitis C Undergoing Liver Transplantation
    Allam SR, Krüger B, Mehrotra A, Schiano T, Schröppel B, Murphy B. PLoS One. 2013;8(1):e54854. doi: 10.1371/journal.pone.0054854. Epub 2013 Jan 30.


  100. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors
    Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. J Clin Virol. 2013 Feb 2. pii: S1386-6532(13)00007-3. doi: 10.1016/j.jcv.2012.12.020. [Epub ahead of print]


  101. Frequency of Thyroid Dysfunctions during Interferon Alpha Treatment of Single and Combination Therapy in Hepatitis C Virus-Infected Patients: A Systematic Review Based Analysis
    Nair Kesavachandran C, Haamann F, Nienhaus A. PLoS One. 2013;8(2):e55364. doi: 10.1371/journal.pone.0055364. Epub 2013 Feb 1.


  102. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting
    Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik L, Mix C, Kirschner J, Manns MP, Wedemeyer H, Cornberg M. PLoS One. 2013;8(2):e55285. doi: 10.1371/journal.pone.0055285. Epub 2013 Feb 1.


  103. A Survey of Hepatitis C Treatment Clinical Practice Patterns Using the Newly Approved Protease Inhibitors
    Chen EY, Lee WM, Hynan LS, Singal AG. J Clin Gastroenterol. 2013 Mar 6. [Epub ahead of print]


  104. The Efficacy and Safety of Telaprevir-based Regimens for Treating Chronic Hepatitis C Virus Genotype 1 Infection: A Meta-analysis of Randomized Trials
    Yang D, Liang HJ, Li D, Wei X, Ma L, Jia Z. Intern Med. 2013;52(6):653-60. Epub 2013 Mar 15.


  105. New therapeutic strategies in HCV: second-generation protease inhibitors
    Clark VC, Peter JA, Nelson DR. Liver Int. 2013 Feb;33 Suppl 1:80-4. doi: 10.1111/liv.12061.


  106. Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin
    Yi NJ, Choi JY, Suh KS, Cho JY, Baik M, Hong G, Lee KW, Kim W, Kim YJ, Yoon JH, Lee HS, Kim DG. J Gastroenterol. 2013 Mar 6. [Epub ahead of print]


  107. Equal efficacy between the two types of peginterferon on HCV: A matter of relapse?
    Brochot E, Nguyen-Khac E, Duverlie G. Antiviral Res. 2013 Feb 16;98(1):1-3. doi: 10.1016/j.antiviral.2013.02.006. [Epub ahead of print]


  108. Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C
    Younossi ZM, Zheng L, Stepanova M, Venkatesan C, Mir HM. Aliment Pharmacol Ther. 2013 Apr;37(7):703-9. doi: 10.1111/apt.12265. Epub 2013 Feb 24.


  109. The impact of timing and prioritisation on the cost-effectiveness of birth-cohort testing and treatment for hepatitis C virus in the U.S
    McEwan P, Ward T, Yuan Y, Kim R, L'italien G. Hepatology. 2013 Feb 6. doi: 10.1002/hep.26304. [Epub ahead of print]


  110. Testing for hepatitis B infection in prospective chemotherapy patients: A retrospective study
    Wang Y, Luo XM, Yang D, Zhang J, Zhuo HY, Zhang J, Jiang Y. World J Gastroenterol. 2013 Feb 14;19(6):923-30. doi: 10.3748/wjg.v19.i6.923.


  111. Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor
    Duvoux C, Firpi R, Grazi GL, Levy G, Renner E, Villamil F. Transpl Int. 2013 Feb 18. doi: 10.1111/tri.12065. [Epub ahead of print]


  112. Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes
    Manos MM, Ho CK, Murphy RC, Shvachko VA. Patient. 2013;6(1):23-34. doi: 10.1007/s40271-013-0005-4.


  113. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
    Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3991-6. doi: 10.1073/pnas.1203110110. Epub 2013 Feb 19.


  114. Intrafamilial transmission of hepatitis C virus
    Indolfi G, Nesi A, Resti M. J Med Virol. 2013 Apr;85(4):608-14. doi: 10.1002/jmv.23522.


  115. Future therapies for chronic hepatitis C
    Dabbouseh NM, Jensen DM. Nat Rev Gastroenterol Hepatol. 2013 Feb 19. doi: 10.1038/nrgastro.2013.17. [Epub ahead of print]


  116. HIV and Hepatitis C Virus: Special Concerns for Patients With Cirrhosis.
    Curry MP. J Infect Dis. 2013 Mar;207 Suppl 1:S40-4. doi: 10.1093/infdis/jis763.


  117. Treatment Outcomes of Treatment-Naïve Hepatitis C Patients Co-Infected with HIV: A Systematic Review and Meta-Analysis of Observational Cohorts
    Davies A, Singh KP, Shubber Z, Ducros P, Mills EJ, Cooke G, Ford N. PLoS One. 2013;8(2):e55373. doi: 10.1371/journal.pone.0055373. Epub 2013 Feb 5.


  118. Association of Interleukin 28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C
    Hodo Y, Honda M, Tanaka A, Nomura Y, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Sakai A, Sasaki M, Nakanuma Y, Moriyama M, Kaneko S. Clin Cancer Res. 2013 Feb 20. [Epub ahead of print]


  119. Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients
    Joshi D, Carey I, Agarwal K. Aliment Pharmacol Ther. 2013 Apr;37(7):659-71. doi: 10.1111/apt.12260. Epub 2013 Feb 21.


  120. Pegylated Interferon-?2a and Ribavirin versus Pegylated Interferon-?2b and Ribavirin in Chronic Hepatitis C : A Meta-Analysis
    Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, Daurès JP, Blanc P. Drugs. 2013 Mar;73(3):263-77. doi: 10.1007/s40265-013-0027-1.


  121. Hepatitis C virus in pregnancy
    Prasad MR, Honegger JR. Am J Perinatol. 2013 Feb;30(2):149-60. doi: 10.1055/s-0033-1334459. Epub 2013 Feb 6.


  122. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-?2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 Trial
    Ogert RA, Howe JA, Vierling JM, Kwo PY, Lawitz EJ, McCone J, Schiff ER, Pound D, Davis MN, Gordon SC, Ravendhran N, Rossaro L, Jacobson IM, Ralston R, Chaudhri E, Qiu P, Pedicone LD, Brass CA, Albrecht JK, Barnard RJ, Hazuda DJ, Howe AY. Antivir Ther. 2013 Feb 12. doi: 10.3851/IMP2549. [Epub ahead of print]


  123. Vitamin D deficiency and vitamin D therapy in chronic hepatitis C
    Ladero JM, Torrejón MJ, Sánchez-Pobre P, Suárez A, Cuenca F, de la Orden V, Devesa MJ, Rodrigo M, Estrada V, López-Alonso G, Agúndez JA. Ann Hepatol. 2013 Mar;12(2):199-204.


  124. Highlights of the 2012 American Association for the Study of Liver Diseases meeting
    Osborn MK. r Med. 2012 Dec;20(5):180-4.


  125. Adherence and completion in hepatitis C management: a systematic review
    Redulla R, Dudley-Brown S. Gastroenterol Nurs. 2013 Jan;36(1):53-8. doi: 10.1097/SGA.0b013e318281634e.


  126. Management of hepatitis C virus infection: the basics
    Naggie S. Top Antivir Med. 2012 Dec;20(5):154-61.


  127. Hepatitis C virus vaccines in the era of new direct-acting antivirals
    Shi C, Ploss A. Expert Rev Gastroenterol Hepatol. 2013 Feb;7(2):171-85. doi: 10.1586/egh.12.72.


  128. Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B
    Hayashi K, Katano Y, Masuda H, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H. Hepatol Res. 2012 Oct 18. doi: 10.1111/hepr.12005. [Epub ahead of print]


  129. The ratio of insulin-like growth factor-I/insulin-like growth factor-binding protein-3 in sera of patients with hepatitis C virus-related chronic liver disease as a predictive marker of insulin resistance
    Himoto T, Tani J, Miyoshi H, Yoneyama H, Mori H, Inukai M, Masugata H, Goda F, Senda S, Haba R, Masaki T. Nutr Res. 2013 Jan;33(1):27-33. doi: 10.1016/j.nutres.2012.11.007. Epub 2012 Dec 20.


  130. Telaprevir Versus Boceprevir in Chronic Hepatitis C: A Meta-Analysis of Data From Phase II and III Trials
    Sitole M, Silva M, Spooner L, Comee MK, Malloy M. Clin Ther. 2013 Feb;35(2):190-7. doi: 10.1016/j.clinthera.2012.12.017. Epub 2013 Jan 29.


  131. Safety and Effectiveness of a Nurse-Led Outreach Program for Assessment and Treatment of Chronic Hepatitis C in the Custodial Setting
    Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D, Rudge G, Boonwaat L, Forrest G, Douglas J, Monkley D. Clin Infect Dis. 2013 Jan 29. [Epub ahead of print]


  132. Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype 1 Infection Response-Guided Therapy
    Lontok E, Mani N, Harrington PR, Miller V. Clin Infect Dis. 2013 Feb 12. [Epub ahead of print]


  133. Review of drug interactions with telaprevir and antiretrovirals
    van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Antivir Ther. 2013 Jan 23. doi: 10.3851/IMP2527. [Epub ahead of print]


  134. Influence of healthcare-associated factors on the efficacy of hepatitis C therapy
    Daw MA, Dau AA, Agnan MM. ScientificWorldJournal. 2012;2012:580216. doi: 10.1100/2012/580216. Epub 2012 Dec 27.


  135. Host genetic variants in the pathogenesis of hepatitis C
    Rau M, Baur K, Geier A. Viruses. 2012 Dec;4(12):3281-302.


  136. Polymorphisms near Interleukin 28B Gene Are Not Associated with Hepatitis B Virus Clearance, Hepatitis B e Antigen Clearance and Hepatocellular Carcinoma Occurrence
    Lee DH, Cho Y, Seo JY, Kwon JH, Cho EJ, Jang ES, Kwak MS, Cheong JY, Cho SW, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim CY, Shin HD, Kim YJ. Intervirology. 2013 Jan 22. [Epub ahead of print]


  137. Neurocognitive Deficits Associated With the Hepatitis C Virus Among Incarcerated Men
    Umaki TM, Denney RL. Clin Neuropsychol. 2013 Jan 24. [Epub ahead of print]


  138. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
    Arzumanyan A, Reis HM, Feitelson MA. Nat Rev Cancer. 2012 Dec 21;13(2):123-35. doi: 10.1038/nrc3449.


  139. Recurrent hepatitis C virus after transplant and the importance of plasma cells on biopsy
    Kallwitz ER. World J Gastroenterol. 2013 Jan 14;19(2):158-60. doi: 10.3748/wjg.v19.i2.158.


  140. Economic burden and current managed care challenges associated with hepatitis c
    Mathis AS. Am J Manag Care. 2012 Dec;18(14 Suppl):s350-9


  141. Interventions to Improve Patient Adherence to Hepatitis C Treatment: Comparative Effectiveness [Internet]
    Sun X, Patnode CD, Williams C, Senger CA, Kapka TJ, Whitlock EP.


  142. A Review of standard and newer treatment strategies in hepatitis c
    Tran TT. Am J Manag Care. 2012 Dec;18(14 Suppl):s340-9.


  143. Telaprevir for genotype 1 chronic hepatitis C: a systematic review and meta-analysis
    Gu L, Chen Q, Xie J, Yan Y, Wu G, Tan J, Liang B, Chen W, Wu P, Su L, Tang N. Pharmazie. 2012 Dec;67(12):963-72.


  144. Serum Apoptosis Markers Related to Liver Damage in Chronic Hepatitis C: sFas as a Marker of Advanced Fibrosis in Children and Adults While M30 of Severe Steatosis Only in Children
    Valva P, Casciato P, Lezama C, Galoppo M, Gadano A, Galdame O, Galoppo MC, Mullen E, De Matteo E, Preciado MV. PLoS One. 2013;8(1):e53519. doi: 10.1371/journal.pone.0053519. Epub 2013 Jan 11.


  145. Overview of epidemiology, diagnosis, and disease progression associated with hepatitis c
    Tran TT. Am J Manag Care. 2012 Dec;18(14 Suppl):s335-9.


  146. Prognostic Gene-Expression Signature for Patients with Hepatitis C-Related Early-Stage Cirrhosis
    Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Gastroenterology. 2013 Jan 17. pii: S0016-5085(13)00078-4. doi: 10.1053/j.gastro.2013.01.021. [Epub ahead of print]


  147. Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail?
    Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM. Am J Gastroenterol. 2013 Jan 22. doi: 10.1038/ajg.2012.449. [Epub ahead of print]


  148. IL28B in the Era of Direct-acting Antivirals for Hepatitis C
    Muir AJ. J Clin Gastroenterol. 2013 Mar;47(3):222-7. doi: 10.1097/MCG.0b013e3182680221.


  149. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma
    Tanaka S, Miyanishi K, Kobune M, Kawano Y, Hoki T, Kubo T, Hayashi T, Sato T, Sato Y, Takimoto R, Kato J. J Gastroenterol. 2013 Jan 19. [Epub ahead of print]


  150. Spleen stiffness: Towards a non-invasive portal sphygmomanometer?
    Abraldes JG, Reverter E, Berzigotti A. Hepatology. 2013 Jan 21. doi: 10.1002/hep.26239. [Epub ahead of print]


  151. Performance of liver stiffness measurements by transient elastography in chronic hepatitis
    Ferraioli G, Tinelli C, Bello BD, Zicchetti M, Lissandrin R, Filice G, Filice C, Above E, Barbarini G, Brunetti E, Calderon W, Gregorio MD, Gulminetti R, Lanzarini P, Ludovisi S, Maiocchi L, Malfitano A, Michelone G, Minoli L, Mondelli M, Novati S, Patruno SF, Perretti A, Poma G, Sacchi P, Zanaboni D, Zaramella M. World J Gastroenterol. 2013 Jan 7;19(1):49-56. doi: 10.3748/wjg.v19.i1.49.


  152. Hepatitis C virus core antigen test in monitoring of dialysis patients
    Li Cavoli G, Zagarrigo C, Schillaci O, Servillo F, Tralongo A, Coglitore M, Spadaro F, Scimeca C, Li Destri N, Rotolo U. Hepat Res Treat. 2012;2012:832021. doi: 10.1155/2012/832021. Epub 2012 Dec 4.


  153. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices
    Di Marco V, Calvaruso V, Grimaudo S, Ferraro D, Pipitone RM, Di Stefano R, Craxì A. J Viral Hepat. 2013 Feb;20(2):113-21. doi: 10.1111/j.1365-2893.2012.01637.x. Epub 2012 Jul 25.


  154. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4
    Domagalski K, Paw?owska M, Tretyn A, Halota W, Pilarczyk M, Smukalska E, Linkowska K, Grzybowski T. Eur J Clin Microbiol Infect Dis. 2013 Jan 13. [Epub ahead of print]


  155. Portal Vein Thrombosis in Patients with End Stage Liver Disease Awaiting Liver Transplantation: Outcome of Anticoagulation
    Werner KT, Sando S, Carey EJ, Vargas HE, Byrne TJ, Douglas DD, Harrison ME, Rakela J, Aqel BA. Dig Dis Sci. 2013 Jan 12. [Epub ahead of print]


  156. Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?
    Pawlotsky JM. Curr Gastroenterol Rep. 2013 Feb;15(2):309. doi: 10.1007/s11894-012-0309-x.


  157. Association of tattooing and hepatitis C virus infection: A multicenter case-control study
    Carney K, Dhalla S, Aytaman A, Tenner CT, Francois F. Hepatology. 2013 Jan 12. doi: 10.1002/hep.26245. [Epub ahead of print]


  158. Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection
    Bonilla-Abadía F, Echeverri AF, Izquierdo JH, Cañas F, Cañas CA. Case Report Rheumatol. 2012;2012:923897. doi: 10.1155/2012/923897. Epub 2012 Dec 16.


  159. Hepatitis C virus core antigen test in monitoring of dialysis patients
    Li Cavoli G, Zagarrigo C, Schillaci O, Servillo F, Tralongo A, Coglitore M, Spadaro F, Scimeca C, Li Destri N, Rotolo U. Hepat Res Treat. 2012;2012:832021. doi: 10.1155/2012/832021. Epub 2012 Dec 4.


  160. Optimal treatment with telaprevir for chronic HCV infection
    Jesudian AB, Jacobson IM. Liver Int. 2013 Feb;33 Suppl 1:3-13. doi: 10.1111/liv.12079.


  161. Hepatitis C virus diversity and hepatic steatosis
    Roingeard P. J Viral Hepat. 2013 Feb;20(2):77-84. doi: 10.1111/jvh.12035. Epub 2012 Nov 29.


  162. How to optimize HCV therapy in genotype 1 patients: management of side-effects
    Chopra A, Klein PL, Drinnan T, Lee SS. Liver Int. 2013 Feb;33 Suppl 1:30-4. doi: 10.1111/liv.12080.


  163. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting
    Seidenberg A, Rosemann T, Senn O. BMC Infect Dis. 2013 Jan 8;13(1):9. doi: 10.1186/1471-2334-13-9.


  164. Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy
    Caviglia GP, Abate ML, Manzini P, Danielle F, Ciancio A, Rosso C, Olivero A, Pellicano R, Touscoz GA, Smedile A, Rizzetto M. Hepat Mon. 2012 Nov;12(11):e7292. doi: 10.5812/hepatmon.7292. Epub 2012 Nov 30.


  165. Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C
    Kraus MR, Schäfer A, Teuber G, Porst H, Paul K, Wollschläger S, Keicher C, Scheurlen M. Hepatology. 2013 Jan 8. doi: 10.1002/hep.26229. [Epub ahead of print]


  166. Current management and perspectives for HCV recurrence after liver transplantation
    Coilly A, Roche B, Samuel D. Liver Int. 2013 Feb;33 Suppl 1:56-62. doi: 10.1111/liv.12062.


  167. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C
    Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Garcia-Alvarez M, Resino S. BMC Med. 2013 Jan 8;11(1):6. [Epub ahead of print]


  168. IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients
    Hsu CS, Hsu SJ, Liu WL, Liu CH, Chen CL, Liu CJ, Chen PJ, Chen DS, Kao JH. Antivir Ther. 2013 Jan 7. doi: 10.3851/IMP2502. [Epub ahead of print]


  169. Interferon free therapy with direct acting antivirals for HCV
    Asselah T, Marcellin P. Liver Int. 2013 Feb;33 Suppl 1:93-104. doi: 10.1111/liv.12076.


  170. HCV therapy in HIV-infected patients
    Sulkowski MS. Liver Int. 2013 Feb;33 Suppl 1:63-7. doi: 10.1111/liv.12082.


  171. How to optimize HCV therapy in genotype 4 patients
    Esmat G, El Kassas M, Hassany M, Gamil ME, El Raziky M. Liver Int. 2013 Feb;33 Suppl 1:41-5. doi: 10.1111/liv.12059.


  172. How to optimize HCV therapy in genotype 2 patients
    Grassi E, Aghemo A. Liver Int. 2013 Feb;33 Suppl 1:35-40. doi: 10.1111/liv.12056.


  173. How to optimize HCV therapy in genotype 1 patients: predictors of response
    Petta S, Craxì A. Liver Int. 2013 Feb;33 Suppl 1:23-9. doi: 10.1111/liv.12053.


  174. How to optimize HCV therapy in genotype 1 patients with cirrhosis
    Bourlière M, Wendt A, Fontaine H, Hézode C, Pol S, Bronowicki JP. Liver Int. 2013 Feb;33 Suppl 1:46-55. doi: 10.1111/liv.12067.


  175. Best strategies for global HCV eradication
    Hagan LM, Schinazi RF. Liver Int. 2013 Feb;33 Suppl 1:68-79. doi: 10.1111/liv.12063.


  176. Optimal treatment with boceprevir for chronic HCV infection
    Maasoumy B, Manns MP. Liver Int. 2013 Feb;33 Suppl 1:14-22. doi: 10.1111/liv.12070.


  177. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C
    Shlomai A, Halfon P, Goldiner I, Zelber-Sagi S, Halpern Z, Oren R, Bruck R. J Viral Hepat. 2013 Feb;20(2):95-102. doi: 10.1111/j.1365-2893.2012.01628.x. Epub 2012 Aug 3.


  178. Hepatitis C treatment - better outcomes through partner support
    Chapman F, McManus A. Australas Med J. 2012;5(11):585-8. doi: 10.4066/AMJ.2012.1442. Epub 2012 Nov 30.


  179. Chronic hepatitis C virus (HCV) disease burden and cost in the United States
    Razavi H, El Khoury A, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Hepatology. 2012 Dec 22. doi: 10.1002/hep.26218. [Epub ahead of print]


  180. Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis
    Kong Y, Wang X, Shang Y, Schroder PM, Liang W, Ling X, Guo Z, He X. PLoS One. 2012;7(12):e52158. doi: 10.1371/journal.pone.0052158. Epub 2012 Dec 20.


  181. Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C
    Shimoyama Y, Nozaki A, Morimoto M, Moriya S, Kondo M, Fukuda H, Numata K, Miyajima E, Oba MS, Taguri M, Morita S, Maeda S, Tanaka K. Hepatol Res. 2012 Dec 5. doi: 10.1111/hepr.12037. [Epub ahead of print]


  182. Risk factors for and incidence of acute hepatitis C after the achievement of blood supply safety in Italy: Results from the national surveillance system
    Spada E, Mele A, Mariano A, Zuccaro O, Tosti ME; on behalf of SEIEVA collaborating group. J Med Virol. 2012 Dec 28. doi: 10.1002/jmv.23485. [Epub ahead of print]


  183. Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin
    Yu ML, Liu CH, Huang CF, Tseng TC, Huang JF, Dai CY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Kao JH. PLoS One. 2012;7(12):e52048. doi: 10.1371/journal.pone.0052048. Epub 2012 Dec 21.


  184. Polymorphisms of the core, NS3 and NS5A proteins of hepatitis C 1 virus genotype 1b associate with development of hepatocellular carcinoma
    El-Shamy A, Shindo M, Shoji I, Deng L, Okuno T, Hotta H. Hepatology. 2012 Dec 24. doi: 10.1002/hep.26205. [Epub ahead of print]


  185. Introduction of an automated system for the diagnosis and quantification of hepatitis B and hepatitis C viruses
    Cabezas-Fernandez M, Cabeza-Barrera M. Source Open Virol J. 2012;6:122-34. doi: 10.2174/1874357901206010122. Epub 2012 Nov 30.


  186. Low Oxygen Tension Enhances Hepatitis C Virus Replication
    Vassilaki N, Kalliampakou KI, Kotta-Loizou I, Befani C, Liakos P, Simos G, Mentis AF, Kalliaropoulos A, Doumba PP, Smirlis D, Foka P, Bauhofer O, Poenisch M, Windisch MP, Lee ME, Koskinas J, Bartenschlager R, Mavromara P. J Virol. 2012 Dec 26. [Epub ahead of print]


  187. Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C
    Komase K, Maekawa S, Miura M, Sueki R, Kadokura M, Shindo H, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. Hepatol Res. 2012 Nov 29. doi: 10.1111/hepr.12032. [Epub ahead of print]


  188. Predictors of Psychopathological Outcome During Peg-Interferon and Ribavirin Therapy in Patients with Chronic HCV-Correlated Hepatitis
    Dell'osso B, Prati G, Palazzo MC, Rumi MG, Cavallaro F, Aghemo A, Colombo M, Altamura AC. J Interferon Cytokine Res. 2013 Jan;33(1):9-14. doi: 10.1089/jir.2012.0060. Epub 2012 Dec 31.


  189. Combination treatment with HCV protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a and 3a virus
    Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TK, Serre SB, Mikkelsen L, Bukh J. Antimicrob Agents Chemother. 2012 Dec 28. [Epub ahead of print]


  190. Update on the treatment of patients with non-genotype 1 HCV infection
    Mangia A, Mottola L, Piazzolla V. Clin Infect Dis. 2012 Dec 27. [Epub ahead of print]


  191. Combinations of Interferon Lambda with Direct-Acting Antiviral Agents are Highly Efficient in Suppressing Hepatitis C Virus Replication
    Friborg J, Levine S, Chen C, Sheaffer AK, Chaniewski S, McPhee F. Antimicrob Agents Chemother. 2012 Dec 28. [Epub ahead of print]


  192. Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: A 16-week prospective study
    Loftis JM, Patterson AL, Wilhelm CJ, McNett H, Morasco BJ, Huckans M, Morgan T, Saperstein S, Asghar A, Hauser P. J Psychosom Res. 2013 Jan;74(1):57-63. doi: 10.1016/j.jpsychores.2012.10.012. Epub 2012 Nov 21.


  193. Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review
    Donato MF, Fabrizi F, Fogazzi GB, Cresseri D, Passerini P, Martin P, Messa P. Int J Artif Organs. 2013 Jan 2:0. doi: 10.5301/ijao.5000166. [Epub ahead of print]


  194. New targets for treatment against HCV infection
    Pan Q, van der Laan LJ. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):505-15. doi: 10.1016/j.bpg.2012.10.002.


  195. Vitamin A deficiency is associated with HCV chronic infection and with unresponsiveness to interferon based antiviral therapy
    Bitetto D, Bortolotti N, Falleti E, Vescovo S, Fabris C, Fattovich G, Cussigh A, Cmet S, Fornasiere E, Ceriani E, Pirisi M, Toniutto P. Hepatology. 2012 Dec 5. doi: 10.1002/hep.26186. [Epub ahead of print]


  196. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations
    North CS, Hong BA, Adewuyi SA, Pollio DE, Jain MK, Devereaux R, Quartey NA, Ashitey S, Lee WM, Lisker-Melman M. Gen Hosp Psychiatry. 2012 Dec 6. pii: S0163-8343(12)00336-2. doi: 10.1016/j.genhosppsych.2012.11.002. [Epub ahead of print]


  197. The role of resistance in HCV treatment
    Vermehren J, Sarrazin C. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):487-503. doi: 10.1016/j.bpg.2012.09.011.


  198. Hepatitis C virus and natural compounds: a new antiviral approach?
    Calland N, Dubuisson J, Rouillé Y, Séron K. Viruses. 2012 Oct 17;4(10):2197-217. doi: 10.3390/v4102197.


  199. Genetic Variants of STAT-4 Affect the Development of Graft Fibrosis After Liver Transplantation for HCV-Induced Liver Disease
    Eurich D, Boas-Knoop S, Struecker B, Neuhaus R, Neuhaus P, Bahra M. Transplantation. 2013 Jan 15;95(1):203-8. doi: 10.1097/TP.0b013e318277e2f6.


  200. Evaluation of a rapid on-site anti-HCV test as a screening tool for hepatitis C virus infection
    Kant J, Möller B, Heyne R, Herber A, Böhm S, Maier M, Liebert UG, Mössner J, Berg T, Wiegand J. Eur J Gastroenterol Hepatol. 2012 Dec 3. [Epub ahead of print]


  201. Occupational Exposures and the Prevalence of Blood-Borne Pathogens in a Deployed Setting: Data from a US Military Trauma Center in Afghanistan
    Okulicz JF, Yun HC, Murray CK. Infect Control Hosp Epidemiol. 2013 Jan;34(1):74-9. doi: 10.1086/668784. Epub 2012 Nov 19.


  202. Evaluation of the Liver Fibrosis Index calculated by using real-time tissue elastography for the non-invasive assessment of liver fibrosis in chronic liver diseases
    Tomeno W, Yoneda M, Imajo K, Suzuki K, Ogawa Y, Shinohara Y, Mawatari H, Fujita K, Shibata W, Kirikoshi H, Maeda S, Nakajima A, Saito S. Hepatol Res. 2012 Nov 12. doi: 10.1111/hepr.12023. [Epub ahead of print]


  203. Project ECHO: a model for complex, chronic care in the Pacific Northwest region of the United States
    Scott JD, Unruh KT, Catlin MC, Merrill JO, Tauben DJ, Rosenblatt R, Buchwald D, Doorenbos A, Towle C, Ramers CB, Spacha DH. J Telemed Telecare. 2012;18(8):481-4. doi: 10.1258/jtt.2012.GTH113. Epub 2012 Dec 3.


  204. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers
    Bruggmann P. J Viral Hepat. 2012 Dec;19(12):829-35. doi: 10.1111/jvh.12008. Epub 2012 Oct 1.


  205. Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Viral Response in Patients with Genotype 1 Chronic Hepatitis C
    Petta S, Rosso C, Leung R, Abate ML, Booth D, Salamone F, Gambino R, Rizzetto M, Caviglia P, Smedile A, Grimaudo S, Cammà C, Craxì A, George J, Bugianesi E. Clin Gastroenterol Hepatol. 2012 Dec 4. pii: S1542-3565(12)01422-X. doi: 10.1016/j.cgh.2012.11.022. [Epub ahead of print]


  206. Second generation direct antivirals and the way to interferon-free regimens in chronic HCV
    Lewis H, Cunningham M, Foster G. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):471-85. doi: 10.1016/j.bpg.2012.09.008.


  207. Neutralizing antibodies and pathogenesis of hepatitis C virus infection
    Fafi-Kremer S, Fauvelle C, Felmlee DJ, Zeisel MB, Lepiller Q, Fofana I, Heydmann L, Stoll-Keller F, Baumert TF. Viruses. 2012 Oct 9;4(10):2016-30. doi: 10.3390/v4102016.


  208. Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
    Edward J. Gane, M.D., Catherine A. Stedman, M.B., Ch.B., Ph.D., Robert H. Hyland, D.Phil., Xiao Ding, Ph.D., Evguenia Svarovskaia, Ph.D., William T. Symonds, Pharm.D., Robert G. Hindes, M.D., and M. Michelle Berrey, M.D., M.P.H. N Engl J Med 2013; 368:34-44January 3, 2013DOI: 10.1056/NEJMoa1208953


  209. Is there a benefit to a routine preoperative screening of infectivity for HIV, hepatitis B and C virus before elective orthopaedic operations?
    Weber P, Eberle J, Bogner JR, Schrimpf F, Jansson V, Huber-Wagner S. Infection. 2012 Dec 7. [Epub ahead of print]


  210. Pathogenesis of hepatitis C during pregnancy and childhood
    Le Campion A, Larouche A, Fauteux-Daniel S, Soudeyns H. Viruses. 2012 Dec 6;4(12):3531-50. doi: 10.3390/v4123531.


  211. Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
    Fred Poordad, M.D., Eric Lawitz, M.D., Kris V. Kowdley, M.D., Daniel E. Cohen, M.D., Thomas Podsadecki, M.D., Sara Siggelkow, R.N., Michele Heckaman, M.S., Lois Larsen, Ph.D., Rajeev Menon, Ph.D., Gennadiy Koev, Ph.D., Rakesh Tripathi, M.S., Tami Pilot-Matias, Ph.D., and Barry Bernstein, M.D. N Engl J Med 2013; 368:45-53January 3, 2013DOI: 10.1056/NEJMoa120880


  212. Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers
    Ponziani FR, Milani A, Gasbarrini A, Zaccaria R, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Cescon M, Burra P, Miglioresi L, Merli M, Paolo DD, Fagiuoli S, Pompili M; on behalf of AISF RECOLT-C Group. Transpl Int. 2012 Dec 11. doi: 10.1111/tri.12027. [Epub ahead of print]


  213. Viral hepatitis induces hepatocellular cancer: what can we learn from epidemiology comparing iran and worldwide findings?
    Smolle E, Zöhrer E, Bettermann K, Haybaeck J. Hepat Mon. 2012 Oct;12(10 HCC):e7879. doi: 10.5812/hepatmon.7879. Epub 2012 Oct 30.


  214. Effects of triple-drug therapy with nitazoxanide, high-dose ribavirin and peginterferon-?-2a in patients with chronic hepatitis C
    Basu PP, Rayapudi K, Shah NJ, Krishnaswamy N, Brown RS. Hepatol Res. 2012 Dec 5. doi: 10.1111/hepr.12013. [Epub ahead of print]


  215. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4
    Antaki N, Bibert S, Kebbewar K, Asaad F, Baroudi O, Alideeb S, Hadad M, Abboud D, Sabah H, Bochud PY, Negro F. J Viral Hepat. 2013 Jan;20(1):59-64. doi: 10.1111/j.1365-2893.2012.01621.x. Epub 2012 May 24.


  216. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences
    Ng J, Wu J. Hepat Mon. 2012 Oct;12(10 HCC):e7635. doi: 10.5812/hepatmon.7635. Epub 2012 Oct 25.


  217. Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis
    Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Clin Infect Dis. 2012 Dec 27. [Epub ahead of print]


  218. Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response
    Tedder RS, Tuke P, Wallis N, Wright M, Nicholson L, Grant PR. J Viral Hepat. 2013 Jan;20(1):65-71. doi: 10.1111/j.1365-2893.2012.01630.x. Epub 2012 Jul 4.


  219. Boceprevir and personalized medicine in hepatitis C virus infection
    Habersetzer F, Leboeuf C, Doffoël M, Baumert TF. Pharmgenomics Pers Med. 2012;5:125-37. doi: 10.2147/PGPM.S24259. Epub 2012 Sep 26.


  220. Rapid hepatitis C virus divergence among chronically infected individuals
    Cruz-Rivera M, Carpio-Pedroza JC, Escobar-Gutiérrez A, Lozano D, Vergara-Castaneda A, Rivera-Osorio P, Martinez-Guarneros A, Chacon CA, Fonseca-Coronado S, Vaughan G. J Clin Microbiol. 2012 Dec 5. [Epub ahead of print]


  221. Boceprevir: A recently approved protease inhibitor for hepatitis C virus infection
    Lam JT, Jacob S. Am J Health Syst Pharm. 2012 Dec 15;69(24):2135-9. doi: 10.2146/ajhp110500.


  222. Relationship of ?-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis
    Taura N, Fukuda S, Ichikawa T, Miyaaki H, Shibata H, Honda T, Yamaguchi T, Kubota Y, Uchida S, Kamo Y, Yoshimura E, Isomoto H, Matsumoto T, Takeshima F, Tsutsumi T, Tsuruta S, Nakao K. Exp Ther Med. 2012 Dec;4(6):972-976. Epub 2012 Sep 17.


  223. Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection
    Feld JJ. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):429-44. doi: 10.1016/j.bpg.2012.09.013.


  224. Natural history of acute and chronic hepatitis C
    Maasoumy B, Wedemeyer H. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):401-12. doi: 10.1016/j.bpg.2012.09.009.


  225. Interferon stimulated genes are associated with peginterferon plus ribavirin treatment response regardless IL28B alleles in HCV/HIV coinfected patients
    Rallon NI, Lopez-Fernandez LA, Garcia MI, Benguria A, Fiorante S, Soriano V, Benito JM. AIDS. 2012 Nov 28. [Epub ahead of print]


  226. The role of viral and host genetics in natural history and treatment of chronic HCV infection
    Doyle JS, Hellard ME, Thompson AJ. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):413-27. doi: 10.1016/j.bpg.2012.09.004.


  227. Baseline serum cholesterol is associated with a response to pegylated interferon alfa-2b and ribavirin therapy for chronic hepatitis C genotype 2
    Taura N, Ichikawa T, Miyaaki H, Kadokawa Y, Tsutsumi T, Tsuruta S, Kato Y, Inoue O, Kinoshita N, Ohba K, Kato H, Ohata K, Masuda J, Hamasaki K, Yatsuhashi H, Nakao K. Gastroenterol Res Pract. 2012;2012:317580. doi: 10.1155/2012/317580. Epub 2012 Nov 5.


  228. Exploratory study on telaprevir given every 8?h at 500?mg or 750?mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients
    Suzuki F, Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I, Kumada H. Hepatol Res. 2012 Nov 29. doi: 10.1111/hepr.12009. [Epub ahead of print]


  229. A combined proteomics and computational approach provides a better understanding of HCV-induced liver disease
    Tripathi LP, Mizuguchi K. Expert Rev Proteomics. 2012 Oct;9(5):493-6. doi: 10.1586/epr.12.47.


  230. Immunology of hepatitis C virus infections
    Spaan M, Janssen HL, Boonstra A. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):391-400. doi: 10.1016/j.bpg.2012.09.005.


  231. The Impact of Hepatitis A Virus Infection on Hepatitis C Virus Infection: A Competitive Exclusion Hypothesis
    Amaku M, Coutinho FA, Chaib E, Massad E. Bull Math Biol. 2012 Nov 29. [Epub ahead of print]


  232. HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents
    Calle Serrano B, Manns MP. Antivir Ther. 2012;17(6 Pt B):1133-46. doi: 10.3851/IMP2425. Epub 2012 Oct 5.


  233. Response guided therapy in patients with chronic hepatitis C - Yesterday, today and tomorrow
    Ferenci P. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):463-9. doi: 10.1016/j.bpg.2012.09.002.


  234. Hepatitis C infection among men who have sex with men, san francisco, 2011
    Raymond HF, Chu P, Nieves-Rivera I, Louie B, McFarland W, Pandori M. Sex Transm Dis. 2012 Dec;39(12):985-6. doi: 10.1097/OLQ.0b013e3182716e59.


  235. Interferon Gamma With Peg-Interferon ? 2a and Ribavirin in Non Responder Patients With Chronic Hepatitis C (ANRS HC16 GAMMATRI)
    Couzigou P, Pérusat S, Bourlière M, Trimoulet P, Poynard T, Leroy V, Marcellin P, Foucher J, Bronowicki JP, Chêne G; the ANRS HC16 GAMMATRI trial Group. J Gastroenterol Hepatol. 2012 Nov 28. doi: 10.1111/jgh.12060. [Epub ahead of print]


  236. Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients
    Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Tanaka J. J Gastroenterol Hepatol. 2012 Nov 28. doi: 10.1111/jgh.12057. [Epub ahead of print]


  237. Virology of hepatitis C virus infection
    Chevaliez S, Pawlotsky JM. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):381-9. doi: 10.1016/j.bpg.2012.09.006.


  238. Telaprevir-Related Dermatitis
    Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS. Arch Dermatol. 2012 Nov 19:1-7. doi: 10.1001/jamadermatol.2013.938. [Epub ahead of print]


  239. Telaprevir to Boceprevir Switch Highlights Lack of Cross-Reactivity
    Carlson A, Gregorich Z, Striker R. Clin Infect Dis. 2012 Dec 7. [Epub ahead of print]


  240. Sexual transmission of HCV among monogamous heterosexual couples: The HCV partners study
    Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, Gish R, Busch M, Reingold AL, Alter MJ. Hepatology. 2012 Nov 23. doi: 10.1002/hep.26164. [Epub ahead of print]


  241. Natural killer cells in hepatitis C virus infection
    Bozzano F, Marras F, Biassoni R, Maria AD. Expert Rev Clin Immunol. 2012 Nov;8(8):775-88. doi: 10.1586/eci.12.71.


  242. None of the Six SNPs of IL28B Could Predict Treatment Responses in Genotype 2 Chronic HCV Infected Patients by Propensity Score Matching Analysis
    Jeng WJ, Lin CY, Chen JY, Huang CW, Huang CH, Sheen IS. PLoS One. 2012;7(11):e48217. doi: 10.1371/journal.pone.0048217. Epub 2012 Nov 16.


  243. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to hepatitis C virus seroprevalence
    Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Hepatology. 2012 Nov 21. doi: 10.1002/hep.26141. [Epub ahead of print]


  244. Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation
    Du Y, Su T, Ding Y, Cao G. Hepat Mon. 2012 Oct;12(10 HCC):e6031. doi: 10.5812/hepatmon.6031. Epub 2012 Oct 20.


  245. The science of direct-acting antiviral and host-targeted agent therapy
    Pawlotsky JM. Antivir Ther. 2012;17(6 Pt B):1109-17. doi: 10.3851/IMP2423. Epub 2012 Oct 5.


  246. Public health issues of hepatitis C virus infection
    Papatheodoridis G, Hatzakis A. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):371-80. doi: 10.1016/j.bpg.2012.09.012.


  247. Protective and Pathological Properties of IL-22 in Liver Disease: Implications for Viral Hepatitis
    Cobleigh MA, Robek MD. Am J Pathol. 2012 Nov 14. pii: S0002-9440(12)00719-5. doi: 10.1016/j.ajpath.2012.08.043. [Epub ahead of print]


  248. Importance of IL-10 and IL-6 during chronic hepatitis c genotype-1 treatment and their relation with IL28B
    Pavón-Castillero EJ, Muñoz-de-Rueda P, López-Segura R, Gila A, Quiles R, Muñoz-Gámez JA, Carazo A, Martínez P, Ruiz-Extremera A, Salmerón J. Cytokine. 2012 Nov 15. pii: S1043-4666(12)00742-9. doi: 10.1016/j.cyto.2012.10.009. [Epub ahead of print]


  249. Virological Responses in Chronic Hepatitis C Patients Undergoing Prolonged Therapy with Low-Dose Peg-IFNα-2a
    Zhou JY, Jiang ZA, Zhou DF, Xing WL, Wang W, Wang YD. Hepatogastroenterology. 2012 Nov 16;60(122). doi: 10.5754/hge12272. [Epub ahead of print]


  250. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
    Pellicelli AM, Romano M, Stroffolini T, Mazzoni E, Mecenate F, Monarca R, Picardi A, Bonaventura ME, Mastropietro C, Vignally P, Andreoli A, Marignani M, D Ambrosio C, Miglioresi L, Nosotti L, Mitidieri O, Gentilucci UV, Puoti C, Barbaro G, Barlattani A, Furlan C, Barbarini G. BMC Gastroenterol. 2012 Nov 16;12(1):162. [Epub ahead of print]


  251. Futility Rules for Telaprevir Combination Treatment for Patients With Hepatitis C Virus Infection
    Adda N, Bartels DJ, Gritz L, Kieffer TL, Tomaka F, Bengtsson L, Luo D, Jacobson IM, Kauffman RS, Picchio G. Clin Gastroenterol Hepatol. 2012 Nov 14. pii: S1542-3565(12)01386-9. doi: 10.1016/j.cgh.2012.10.045. [Epub ahead of print]


  252. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis
    Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, Mills EJ. QJM. 2012 Nov 17. [Epub ahead of print]


  253. Current progress in the treatment of chronic hepatitis C
    Alexopoulou A, Papatheodoridis GV. World J Gastroenterol. 2012 Nov 14;18(42):6060-9. doi: 10.3748/wjg.v18.i42.6060.


  254. Cryoglobulinemia is an independent factor negatively associated with sustained virological response in chronic hepatitis C patients
    Fan XH, Wu CH, Wang LF, Zheng YY, Yao Y, Lu HY, Xu XY, Wei L. Chin Med J (Engl). 2012 Nov;125(22):4014-7.


  255. Pharmacokinetic Interactions Between the HCV Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir
    Hulskotte EG, Feng HP, Xuan F, van Zutven MG, Treitel MA, Hughes EA, O'Mara E, Youngberg SP, Wagner JA, Butterton JR. Clin Infect Dis. 2012 Nov 15. [Epub ahead of print]


  256. Comparison of the efficacy of ribavirin plus peginterferon alfa-2b for chronic hepatitis C infection in patients with and without coagulation disorders
    Honda T, Katano Y, Kuzuya T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Toyoda H, Kumada T, Yamamoto K, Matsushita T, Kojima T, Takamatsu J, Goto H. J Med Virol. 2012 Nov 14. doi: 10.1002/jmv.23444. [Epub ahead of print]


  257. Improved Inflammatory Activity With Peginterferon Alfa-2b Maintenance Therapy in Non-cirrhotic Prior Nonresponders: a Randomized Study
    Poynard T, Bruix J, Schiff ER, Diago M, Berg T, Moreno-Otero R, Lyra AC, Carrilho F, Griffel LH, Boparai N, Jiang R, Burroughs M, Brass CA, Albrecht JK. J Hepatol. 2012 Nov 14. pii: S0168-8278(12)00831-8. doi: 10.1016/j.jhep.2012.11.001. [Epub ahead of print]


  258. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: A multicenter study
    Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, Ginba H, Matsuyama K, Izumi N. J Med Virol. 2013 Jan;85(1):65-70. doi: 10.1002/jmv.23428.


  259. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: Is it feasible?
    Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, Leroy V. J Clin Virol. 2012 Nov 10. pii: S1386-6532(12)00390-3. doi: 10.1016/j.jcv.2012.10.009. [Epub ahead of print]


  260. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection
    Wyles DL. Top Antivir Med. 2012 Oct;20(4):139-45.


  261. Anthropometric and Clinical Factors Associated with Mortality in Subjects with Nonalcoholic Fatty Liver Disease
    Otgonsuren M, Stepanova M, Gerber L, Younossi ZM. Dig Dis Sci. 2012 Nov 10. [Epub ahead of print]


  262. Hepatitis C Testing, Infection, and Linkage to Care Among Racial and Ethnic Minorities in the United States, 2009-2010
    Tohme RA, Xing J, Liao Y, Holmberg SD. Am J Public Health. 2012 Nov 15. [Epub ahead of print]


  263. Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment
    Hernández-Guerra M, González-Méndez Y, de Molina P, Gimeno-García AZ, Carrillo M, Casanova C, Pumarola T, Jimenez A, Hernández-Porto M, Torres A, Quintero E. PLoS One. 2012;7(11):e48610. doi: 10.1371/journal.pone.0048610. Epub 2012 Nov 8.


  264. Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype
    Motomura T, Shirabe K, Furusyo N, Yoshizumi T, Ikegami T, Soejima Y, Akahoshi T, Tomikawa M, Fukuhara T, Hayashi J, Maehara Y. BMC Gastroenterol. 2012 Nov 12;12:158. doi: 10.1186/1471-230X-12-158.


  265. Discordance Among Transient Elastography, Aminotransferase to Platelet Ratio Index, and Histologic Assessments of Liver Fibrosis in Patients with Chronic Hepatitis C
    Gara N, Zhao X, Kleiner DE, Liang TJ, Hoofnagle JH, Ghany MG. Clin Gastroenterol Hepatol. 2012 Nov 7. pii: S1542-3565(12)01312-2. doi: 10.1016/j.cgh.2012.10.044. [Epub ahead of print]


  266. The changing face of hepatitis C in the new era of direct-acting antivirals
    Soriano V, Labarga P, Fernández-Montero JV, Benito JM, Poveda E, Rallon N, Sánchez C, Vispo E, Barreiro P. Antiviral Res. 2012 Nov 9. pii: S0166-3542(12)00251-3. doi: 10.1016/j.antiviral.2012.10.011. [Epub ahead of print]


  267. Managing adverse effects and complications in completing treatment for hepatitis C virus infection
    Sherman KE. Top Antivir Med. 2012 Oct;20(4):125-8.


  268. Association of caffeine intake and histological features of chronic hepatitis C
    Costentin CE, Roudot-Thoraval F, Zafrani ES, Medkour F, Pawlotsky JM, Mallat A, Hézode C. J Hepatol. 2011 Jun;54(6):1123-9. Epub 2011 Feb 24.


  269. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients
    Charlebois A, Lee L, Cooper E, Mason K, Powis J. J Viral Hepat. 2012 Dec;19(12):836-42. doi: 10.1111/j.1365-2893.2012.01648.x. Epub 2012 Jul 31.


  270. The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice
    Garcia-Saenz-de-Sicilia M, Mukherjee S. Expert Rev Clin Pharmacol. 2012 Sep;5(5):587-93. doi: 10.1586/ecp.12.49.


  271. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions
    Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, Klinker H, Larrey D, Nikitin I, Pol S, Puoti M, Romero-Gómez M, Wedemeyer H, Zeuzem S. J Hepatol. 2012 Nov 5. pii: S0168-8278(12)00828-8. doi: 10.1016/j.jhep.2012.10.027. [Epub ahead of print]


  272. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism
    Del Campo JA, Ampuero J, Rojas L, Conde M, Rojas A, Maraver M, Millán R, García-Valdecasas M, García-Lozano JR, González-Escribano MF, Romero-Gómez M. Aliment Pharmacol Ther. 2012 Nov 5. doi: 10.1111/apt.12113. [Epub ahead of print]


  273. Hepatitis C virus infection and autoimmune diseases
    Paroli M, Iannucci G, Accapezzato D. Int J Gen Med. 2012;5:903-7. doi: 10.2147/IJGM.S37580. Epub 2012 Oct 23.


  274. IL28B genetic variation and hepatitis C virus-specific CD4(+) T-cell responses in anti-HCV-positive blood donors
    Bes M, Sauleda S, Campos-Varela I, Rodriguez-Frias F, Casamitjana N, Homs M, Piron M, Quer J, Tabernero D, Guardia J, Puig L, Esteban JI. J Viral Hepat. 2012 Dec;19(12):867-871. doi: 10.1111/j.1365-2893.2012.01631.x. Epub 2012 Jul 4.


  275. Prospects for Interferon-Free Treatment of Hepatitis C
    Stedman CA. J Gastroenterol Hepatol. 2012 Nov 9. doi: 10.1111/jgh.12028. [Epub ahead of print]


  276. Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients
    Tanaka T, Selzner N, Therapondos G, Renner EL, Lilly LB. Transpl Int. 2012 Nov 8. doi: 10.1111/j.1432-2277.2012.01571.x. [Epub ahead of print]


  277. Increased hepatitis C virus vaccine clinical trial literacy following a brief intervention among people who inject drugs
    White B, Madden A, Hellard M, Kerr T, Prins M, Page K, Dore GJ, Maher L. Drug Alcohol Rev. 2012 Nov 1. doi: 10.1111/dar.12000. [Epub ahead of print]


  278. Hepatitis C virus genotype 5: an orphan virus
    Antaki N, Abboud D, Antaki F, Craxi A. Antivir Ther. 2012 Oct 30. doi: 10.3851/IMP2449. [Epub ahead of print]


  279. Presentation and Prognosis of Cardiac Involvement in Hepatitis C Virus-Related Vasculitis
    Terrier B, Karras A, Cluzel P, Collet JP, Sène D, Saadoun D, Cacoub P. Am J Cardiol. 2012 Oct 29. pii: S0002-9149(12)02206-0. doi: 10.1016/j.amjcard.2012.09.028. [Epub ahead of print]


  280. A simple strategy to identify acute HCV infection among newly incarcerated injection drug users
    Kim AY, Nagami EH, Birch CE, Bowen MJ, Lauer GM, McGovern BH. Hepatology. 2012 Oct 30. doi: 10.1002/hep.26113. [Epub ahead of print]


  281. Checkmate to liver biopsy in chronic hepatitis C?
    Trifan A, Stanciu C. World J Gastroenterol. 2012 Oct 21;18(39):5514-20. doi: 10.3748/wjg.v18.i39.5514.


  282. Hepatitis C and renal transplantation
    Morales JM, Aguado JM. Curr Opin Organ Transplant. 2012 Dec;17(6):609-15. doi: 10.1097/MOT.0b013e32835a2bac.


  283. Perspectives and challenges of interferon-free therapy for chronic hepatitis C
    Lange CM, Zeuzem S. J Hepatol. 2012 Oct 24. pii: S0168-8278(12)00818-5. doi: 10.1016/j.jhep.2012.10.019. [Epub ahead of print]


  284. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: A prospective, multicenter study
    Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J. J Hepatol. 2012 Oct 22. pii: S0168-8278(12)00816-1. doi: 10.1016/j.jhep.2012.10.017. [Epub ahead of print]


  285. Promotion of hepatocellular carcinoma by hepatitis C virus
    Bühler S, Bartenschlager R. Dig Dis. 2012;30(5):445-52. doi: 10.1159/000341688. Epub 2012 Oct 24.


  286. Futility of antiviral treatments for hepatitis C: An evolving concept entering the direct antiviral agents era
    Bruno S, Mangia A. Dig Liver Dis. 2012 Oct 24. pii: S1590-8658(12)00369-6. doi: 10.1016/j.dld.2012.09.011. [Epub ahead of print]


  287. Host factors determining the efficacy of hepatitis C treatment
    Chuang WL, Yu ML. J Gastroenterol. 2012 Oct 27. [Epub ahead of print]


  288. The Role of Attachment Style and Depression in Patients with Hepatitis C
    Sockalingam S, Blank D, Jarad AA, Alosaimi F, Hirschfield G, Abbey SE. J Clin Psychol Med Settings. 2012 Oct 30. [Epub ahead of print]


  289. Hepatitis C Virus Infection, Mixed Cryoglobulinemia, and Kidney Disease
    Fabrizi F, Plaisier E, Saadoun D, Martin P, Messa P, Cacoub P. Am J Kidney Dis. 2012 Oct 25. pii: S0272-6386(12)01230-9. doi: 10.1053/j.ajkd.2012.08.040. [Epub ahead of print]


  290. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C
    Amorim TG, Staub GJ, Lazzarotto C, Silva AP, Manes J, Ferronato Mda G, Shiozawa MB, Narciso-Schiavon JL, Dantas-Correa EB, Schiavon Lde L. Ann Hepatol. 2012 Nov;11(6):855-61.


  291. Lipids and HCV
    Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RD. Semin Immunopathol. 2012 Oct 31. [Epub ahead of print]


  292. Association Between Chronic Hepatitis C Virus Infection and Bone Mineral Density
    Lin JC, Hsieh TY, Wu CC, Chen PJ, Chueh TH, Chang WK, Chu HC. Calcif Tissue Int. 2012 Oct 5. [Epub ahead of print]


  293. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin
    Zeuzem S, Rodríguez-Torres M, Rajender Reddy K, Marcellin P, Diago M, Craxi A, Pockros P, Rizzetto M, Bernstein D, Shiffman ML, Lin A, Tatsch F, Hadziyannis S. J Viral Hepat. 2012 Nov;19(11):766-774. doi: 10.1111/j.1365-2893.2012.01624.x. Epub 2012 May 14.


  294. Interferon therapy of acute hepatitis C in dialysis patients: meta-analysis
    Fabrizi F, Dixit V, Messa P, Martin P. J Viral Hepat. 2012 Nov;19(11):784-91. doi: 10.1111/j.1365-2893.2012.01607.x. Epub 2012 Mar 30.


  295. Allele-Specific PCR for Determination of IL28B Genotype
    Cook L, Diem K, Kim W, Scott JD, Jerome KR. J Clin Microbiol. 2012 Oct 10. [Epub ahead of print]


  296. Living donor liver transplantation for hepatitis C
    Takada Y, Uemoto S. Surg Today. 2012 Oct 6. [Epub ahead of print]


  297. Hepatitis C virus and other risk factors in hepatocellular carcinoma
    Schiefelbein E, Zekri AR, Newton DW, Soliman GA, Banerjee M, Hung ChW, Seifeldin IA, Lo AC, Soliman AS. Acta Virol. 2012;56(3):235-40.


  298. Cholestatic hepatitis C following liver transplantation: An outcome-based histological definition, clinical predictors and prognosis
    Verna EC, Abdelmessih R, Salomao MA, Lefkowitch J, Moreira RK, Brown RS Jr. Liver Transpl. 2012 Oct 18. doi: 10.1002/lt.23559. [Epub ahead of print]


  299. Biphasic pattern of depression and its predictors during pegylated interferon-based therapy in chronic hepatitis B and C patients
    Huang YW, Hu JT, Hu FC, Chang CJ, Chang HY, Kao JH, Yang SS, Chen DS. Antivir Ther. 2012 Oct 17. doi: 10.3851/IMP2441. [Epub ahead of print]


  300. Incidence of hepatitis C virus infection in patients on hemodialysis: A systematic review and meta-analysis
    Su Y, Norris JL, Zang C, Peng Z, Wang N. Hemodial Int. 2012 Oct 16. doi: 10.1111/j.1542-4758.2012.00761.x. [Epub ahead of print]


  301. Donor-Derived Infection: Epidemiology and Outcomes
    Kaul DR. Curr Infect Dis Rep. 2012 Oct 17. [Epub ahead of print]


  302. Why should infectious disease physicians care for the hepatitis C-infected patient?
    Godofsky E. Infect Dis Clin North Am. 2012 Dec;26(4):839-47. doi: 10.1016/j.idc.2012.08.001.


  303. Elevated Serum IL-8 Is Associated with the Presence of Hepatocellular Carcinoma and Independently Predicts Survival
    Welling TH, Fu S, Wan S, Zou W, Marrero JA. Cancer Invest. 2012 Oct 16. [Epub ahead of print]


  304. Staging of Liver Disease: Which Option is Right for My Patient?
    Bhogal H, Sterling RK. Infect Dis Clin North Am. 2012 Dec;26(4):849-61. doi: 10.1016/j.idc.2012.08.002.


  305. IL28B Polymorphisms as a Pretreatment Predictor of Response to HCV Treatment
    Berger CT, Kim AY. Infect Dis Clin North Am. 2012 Dec;26(4):863-77. doi: 10.1016/j.idc.2012.08.010.


  306. Type III Interferons, IL-28 and IL-29, Are Increased in Chronic HCV Infection and Induce Myeloid Dendritic Cell-Mediated FoxP3+ Regulatory T Cells
    Dolganiuc A, Kodys K, Marshall C, Saha B, Zhang S, Bala S, Szabo G. PLoS One. 2012;7(10):e44915. doi: 10.1371/journal.pone.0044915. Epub 2012 Oct 10.


  307. Tyrosine metabolism during interferon-alpha administration: Association with fatigue and CSF dopamine concentrations
    Felger JC, Li L, Marvar PJ, Woolwine BJ, Harrison DG, Raison CL, Miller AH. Brain Behav Immun. 2012 Oct 13. pii: S0889-1591(12)00472-2. doi: 10.1016/j.bbi.2012.10.010. [Epub ahead of print]


  308. A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy
    Yuan H, Adams-Huet B, Petersen T, Attar N, Lee WM, Jain MK. J Med Virol. 2012 Dec;84(12):1913-9. doi: 10.1002/jmv.23407.


  309. Accuracy of Rapid and Point-of-Care Screening Tests for Hepatitis C: A Systematic Review and Meta-analysis
    Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Ann Intern Med. 2012 Oct 16;157(8):558-66. doi: 10.7326/0003-4819-157-8-201210160-00006.


  310. Association between genetic mutations and the development of autoimmune thyroiditis in patients with chronic hepatitis C treated with interferon alpha
    Krupinska J, Urbanowicz W, Kaczmarczyk M, Kulig G, Sowinska-Przepiera EB, Andrysiak-Mamos EB, Syrenicz A. Thyroid Res. 2012 Oct 16;5(1):10. [Epub ahead of print]


  311. Radiofrequency ablation combined with transarterial chemoembolization for subcapsular hepatocellular carcinoma: A prospective cohort study
    Morimoto M, Numata K, Kondo M, Moriya S, Morita S, Maeda S, Tanaka K. Eur J Radiol. 2012 Oct 12. pii: S0720-048X(12)00450-0. doi: 10.1016/j.ejrad.2012.09.014. [Epub ahead of print]


  312. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: Analysis from the sprint-2 trial
    Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Reddy KR, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM. Hepatology. 2012 Oct 18. doi: 10.1002/hep.26096. [Epub ahead of print]


  313. Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy
    Martinez SM, Foucher J, Combis JM, Métivier S, Brunetto M, Capron D, Bourlière M, Bronowicki JP, Dao T, Maynard-Muet M, Lucidarme D, Merrouche W, Forns X, de Lédinghen V. PLoS One. 2012;7(10):e47715. doi: 10.1371/journal.pone.0047715. Epub 2012 Oct 17.


  314. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus
    Jenkins ET, Jensen DM. Infect Dis Clin North Am. 2012 Dec;26(4):879-91. doi: 10.1016/j.idc.2012.08.007.


  315. Approach to the Treatment-naïve Patient with HCV Genotype 1 Infection
    Muir AJ. Infect Dis Clin North Am. 2012 Dec;26(4):893-901. doi: 10.1016/j.idc.2012.08.012.


  316. Hepatitis C virus drug resistance: implications for clinical management
    Wyles DL. Infect Dis Clin North Am. 2012 Dec;26(4):967-78. doi: 10.1016/j.idc.2012.08.005.


  317. Hepatitis C virus-host interactions, replication, and viral assembly
    Shulla A, Randall G. Curr Opin Virol. 2012 Oct 17. pii: S1879-6257(12)00159-9. doi: 10.1016/j.coviro.2012.09.013. [Epub ahead of print]


  318. Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection
    Flemming JA, Terrault NA. Infect Dis Clin North Am. 2012 Dec;26(4):903-15. doi: 10.1016/j.idc.2012.08.008.


  319. Future classes of hepatitis C virus therapeutic agents
    Chen JY, Chung RT. Infect Dis Clin North Am. 2012 Dec;26(4):949-66. doi: 10.1016/j.idc.2012.08.003.


  320. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV
    Slim J, Afridi MS. Infect Dis Clin North Am. 2012 Dec;26(4):917-29. doi: 10.1016/j.idc.2012.08.006.


  321. Diagnosis and treatment of acute hepatitis C virus infection
    Boesecke C, Wedemeyer H, Rockstroh JK. Infect Dis Clin North Am. 2012 Dec;26(4):995-1010. doi: 10.1016/j.idc.2012.08.011.


  322. NK cells in hepatitis C: role in disease susceptibility and therapy
    Lunemann S, Schlaphoff V, Cornberg M, Wedemeyer H. Dig Dis. 2012;30 Suppl 1:48-54. doi: 10.1159/000341680. Epub 2012 Oct 11.


  323. Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response
    Weintraub SJ, Fleckenstein JF, Marion TN, Madey MA, Mahmoudi TM, Schechtman KB. Am J Clin Nutr. 2012 Sep 26. [Epub ahead of print]


  324. Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program
    Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. J Subst Abuse Treat. 2012 Oct 2. pii: S0740-5472(12)00142-0. doi: 10.1016/j.jsat.2012.08.007. [Epub ahead of print]


  325. Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with PegIFN and Ribavirin Depends on HCV Genotypes: Results from a Meta-Analysis
    Jia Z, Ding Y, Tian S, Niu J, Jiang J. PLoS One. 2012;7(9):e45698. doi: 10.1371/journal.pone.0045698. Epub 2012 Sep 21.


  326. Three polymorphisms in the IL-10 gene and the risk of HCV infection: a meta-analysis plus a Chinese Association Study involving 1140 subjects
    Li J, Liu Y, Xu F, Chen J, Chen Y. Epidemiol Infect. 2012 Sep 27:1-12. [Epub ahead of print]


  327. Host-targeting agents for prevention and treatment of viral hepatitis C- perspectives and challenges
    Zeisel MB, Lupberger J, Fofana I, Baumert TF. J Hepatol. 2012 Oct 4. pii: S0168-8278(12)00753-2. doi: 10.1016/j.jhep.2012.09.022. [Epub ahead of print]


  328. Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis
    Sogawa H, Shrager B, Jibara G, Tabrizian P, Roayaie S, Schwartz M. HPB (Oxford). 2012 Aug 30. doi: 10.1111/j.1477-2574.2012.00548.x. [Epub ahead of print]


  329. Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature
    Roed T, Lebech AM, Kjaer A, Weis N. Clin Physiol Funct Imaging. 2012 Nov;32(6):421-30. doi: 10.1111/j.1475-097X.2012.01152.x. Epub 2012 Jul 30.


  330. Bone alterations in hepatitis C virus infected patients
    Pelazas-González R, González-Reimers E, Alemán-Valls MR, Santolaria-Fernández F, López-Prieto J, González-Díaz A, Gómez-Sirvent JL, de la Vega-Prieto MJ. Eur J Intern Med. 2012 Sep 29. pii: S0953-6205(12)00245-2. doi: 10.1016/j.ejim.2012.09.007. [Epub ahead of print]


  331. Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients : an indirect comparison using Bayesian network meta-analysis
    Cure S, Diels J, Gavart S, Bianic F, Jones E. Curr Med Res Opin. 2012 Sep 27. [Epub ahead of print]


  332. Improvement of Thrombocytopenia in Hepatitis C-Related Advanced Fibrosis Patients After Sustained Virological Response
    Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Lu SN. Source Dig Dis Sci. 2012 Sep 22. [Epub ahead of print]


  333. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C
    Cie?la A, Boci?ga-Jasik M, Sobczyk-Krupiarz I, G?owacki MK, Owczarek D, Cibor D, Sanak M, Mach T. World J Gastroenterol. 2012 Sep 21;18(35):4892-7.


  334. Effectiveness of a Risk Screener in Identifying Hepatitis C Virus in a Primary Care Setting
    Drainoni ML, Litwin AH, Smith BD, Koppelman EA, McKee MD, Christiansen CL, Gifford AL, Weinbaum CM, Southern WN. Am J Public Health. 2012 Nov;102(11):e115-e121. Epub 2012 Sep 20.


  335. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population
    Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ. J Med Virol. 2012 Nov;84(11):1744-50. doi: 10.1002/jmv.23399.


  336. Clinical relevance of HCV antiviral drug resistance
    Welsch C, Zeuzem S. Curr Opin Virol. 2012 Sep 21. pii: S1879-6257(12)00134-4. doi: 10.1016/j.coviro.2012.08.008. [Epub ahead of print]


  337. IL28B polymorphism in hepatitis C and liver transplantation
    Duarte-Rojo A, Deneke MG, Charlton MR. Liver Transpl. 2012 Sep 24. doi: 10.1002/lt.23554. [Epub ahead of print]


  338. Treatment Response and Tolerability of Pegylated Interferon-? Plus Ribavirin Combination Therapy in elderly Patients (? 65 years) With Chronic Hepatitis C in Korea
    Kim HI, Kim IH, Jeon BJ, Lee S, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG. Hepat Mon. 2012 Jul;12(7):430-6. Epub 2012 Jul 30.


  339. BASELINE CHARACTERISTICS AND MORTALITY AMONG PEOPLE IN CARE FOR CHRONIC VIRAL HEPATITIS: THE CHRONIC HEPATITIS COHORT STUDY (CHeCS)
    Moorman AC, Gordon SC, Rupp LB, Spradling PR, Teshale EH, Lu M, Nerenz DR, Nakasato CC, Boscarino JA, Henkle EM, Oja-Tebbe NJ, Xing J, Ward JW, Holmberg SD; for the Chronic Hepatitis Cohort Study (CHeCS) Investigators. Clin Infect Dis. 2012 Sep 18. [Epub ahead of print]


  340. Predictive factors of sustained virological response for recurrent hepatitis C virus after liver transplantation: the hungarian experience
    Nemes B, Gelley F, Zádori G, Kiss A, Nagy P, Gerlei Z, Lengyel G, Sárváry E. Transplant Proc. 2012 Sep;44(7):2162-3. doi: 10.1016/j.transproceed.2012.07.099.


  341. Rapid and sharp decline in hepatitis C virus upon monotherapy with NS3 protease inhibitor, ACH-1625
    Agarwal A, Zhang B, Olek E, Robison H, Robarge L, Deshpande M. Antivir Ther. 2012 Sep 13. doi: 10.3851/IMP2359. [Epub ahead of print]


  342. Prediction of a favorable clinical course in hepatitis C virus carriers with persistently normal serum alanine aminotransferase levels: A long-term follow-up study
    Nishimura T, Yamaguchi K, Fujii H, Okada Y, Yokomizo C, Niimi T, Sumida Y, Yasui K, Mitsuyoshi H, Minami M, Umemura A, Shima T, Okanoue T, Itoh Y. Hepatol Res. 2012 Sep 14. doi: 10.1111/j.1872-034X.2012.01091.x. [Epub ahead of print]


  343. Monitoring the natural evolution and response to treatment of post liver transplant recurrent hepatitis C using transient elastography: preliminary results
    Bellido-Muñoz F, Giráldez-Gallego A, Roca-Oporto C, García-Cayuela T, Pascasio-Acevedo JM, Sousa-Martín JM. Transplant Proc. 2012 Sep;44(7):2082-6. doi: 10.1016/j.transproceed.2012.07.090.


  344. Measurement and Clinical Significance of Interleukin 28B in Hepatitis C Virus-Infected Liver Transplant Patients
    Gerlei Z, Sárváry E, Lengyel G, Görög D, Fehérvári I, Nemes B, Kóbori L, Langer RM. Transplant Proc. 2012 Sep;44(7):2154-6. doi: 10.1016/j.transproceed.2012.07.101.


  345. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection
    Himoto T, Masaki T. Clin Dev Immunol. 2012;2012:871401. Epub 2012 Sep 5. Department of Gastroenterology and Neurology, Kagawa University School of Medicine, Kagawa, Japan ; Department of Integrated Medicine, Kagawa University School of Medicine, 1750-1, Ikenobe, Miki-Cho, Kita-Gun, Kagawa 761-0793, Japan.


  346. Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C
    Chang MH, Gordon LA, Fung HB. Clin Ther. 2012 Sep 10. pii: S0149-2918(12)00490-0. doi: 10.1016/j.clinthera.2012.08.009. [Epub ahead of print]


  347. Chronic Pain Treatment and Health Service Utilization of Veterans with Hepatitis C Virus Infection
    Lovejoy TI, Dobscha SK, Cavanagh R, Turk DC, Morasco BJ.


  348. Ribavirin Enhances the Action of Interferon-? against Hepatitis C Virus by Promoting the p53 Activity through the ERK1/2 Pathway
    Liu WL, Yang HC, Su WC, Wang CC, Chen HL, Wang HY, Huang WH, Chen DS, Lai MY. PLoS One. 2012;7(9):e43824. Epub 2012 Sep 4.


  349. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study
    Kielland KB, Skaug K, Amundsen EJ, Dalgard O. J Hepatol. 2012 Sep 4. [Epub ahead of print]


  350. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs)
    Sheridan DA, Neely RD, Bassendine MF. Clin Res Hepatol Gastroenterol. 2012 Sep 5. [Epub ahead of print]


  351. High Predictability of a Sustained Virological Response (87%) in Chronic Hepatitis C Virus Genotype 1 Infection Treatment by Combined IL28B Genotype Analysis and ?-Glutamyltransferase/Alanine Aminotransferase Ratio: A Retrospective Single-Center Study
    Amanzada A, Goralczyk AD, Schneider S, Moriconi F, Lindhorst A, Mihm S, Van Thiel DH, Ramadori G. Digestion. 2012 Sep 5;86(3):218-227. [Epub ahead of print]


  352. Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C
    Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Lenaour G, Vaillant JC, Ratziu V, Charlotte F; the Fibrosis-TAGS group. Clin Res Hepatol Gastroenterol. 2012 Sep 5. [Epub ahead of print]


  353. Quantifying the fraction of cirrhosis attributable to alcohol among chronic HCV patients: Implications for treatment cost-effectiveness
    Innes HA, Hutchinson SJ, Barclay S, Cadzow E, Dillon JF, Fraser A, Goldberg DJ, Mills PR, McDonald SA, Morris J, Stanley A, Hayes P; on behalf of the Hepatitis C Clinical Database Monitoring Committee. Hepatology. 2012 Sep 7. doi: 10.1002/hep.26051. [Epub ahead of print]


  354. Racial Differences in the Association Between Adiposity Measures and the Risk of Hepatitis C-related Liver Disease
    White DL, Tavakoli-Tabasi S, Kuzniarek J, Ramsey DJ, El-Serag HB. J Clin Gastroenterol. 2012 Oct;46(9):779-788.


  355. Short report: Telaprevir-based triple therapy in liver transplanted HCV patients: A 12 week pilot study providing safety and efficacy
    Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP. Liver Transpl. 2012 Sep 1. doi: 10.1002/lt.23542. [Epub ahead of print]


  356. Telaprevir: A Hepatitis C NS3/4A Protease Inhibitor
    Matthews SJ, Lancaster JW.Clin Ther. 2012 Aug 27. [Epub ahead of print]


  357. A new tool to study ribavirin-induced haemolysis
    Brochot E, François C, Castelain S, Helle F, Van Nhien AN, Duchaussoy I, Capron D, Nguyen-Khac E, Duverlie G. Antivir Ther. 2012 Sep 5. doi: 10.3851/IMP2308. [Epub ahead of print]


  358. Intensified Peginterferon ?-2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density Lipoprotein
    Harrison SA, Abdurakhmanov D, Shiffman ML, Bakulin I, Mazur W, Rodriguez-Torres M, Silva GF, Cheinquer H, Messinger D, Connell EV, McKenna M, Tatsch F, Reddy KR; on behalf of the PROGRESS Investigators. J Clin Gastroenterol. 2012 Aug 30. [Epub ahead of print]


  359. Interferon-free hepatitis C therapy: how close are we?
    Pockros PJ. Drugs. 2012 Oct 1;72(14):1825-31. doi: 10.2165/11635560-000000000-00000.


  360. Assessment of the quality of evidence underlying international guidelines in liver disease
    Rowe IA, Parker R, Armstrong MJ, King AL, Houlihan DD, Mutimer D. Am J Gastroenterol. 2012 Sep;107(9):1276-82. doi: 10.1038/ajg.2012.71.


  361. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis
    Liu JY, Sheng YJ, Hu HD, Zhong Q, Wang J, Tong SW, Zhou Z, Zhang DZ, Hu P, Ren H. Virol J. 2012 Sep 6;9(1):186. [Epub ahead of print]


  362. Accumulation of platelets in the liver may be an important contributory factor to thrombocytopenia and liver fibrosis in chronic hepatitis C
    Kondo R, Yano H, Nakashima O, Tanikawa K, Nomura Y, Kage M. J Gastroenterol. 2012 Aug 22. [Epub ahead of print]


  363. Hepatitis C virus infection and nonalcoholic steatohepatitis
    Patel A, Harrison SA. Gastroenterol Hepatol (N Y). 2012 May;8(5):305-12.


  364. Insulin resistance in chronic hepatitis C: the search for effective drug treatment continues
    Harrison SA, Lincoln MJ, Roberts KK. Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):401-3.


  365. Genomic variation-guided management in chronic hepatitis C
    Hsu CS, Kao JH. Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):497-506.


  366. Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response
    Gupta S, Singh R. PLoS One. 2012;7(7):e41209. Epub 2012 Jul 24.


  367. Infectious disease. Calling all baby boomers: get your hepatitis C test
    Cohen J. Science. 2012 Aug 24;337(6097):903.


  368. The ongoing impacts of hepatitis c - a systematic narrative review of the literature
    Miller ER, McNally S, Wallace J, Schlichthorst M. BMC Public Health. 2012 Aug 18;12(1):672. [Epub ahead of print]


  369. HCV-Related Nervous System Disorders
    Monaco S, Ferrari S, Gajofatto A, Zanusso G, Mariotto S. Clin Dev Immunol. 2012;2012:236148. Epub 2012 Jul 30.


  370. Liver transplantation and hepatitis C
    Akamatsu N, Sugawara Y. Int J Hepatol. 2012;2012:686135. Epub 2012 Jul 26.


  371. New developments in the management of hepatitis C virus infection: focus on boceprevir
    Berenguer M, López-Labrador FX. Biologics. 2012;6:249-56. Epub 2012 Aug 3.


  372. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965
    Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. MMWR Recomm Rep. 2012 Aug 17;61(RR-4):1-32.


  373. Performance of an antigen-antibody combined assay for hepatitis C virus testing without venipuncture
    Larrat S, Bourdon C, Baccard M, Garnaud C, Mathieu S, Quesada JL, Signori-Schmuck A, Germi R, Blanc M, Leclercq P, Hilleret MN, Leroy V, Zarski JP, Morand P. J Clin Virol. 2012 Aug 14. [Epub ahead of print]


  374. Progress toward prevention and control of hepatitis C virus infection - egypt, 2001-2012
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep.2012 Jul 27;61:545-9.


  375. Hepatitis B and C Virus Infection Among 1.2 Million Persons With Access to Care: Factors Associated With Testing and Infection Prevalence
    Spradling PR, Rupp L, Moorman AC, Lu M, Teshale EH, Gordon SC, Nakasato C, Boscarino JA, Henkle EM, Nerenz DR, Denniston MM, Holmberg SD; the Chronic Hepatitis Cohort Study (CHeCS) Investigators. Clin Infect Dis. 2012 Aug 8. [Epub ahead of print]


  376. Process of Care for HCV Infection Is Linked to Treatment Outcome and Virologic Response
    Kanwal F, Hoang T, Chrusciel T, Kramer J, El-Serag H, Dominitz J, Asch SM. Clin Gastroenterol Hepatol. 2012 Jul 24. [Epub ahead of print]


  377. Immunological HCV-Associated Thrombocytopenia: Short Review
    Dimitroulis D, Valsami S, Stamopoulos P, Kouraklis G. Clin Dev Immunol. 2012;2012:378653. Epub 2012 Jul 10.


  378. An Examination of Liver Offers to Candidates on the Liver Transplant Wait-List
    Lai JC, Feng S, Roberts JP. Gastroenterology. 2012 Jul 26. [Epub ahead of print]


  379. Effect on HCV Replication by Combinations of Direct Acting Antivirals Including NS5A Inhibitor Daclatasvir
    Pelosi LA, Voss S, Liu M, Gao M, Lemm JA. Antimicrob Agents Chemother. 2012 Jul 30. [Epub ahead of print]


  380. Hepatitis C virus infection and mixed cryoglobulinemia
    Lauletta G, Russi S, Conteduca V, Sansonno L. Clin Dev Immunol. 2012;2012:502156. Epub 2012 Jul 10.


  381. Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis
    Farci P, Wollenberg K, Diaz G, Engle RE, Lai ME, Klenerman P, Purcell RH, Pybus OG, Alter HJ. Proc Natl Acad Sci U S A. 2012 Jul 24. [Epub ahead of print]


  382. Therapeutic Approach to the Treatment-Naive Patient With Hepatitis C Virus Genotype 1 Infection: A Step-by-Step Approach
    Sherman KE. Clin Infect Dis. 2012 Aug 8. [Epub ahead of print]


  383. Telaprevir and boceprevir in african americans with genotype 1 chronic hepatitis C: implications for patients and providers
    Burton MJ, Passarella MJ, McGuire BM. South Med J. 2012 Aug;105(8):431-6.


  384. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients
    Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, Torres HA. J Hepatol. 2012 Aug 4. [Epub ahead of print]


  385. Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection
    Joseph AM. Ther Adv Musculoskelet Dis. 2012 Feb;4(1):35-40.


  386. Review of Patient-Reported Outcome Measures in Chronic Hepatitis C
    Kleinman L, Mannix S, Yuan Y, Kummer S, L'italien G, Revicki D. Health Qual Life Outcomes. 2012 Aug 7;10(1):92. [Epub ahead of print]


  387. Vitamin D for Your Patients with Chronic Hepatitis C?
    Rahman AH, Branch AD. J Hepatol. 2012 Aug 4. [Epub ahead of print]


  388. New Pharmacotherapy for Hepatitis C
    Assis DN, Lim JK. Clin Pharmacol Ther. 2012 Aug 1. doi: 10.1038/clpt.2012.103. [Epub ahead of print]


  389. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin
    Kondo C, Atsukawa M, Tsubota A, Itokawa N, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Sakamoto C. J Viral Hepat. 2012 Sep;19(9):615-22. doi: 10.1111/j.1365-2893.2011.01584.x. Epub 2012 Feb 9.


  390. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?
    Fabrizi F, Dixit V, Messa P. J Viral Hepat. 2012 Sep;19(9):601-7. doi: 10.1111/j.1365-2893.2012.01633.x. Epub 2012 Jul 17.


  391. Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation
    Ackefors M, Gjertsen H, Wernerson A, Weiland O. J Viral Hepat. 2012 Sep;19(9):635-9. doi: 10.1111/j.1365-2893.2012.01587.x. Epub 2012 Feb 17.


  392. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus
    Feinstone SM, Hu DJ, Major ME. Clin Infect Dis. 2012 Jul;55 Suppl 1:S25-32.


  393. Hepatitis C virus infection in alcoholic hepatitis: prevalence patterns and impact on in-hospital mortality
    Singal AK, Kuo YF, Anand BS. Eur J Gastroenterol Hepatol. 2012 Jun 24. [Epub ahead of print]


  394. Effect of discounting on estimation of benefits determined by hepatitis C treatment.
    Messori A, Fadda V, Maratea D, Trippoli S. World J Gastroenterol. 2012 Jun 21;18(23):3032-4.


  395. Laboratory diagnostics for hepatitis C virus infection
    Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Clin Infect Dis. 2012 Jul;55 Suppl 1:S43-8.


  396. Global burden of hepatitis C: considerations for healthcare providers in the United States
    Averhoff FM, Glass N, Holtzman D. Clin Infect Dis. 2012 Jul;55 Suppl 1:S10-5.


  397. Evolving epidemiology of hepatitis C virus in the United States
    Klevens RM, Hu DJ, Jiles R, Holmberg SD. Clin Infect Dis. 2012 Jul;55 Suppl 1:S3-9.


  398. New perspectives in occult hepatitis C virus infection
    Carreño V, Bartolomé J, Castillo I, Quiroga JA. World J Gastroenterol. 2012 Jun 21;18(23):2887-94.


  399. Symptomatic Treatment of Interferon-?-Induced Depression in Hepatitis C: A Systematic Review
    Baraldi S, Hepgul N, Mondelli V, Pariante CM. J Clin Psychopharmacol. 2012 Aug;32(4):531-43.


  400. New perspectives in occult hepatitis C virus infection
    Carreño V, Bartolomé J, Castillo I, Quiroga JA. World J Gastroenterol. 2012 Jun 21;18(23):2887-94.


  401. Centers for disease control and prevention initiatives to prevent hepatitis C virus infection: a selective update
    Smith BD, Jorgensen C, Zibbell JE, Beckett GA. Clin Infect Dis. 2012 Jul;55 Suppl 1:S49-53.


  402. Investigation of residual hepatitis C virus in presumed recovered subjects
    Fujiwara K, Allison RD, Wang RY, Bare P, Matsuura K, Schechterly C, Murthy K, Marincola FM, Alter HJ. Hepatology. 2012 Jun 23. doi: 10.1002/hep.25921. [Epub ahead of print]


  403. Chronic Hepatitis C and Antiviral Treatment Regimens: Where Can Psychology Contribute?
    Evon DM, Golin CE, Fried MW, Keefe FJ. J Consult Clin Psychol. 2012 Jun 25. [Epub ahead of print]


  404. Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C
    Fox AN, Jacobson IM. Clin Infect Dis. 2012 Jul;55 Suppl 1:S16-24.


  405. Impact of ribavirin dose on retreatment of chronic hepatitis C patients
    Stern C, Martinot-Peignoux M, Ripault MP, Boyer N, Castelnau C, Valla D, Marcellin P. World J Gastroenterol. 2012 Jun 21;18(23):2966-72.


  406. Preventive versus
    Huisman EJ, van Hoek B, van Soest H, van Nieuwkerk KM, Arends JE, Siersema PD, van Erpecum KJ. J Hepatol. 2012 Jun 30. [Epub ahead of print]


  407. Hepatitis C therapy in non-genotype 1 patients: the near future
    Wartelle-Bladou C, Le Folgoc G, Bourlière M, Lecomte L. J Viral Hepat. 2012 Aug;19(8):525-36. doi: 10.1111/j.1365-2893.2012.01634.x.


  408. Racial Differences in Fibrosis Progression After HCV-Related Liver Transplantation
    Layden JE, Cotler S, Brown KA, Lucey MR, Te HS, Eswaran S, Fimmel C, Layden TJ, Clark NM. Transplantation. 2012 Jul 27;94(2):178-84.


  409. A Community-Based Cross-Sectional Study: The Association of Lipids with Hepatitis C Seropositivity and Diabetes Mellitus
    Liu JL, Chen JY, Chen CT, Wang JH, Lin CY, Chen PF, Hung CH, Kee KM, Lee CM, Tsai LS, Chen SC, Lin SC, Lu SN. J Gastroenterol Hepatol. 2012 Jun 28. doi: 10.1111/j.1440-1746.2012.07212.x. [Epub ahead of print]


  410. Assessing Long-Term Treatment Efficacy in Chronic Hepatitis B and C: Between Evidence and Common Sense
    Aghemo A, Lampertico P, Colombo M. J Hepatol. 2012 Jun 27. [Epub ahead of print]


  411. Peginterferon-?-2b and Ribavirin for Hepatitis C Recurrence Postorthotopic Liver Transplantation
    Gordon FD, Kwo P, Ghalib R, Crippin J, Vargas HE, Brown KA, Schiano T, Chaudhri E, Pedicone LD, Brown RS Jr. J Clin Gastroenterol. 2012 Jun 25. [Epub ahead of print]


  412. Fatigue Before, During and After Antiviral Therapy of Chronic Hepatitis C: Results from the Virahep-C Study
    Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. J Hepatol. 2012 Jul 1. [Epub ahead of print]


  413. Cytokinome Profile of Patients with Type 2 Diabetes and/or Chronic Hepatitis C Infection
    Costantini S, Capone F, Guerriero E, Marfella R, Sorice A, Maio P, Di Stasio M, Paolisso G, Castello G, Colonna G. PLoS One. 2012;7(6):e39486. Epub 2012 Jun 20.


  414. A 25-Year Study of the Clinical and Histologic Outcomes of Hepatitis C Virus Infection and Its Modes of Transmission in a Cohort of Initially Asymptomatic Blood Donors
    Allison RD, Conry-Cantilena C, Koziol D, Schechterly C, Ness P, Gibble J, Kleiner DE, Ghany MG, Alter HJ. J Infect Dis. 2012 Jul 20. [Epub ahead of print]


  415. Altered regional homogeneity in the development of minimal hepatic encephalopathy: a resting-state functional MRI study
    Ni L, Qi R, Zhang LJ, Zhong J, Zheng G, Zhang Z, Zhong Y, Xu Q, Liao W, Jiao Q, Wu X, Fan X, Lu GM. 12;7(7):e42016. Epub 2012 Jul 25.


  416. Escitalopram for the Prevention of Peginterferon-?2a-Associated Depression in Hepatitis C Virus-Infected Patients Without Previous Psychiatric Disease: A Randomized Trial
    Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, Spengler U, Schlaepfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T. Ann Intern Med. 2012 Jul 17;157(2):94-103.


  417. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial
    Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, Meyers CM, Reddy KR; Silymarin in NASH and C Hepatitis (SyNCH) Study Group. JAMA. 2012 Jul 18;308(3):274-82. Collaborators (38)


  418. Increased Risk of Severe Hepatitis C Virus Recurrence After Liver Transplantation in Patients With a T Allele of IL28B rs12979860
    Cisneros E, Baños I, Citores MJ, Duca A, Salas C, Noblejas A, Cañizares M, Millán I, Cuervas-Mons V, Vilches C. Transplantation. 2012 Jul 10. [Epub ahead of print]


  419. The Performance of Process Measures in Hepatitis C
    Kanwal F, Hoang T, Kramer J, Chrusciel T, El-Serag H, Dominitz JA, Asch SM. Am J Gastroenterol. 2012 Jul 10. doi: 10.1038/ajg.2012.201. [Epub ahead of print]


  420. Patients' Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection
    Kauf TL, Mohamed AF, Hauber AB, Fetzer D, Ahmad A. Patient. 2012 Jul 10. doi: 10.2165/11633580-000000000-00000. [Epub ahead of print]


  421. A review on an update of NS5B polymerase hepatitis C virus inhibitors
    Varshney J, Sharma PK, Sharma A. Eur Rev Med Pharmacol Sci. 2012 May;16(5):667-71.


  422. The Course of Posttransplant Hepatitis C Infection: Comparative Impact of Donor and Recipient Source of the Favorable IL28B Genotype and Other Variables
    Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt KD, Heimbach JK, McHutchison JG, Poterucha JJ, Vargas-Vorackova F, Charlton MR. Transplantation. 2012 Jul 27;94(2):197-203.


  423. HCV Infection Prevalence Lower Than Expected among 18-40-Year-Old Injection Drug Users in San Diego, CA
    Garfein RS, Rondinelli A, Barnes RF, Cuevas J, Metzner M, Velasquez M, Rodriguez D, Reilly M, Xing J, Teshale EH. J Urban Health. 2012 Jul 6. [Epub ahead of print]


  424. A formula to estimate the optimal dosage of ribavirin for the treatment of chronic hepatitis C: influence of ITPA polymorphisms
    Krishnan SM, Dixit NM. Antivir Ther. 2012 Jul 18. doi: 10.3851/IMP2251. [Epub ahead of print]


  425. Efficacy of antiviral therapy for hepatitis C post liver transplant on cyclosporine versus tacrolimus: A systematic review and meta-analysis
    Rabie R, Mumtaz K, Renner EL. Liver Transpl. 2012 Jul 23. doi: 10.1002/lt.23516. [Epub ahead of print]


  426. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus
    Rocco A, Compare D, Coccoli P, Esposito C, Di Spirito A, Barbato A, Strazzullo P, Nardone G. Gut. 2012 Jul 17. [Epub ahead of print]


  427. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the realize trial
    Meyer SD, Dierynck I, Ghys A, Beumont M, Daems B, Baelen BV, Sullivan JC, Bartels DJ, Kieffer TL, Zeuzem S, Picchio G. Hepatology. 2012 Jul 16. doi: 10.1002/hep.25962. [Epub ahead of print]


  428. HCV in liver transplantation
    Germani G, Tsochatzis E, Papastergiou V, Burroughs AK. Semin Immunopathol. 2012 Jul 25. [Epub ahead of print]


  429. Laboratory evaluation of rapid test kits to detect hepatitis?C antibody for use in predonation screening in emergency settings
    O'Connell RJ, Gates RG, Bautista CT, Imbach M, Eggleston JC, Beardsley SG, Manak MM, Gonzales R, Rentas FJ, Macdonald VW, Cardo LJ, Reiber DT, Stramer SL, Michael NL, Peel SA. Transfusion. 2012 Jul 23. doi: 10.1111/j.1537-2995.2012.03770.x. [Epub ahead of print]


  430. Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study
    Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ; for the R.E.V.E.A.L.-HCV Study Group. J Infect Dis. 2012 Aug;206(4):469-477. Epub 2012 Jul 17.


  431. Long-term antiviral treatment for recurrent hepatitis C after liver transplantation
    Bertuzzo VR, Cescon M, Morelli MC, Di Gioia P, Tamè M, Lorenzini S, Andreone P, Ercolani G, Del Gaudio M, Ravaioli M, Cucchetti A, Dazzi A, D'Errico-Grigioni A, Pinna AD. Dig Liver Dis. 2012 Jul 20. [Epub ahead of print]


  432. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus
    Feinstone SM, Hu DJ, Major ME. Clin Infect Dis. 2012 Jul;55 Suppl 1:S25-32.


  433. Hepatitis C virus infection in alcoholic hepatitis: prevalence patterns and impact on in-hospital mortality
    Singal AK, Kuo YF, Anand BS. Eur J Gastroenterol Hepatol. 2012 Jun 24. [Epub ahead of print]


  434. Effect of discounting on estimation of benefits determined by hepatitis C treatment.
    Messori A, Fadda V, Maratea D, Trippoli S. World J Gastroenterol. 2012 Jun 21;18(23):3032-4.


  435. Laboratory diagnostics for hepatitis C virus infection
    Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Clin Infect Dis. 2012 Jul;55 Suppl 1:S43-8.


  436. Global burden of hepatitis C: considerations for healthcare providers in the United States
    Averhoff FM, Glass N, Holtzman D. Clin Infect Dis. 2012 Jul;55 Suppl 1:S10-5.


  437. Evolving epidemiology of hepatitis C virus in the United States
    Klevens RM, Hu DJ, Jiles R, Holmberg SD. Clin Infect Dis. 2012 Jul;55 Suppl 1:S3-9.


  438. New perspectives in occult hepatitis C virus infection
    Carreño V, Bartolomé J, Castillo I, Quiroga JA. World J Gastroenterol. 2012 Jun 21;18(23):2887-94.


  439. Symptomatic Treatment of Interferon-?-Induced Depression in Hepatitis C: A Systematic Review
    Baraldi S, Hepgul N, Mondelli V, Pariante CM. J Clin Psychopharmacol. 2012 Aug;32(4):531-43.


  440. New perspectives in occult hepatitis C virus infection
    Carreño V, Bartolomé J, Castillo I, Quiroga JA. World J Gastroenterol. 2012 Jun 21;18(23):2887-94.


  441. Centers for disease control and prevention initiatives to prevent hepatitis C virus infection: a selective update
    Smith BD, Jorgensen C, Zibbell JE, Beckett GA. Clin Infect Dis. 2012 Jul;55 Suppl 1:S49-53.


  442. Investigation of residual hepatitis C virus in presumed recovered subjects
    Fujiwara K, Allison RD, Wang RY, Bare P, Matsuura K, Schechterly C, Murthy K, Marincola FM, Alter HJ. Hepatology. 2012 Jun 23. doi: 10.1002/hep.25921. [Epub ahead of print]


  443. Chronic Hepatitis C and Antiviral Treatment Regimens: Where Can Psychology Contribute?
    Evon DM, Golin CE, Fried MW, Keefe FJ. J Consult Clin Psychol. 2012 Jun 25. [Epub ahead of print]


  444. Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C
    Fox AN, Jacobson IM. Clin Infect Dis. 2012 Jul;55 Suppl 1:S16-24.


  445. Impact of ribavirin dose on retreatment of chronic hepatitis C patients
    Stern C, Martinot-Peignoux M, Ripault MP, Boyer N, Castelnau C, Valla D, Marcellin P. World J Gastroenterol. 2012 Jun 21;18(23):2966-72.


  446. Finasteride and Methadone Use and Risk of Advanced Hepatitis C Related Liver Disease
    White DL, Hashmi A, Ramsey DJ, Kuzniarek J, Tavakoli-Tabasi S, El-Serag HB. Dig Dis Sci. 2012 Jun 5. [Epub ahead of print]


  447. A Population-Based Study of the Epidemiology of Hepatitis C in a North American Population
    Julia U, Bruce TR, Douglas T, Yossel MG. J Hepatol. 2012 Jun 2. [Epub ahead of print]


  448. Results from a large-scale epidemiologic look-back investigation of improperly reprocessed endoscopy equipment
    Holodniy M, Oda G, Schirmer PL, Lucero CA, Khudyakov YE, Xia G, Lin Y, Valdiserri R, Duncan WE, Davey VJ, Cross GM. Infect Control Hosp Epidemiol. 2012 Jul;33(7):649-56. Epub 2012 May 7.


  449. A Meta-Analysis of the Existing Knowledge of Immunoreactivity against Hepatitis C Virus (HCV)
    Kim Y, Vaughan K, Greenbaum J, Peters B, Law M, Sette A. PLoS One. 2012;7(5):e38028. Epub 2012 May 31.


  450. The Burden of Untreated Hepatitis C Virus Infection: A US Patients' Perspective
    El Khoury AC, Vietri J, Prajapati G. Dig Dis Sci. 2012 Jun 5. [Epub ahead of print]


  451. Increased α-Fetoprotein Predicts Steatosis among Patients with Chronic Hepatitis C Genotype 4
    Mousa N, Gad Y, Abdel-Aziz A, Abd-Elaal I. Int J Hepatol. 2012;2012:636392. Epub 2012 May 14.


  452. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents
    Poordad F, Dieterich D. J Viral Hepat. 2012 Jul;19(7):449-64. doi: 10.1111/j.1365-2893.2012.01617.x.


  453. Assessment of factors associated with pre-diabetes in HCV infection including direct and dynamic measurements of insulin action
    Mukhtar NA, Ayala C, Maher JJ, Khalili M. J Viral Hepat. 2012 Jul;19(7):480-7. doi: 10.1111/j.1365-2893.2011.01568.x. Epub 2011 Dec 18.


  454. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin
    Guedj H, Guedj J, Negro F, Lagging M, Westin J, Bochud PY, Bibert S, Neumann AU; for the DITTO-HCV study group. J Viral Hepat. 2012 Jul;19(7):488-496. doi: 10.1111/j.1365-2893.2011.01569.x. Epub 2011 Dec 22.


  455. Serum ferritin levels in chronic hepatitis C patients during antiviral therapy and prediction of treatment response
    Barut S, Günal O, Erkorkmaz U. Scand J Infect Dis. 2012 Jun 10. [Epub ahead of print]


  456. Lipid profiling of pre-treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C
    Cobbold JF, Cox IJ, Brown AS, Williams HR, Goldin RD, Thomas HC, Thursz MR, Taylor-Robinson SD. Hepatol Res. 2012 Jul;42(7):714-20. doi: 10.1111/j.1872-034X.2012.00975.x.


  457. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C
    Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC. Am J Gastroenterol. 2012 Jun 12. doi: 10.1038/ajg.2012.137. [Epub ahead of print]


  458. Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials
    Aghemo A, Degasperi E, Colombo M. Dig Liver Dis. 2012 Jun 11. [Epub ahead of print]


  459. Hepatitis C Virus-Associated Primary Hepatocellular Carcinoma in Non-cirrhotic Patients
    Albeldawi M, Soliman M, Lopez R, Zein NN. Dig Dis Sci. 2012 Jun 14. [Epub ahead of print]


  460. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care
    Pearlman BL. www.thelancet.com/infectionPublished Online May 29, 2012 DOI:10.1016/S1473- 3099(12)70060-9


  461. Hepatitis C virus prevention, care, and treatment: from policy to practice
    Ward JW, Valdiserri RO, Koh HK. Clin Infect Dis. 2012 Jul;55 Suppl 1:S58-63.


  462. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication
    Metz P, Dazert E, Ruggieri A, Mazur J, Kaderali L, Kaul A, Zeuge U, Trippler M, Lohmann V, Binder M, Frese M, Bartenschlager R. Hepatology. 2012 Jun 18. doi: 10.1002/hep.25908. [Epub ahead of print]


  463. Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments
    Enjoji M, Kohjima M, Kotoh K, Nakamuta M. Int J Hepatol. 2012;2012:264017. Epub 2012 Jun 4.


  464. Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1
    Amanzada A, Schneider S, Moriconi F, Lindhorst A, Suermann T, van Thiel DH, Mihm S, Ramadori G. J Med Virol. 2012 Aug;84(8):1208-16. doi: 10.1002/jmv.23323.


  465. Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1
    Palmer M, Rubin R, Rustgi V; Taribavirin Viral Kinetic Study Group. Aliment Pharmacol Ther. 2012 Jun 19. doi: 10.1111/j.1365-2036.2012.05188.x. [Epub ahead of print]


  466. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma
    Khattab MA, Eslam M, Mousa YI, Ela-Adawy N, Fathy S, Shatat M, Abd-Aalhalim H, Kamal A, Sharawe MA. Ann Hepatol. 2012 Jul;11(4):487-94.


  467. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
    Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hézode C, Lim JK, Bronowicki JP, Abrams GA, Bräu N, Morris DW, Thuluvath PJ, Reindollar RW, Yin PD, Diva U, Hindes R, McPhee F, Hernandez D, Wind-Rotolo M, Hughes EA, Schnittman S. Lancet Infect Dis. 2012 Jun 15. [Epub ahead of print]


  468. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection
    Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S, Folgori A, Rehermann B. Hepatology. 2012 Jun 18. doi: 10.1002/hep.25897. [Epub ahead of print]


  469. Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients
    Rodríguez-Torres M, Burguera J, Hallman D, Rodríguez-Orengo J, Echeandia M. Ann Hepatol. 2012 Jul;11(4):450-63.


  470. Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection
    Vermehren J, Susser S, Berger A, Perner D, Peiffer KH, Allwinn R, Zeuzem S, Sarrazin C. J Clin Virol. 2012 Jun 12. [Epub ahead of print]


  471. Treating hepatitis C infection by targeting the host
    Salloum S, Tai AW. Transl Res. 2012 Jun;159(6):421-9. Epub 2012 Jan 10.


  472. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care
    Pearlman BL. Lancet Infect Dis. 2012 May 28. [Epub ahead of print]


  473. Interferon Responsiveness Does not Change in Treatment-Experienced Hepatitis C Subjects: Implications for Drug Development and Clinical Decisions
    Liu J, Florian J, Birnkrant D, Murray J, Jadhav PR. Clin Infect Dis. 2012 May 31. [Epub ahead of print]


  474. Basic answers to complicated questions for the course of chronic hepatitis C treatment
    Ormeci N, Erdem H. Expert Rev Gastroenterol Hepatol. 2012 Jun;6(3):371-82.


  475. Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection
    Jin R, Fossler MJ, McHutchison JG, Howell CD, Dowling TC. AAPS J. 2012 Sep;14(3):571-80. Epub 2012 May 26.


  476. Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined
    O'Leary JG, Neri MA, Trotter JF, Davis GL, Klintmalm GB. Transpl Int. 2012 May 30. doi: 10.1111/j.1432-2277.2012.01498.x. [Epub ahead of print]


  477. Hepatitis C among Clients of Health Care for the Homeless Primary Care Clinics
    Strehlow AJ, Robertson MJ, Zerger S, Rongey C, Arangua L, Farrell E, O'Sullivan A, Gelberg L. J Health Care Poor Underserved. 2012;23(2):811-33.


  478. Identifying newly acquired cases of hepatitis C using surveillance: a literature review
    Sacks-Davis R, VAN Gemert C, Bergeri I, Stoove M, Hellard M. Epidemiol Infect. 2012 Jun 1:1-10. [Epub ahead of print]


  479. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C
    Stättermayer AF, Rutter K, Beinhardt S, Scherzer TM, Stadlmayr A, Hofer H, Wrba F, Steindl-Munda P, Krebs M, Datz C, Trauner M, Ferenci P. J Hepatol. 2012 May 24. [Epub ahead of print]


  480. A sustained virological response prevents development of insulin resistance in chronic hepatitis C patients
    Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V, Colombo M. Hepatology. 2012 May 22. doi: 10.1002/hep.25867. [Epub ahead of print]


  481. Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients
    Lee SS, Roberts SK, Berak H, Dusheiko GM, Harley HA, Gane EJ, Husa P, Horsmans YJ, Hadziyannis SJ, Jenny Heathcote E, Messinger D, Tatsch F, Han KH, Ferenci P. Liver Int. 2012 May 24. doi: 10.1111/j.1478-3231.2012.02819.x. [Epub ahead of print]


  482. Refinement of stopping rules during treatment of hepatitis c-genotype 1 infection with boceprevir combined with peginterferon/ribavirin
    Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, Dinubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP. Hepatology. 2012 May 22. doi: 10.1002/hep.25865. [Epub ahead of print]


  483. Factors that Predict Response of Patients with HCV Infection to Boceprevir
    Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators. Gastroenterology. 2012 May 21. [Epub ahead of print]


  484. The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C
    Thomas E, Ghany MG, Liang TJ. Antivir Chem Chemother. 2012 May 16. doi: 10.3851/IMP2125. [Epub ahead of print]


  485. Association of HCV core antigen seropositivity with long-term mortality in patients on regular hemodialysis
    Kato A, Takita T, Furuhashi M, Fujimoto T, Suzuki H, Maruyama Y, Sakao Y, Miyajima H. Nephron Extra. 2012 Jan;2(1):76-86. Epub 2012 Mar 28.


  486. Unexpected Maintenance of Hepatitis C Viral Diversity Following Liver Transplantation
    Gray RR, Strickland SL, Veras NM, Goodenow MM, Pybus OG, Lemon SM, Fried MW, Nelson DR, Salemi M. J Virol. 2012 May 23. [Epub ahead of print]


  487. Effect of soy protein supplementation in patients with chronic hepatitis C: A randomized clinical trial
    Oliveira LP, de Jesus RP, Boulhosa RS, Mendes CM, Gnoatto MC, Lemaire DC, Toralles MB, Cavalcante LN, Lyra AC, Lyra LG. World J Gastroenterol. 2012 May 14;18(18):2203-11.


  488. Treatment of Recurrent HCV Infection Following Liver Transplantation: Results of a Multicenter, Randomized, versus placebo, Trial of ribavirin alone as maintenance therapy after one year of Peginterferon Alfa-2A plus Ribavirin
    Calmus Y, Duvoux C, Pageaux G, Wolf P, Rostaing L, Vanlemmens C, Botta-Fridlund D, Dharancy S, Gugenheim J, Durand F, Néau-Cransac M, Boillot O, Chazouillères O, Samelson L, Boudjema K, Samuel D. J Hepatol. 2012 May 18. [Epub ahead of print]


  489. Rewards program is the best and they have the most direct flights out of Newark. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
    Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J. J Hepatol. 2012 May 18. [Epub ahead of print]


  490. Cytokines and HCV-Related Disorders
    Fallahi P, Ferri C, Ferrari SM, Corrado A, Sansonno D, Antonelli A. Clin Dev Immunol. 2012;2012:468107. Epub 2012 May 7.


  491. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population
    Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Castille JM, Housset C, Ratziu V, Imbert-Bismut F. J Hepatol. 2012 May 18. [Epub ahead of print]


  492. Impact of disease severity on health care costs in patients with chronic hepatitis C (CHC) virus infection
    Gordon S, Pockros P, Terrault N, Hoop R, Buikema A, Nerenz D, Hamzeh F. Hepatology. 2012 May 18. doi: 10.1002/hep.25842. [Epub ahead of print]


  493. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/HIV Coinfection
    Lo Re V 3rd, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, Kostman JR, Tebas P, Leonard MB, Localio AR. Hepatology. 2012 May 22. doi: 10.1002/hep.25866. [Epub ahead of print]


  494. Association of chronic hepatitis C with recurrent brief depression
    Carta MG, Angst J, Moro MF, Mura G, Hardoy MC, Balestrieri C, Chessa L, Serra G, Lai ME, Farci P. J Affect Disord. 2012 May 18. [Epub ahead of print]


  495. Advances in the treatment of hepatitis C virus infection
    Thomas DL. Top Antivir Med. 2012 Apr;20(1):5-10.


  496. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus
    Barritt AS 4th, Fried MW. Gastroenterology. 2012 May;142(6):1314-1323.e1.


  497. Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection
    Kwo PY. Therap Adv Gastroenterol. 2012 May;5(3):179-88.


  498. Circulating Microparticles as Disease-Specific Biomarkers of Severity of Inflammation in Patients with Hepatitis C or Nonalcoholic Steatohepatitis
    Kornek M, Lynch M, Mehta SH, Lai M, Exley M, Afdhal NH, Schuppan D. Gastroenterology. 2012 Apr 23. [Epub ahead of print]


  499. Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals
    Naggie S, Sulkowski MS. Gastroenterology. 2012 May;142(6):1324-1334.e3.


  500. New virologic tools for management of chronic hepatitis B and C
    Chevaliez S, Rodriguez C, Pawlotsky JM. Gastroenterology. 2012 May;142(6):1303-1313.e1.


  501. Anti-hepatitis C virus drugs in development
    Schaefer EA, Chung RT. Gastroenterology. 2012 May;142(6):1340-1350.e1


  502. The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection
    Clark PJ, Thompson AJ, Zhu Q, Vock DM, Zhu M, Patel K, Harrison SA, Naggie S, Ge D, Tillmann HL, Urban TJ, Shianna K, Fellay J, Goodman Z, Noviello S, Pedicone LD, Afdhal N, Sulkowski M, Albrecht JK, Goldstein DB, McHutchison JG, Muir AJ. Dig Dis Sci. 2012 Apr 29. [Epub ahead of print]


  503. Hepatitis C virus therapeutics: at the end of the beginning
    Schooley RT. Top Antivir Med. 2012 Apr;20(1):17-9.


  504. Estimating incidence rates with misclassified disease status: a likelihood-based approach, with application to hepatitis C virus
    Shebl FM, El-Kamary SS, Shardell M, Langenberg P, Dorgham LS, Maguire JH, Magder LS. Int J Infect Dis. 2012 Apr 27. [Epub ahead of print]


  505. Viral hepatitis in liver transplantation
    Crespo G, Mariño Z, Navasa M, Forns X. Gastroenterology. 2012 May;142(6):1373-1383.e1.


  506. The impact of host metabolic factors on treatment outcome in chronic hepatitis C
    Savvoula S, Dimitrios C, George P, Spilios M, Christos T, John G. Gastroenterol Res Pract. 2012;2012:420156. Epub 2012 Apr 22.


  507. Notes from the field : hepatitis C virus infections among young adults - rural wisconsin, 2010
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2012 May 18;61:358.


  508. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-? and ribavirin
    Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Aliment Pharmacol Ther. 2012 May 16. doi: 10.1111/j.1365-2036.2012.05131.x. [Epub ahead of print]


  509. Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA
    Jewett A, Smith BD, Garfein RS, Cuevas-Mota J, Teshale EH, Weinbaum CM. J Clin Virol. 2012 Jul;54(3):213-7. Epub 2012 May 3.


  510. Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response
    Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Mehrnoush L, Salimi S, Kheradvar O. Hepat Mon. 2012 Mar;12(3):190-5. Epub 2012 Mar 28.


  511. Comprehensive analysis for viral elements and il28b polymorphisms in response to peginterferon plus ribavirin therapy in hcv-1b infection
    Maekawa S, Sakamoto M, Miura M, Kadokura M, Sueki R, Komase K, Shindo H, Komatsu N, Shindo K, Kanayama A, Ohmori T, Amemiya F, Takano S, Yamaguchi T, Nakayama Y, Kitamura T, Inoue T, Okada S, Enomoto N. Hepatology. 2012 May 10. doi: 10.1002/hep.25826. [Epub ahead of print]


  512. 'Les liaisons dangereuses': Hepatitis C, Rituximab and B-cell non-Hodgkin's lymphomas
    Marignani M, Fonzo Md, Begini P, Gigante E, Deli I, Pellicelli AM, Gallina S, de Santis E, Delle Fave G, Cox MC. World J Gastrointest Pharmacol Ther. 2012 Apr 6;3(2):21-8.


  513. Chronic hepatitis C: Treat or wait? Medical decision making in clinical practice
    Niederau C, Hüppe D, Zehnter E, Möller B, Heyne R, Christensen S, Pfaff R, Theilmeier A, Alshuth U, Mauss S. World J Gastroenterol. 2012 Mar 28;18(12):1339-47.


  514. Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12?weeks of pegylated interferon-?-2a plus ribavirin and RVR
    Restivo L, Zampino R, Guerrera B, Ruggiero L, Adinolfi LE. J Viral Hepat. 2012 May;19(5):346-53. doi: 10.1111/j.1365-2893.2011.01555.x. Epub 2011 Nov 9.


  515. Reliability and validity of a self-efficacy instrument for hepatitis C antiviral treatment regimens
    Bonner JE, Esserman D, Evon DM. J Viral Hepat. 2012 May;19(5):316-26. doi: 10.1111/j.1365-2893.2011.01550.x. Epub 2011 Nov 24.


  516. Response Guided Telaprevir Therapy in Prior Relapsers?: The Role of Bridging Data from Treatment-Naïve and Experienced Subjects
    Liu J, Jadhav PR, Amur S, Fleischer R, Hammerstrom T, Lewis L, Naeger L, O'Rear J, Pacanowski M, Robertson S, Seo S, Soon G, Birnkrant D. Hepatology. 2012 Apr 6. doi: 10.1002/hep.25764. [Epub ahead of print]


  517. Neuropsychological tools in hepatology: a survival guide for the clinician
    Montagnese S, Schiff S, De Rui M, Crossey MM, Amodio P, Taylor-Robinson SD. J Viral Hepat. 2012 May;19(5):307-15. doi: 10.1111/j.1365-2893.2012.01592.x.


  518. How can we utilize livers from advanced aged donors for liver transplantation for hepatitis C?
    Uemura T, Nikkel LE, Hollenbeak CS, Ramprasad V, Schaefer E, Kadry Z. Transpl Int. 2012 Apr 6. doi: 10.1111/j.1432-2277.2012.01474.x. [Epub ahead of print]


  519. Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity
    Stepanova M, Lam B, Younossi Y, Srishord MK, Younossi ZM. J Viral Hepat. 2012 May;19(5):341-5. doi: 10.1111/j.1365-2893.2011.01554.x. Epub 2011 Nov 9.


  520. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response
    Clark PJ, Thompson AJ, Zhu M, Vock DM, Zhu Q, Ge D, Patel K, Harrison SA, Urban TJ, Naggie S, Fellay J, Tillmann HL, Shianna K, Noviello S, Pedicone LD, Esteban R, Kwo P, Sulkowski MS, Afdhal N, Albrecht JK, Goldstein DB, McHutchison JG, Muir AJ; for the IDEAL investigators. J Viral Hepat. 2012 May;19(5):332-340. doi: 10.1111/j.1365-2893.2011.01553.x. Epub 2012 Feb 22.


  521. Hepatitis C virus network based classification of hepatocellular cirrhosis and carcinoma
    Huang T, Wang J, Cai YD, Yu H, Chou KC. PLoS One. 2012;7(4):e34460. Epub 2012 Apr 6.


  522. End-stage renal disease and African American race are independent predictors of mild liver fibrosis in patients with chronic hepatitis C infection
    Aslinia FM, Wasan SK, Mindikoglu AL, Adeyemo OA, Philosophe B, Drachenberg C, Howell CD. J Viral Hepat. 2012 May;19(5):371-6. doi: 10.1111/j.1365-2893.2011.01565.x. Epub 2012 Jan 16.


  523. Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography
    Masuzaki R, Tateishi R, Yoshida H, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Asaoka Y, Kondo Y, Goto T, Ikeda H, Shiina S, Omata M, Koike K. World J Gastroenterol. 2012 Mar 28;18(12):1385-90.


  524. The high comorbidity burden of the hepatitis C virus infected population in the United States
    Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM. BMC Infect Dis. 2012 Apr 11;12(1):86. [Epub ahead of print]


  525. Hepatitis C virus and the brain
    Fletcher NF, McKeating JA. J Viral Hepat. 2012 May;19(5):301-6. doi: 10.1111/j.1365-2893.2012.01591.x.


  526. The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan
    Russell M, Pauly MP, Moore CD, Chia C, Dorrell J, Cunanan RJ, Witt G, Martin S. Hepatology. 2012 Apr 5. doi: 10.1002/hep.25755. [Epub ahead of print]


  527. Hepatitis C Treatment Highlights from AASLD 2011
    Cooper C. Clin Infect Dis. 2012 Apr 4. [Epub ahead of print]


  528. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C
    Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM. Can J Gastroenterol. 2012 Apr;26(4):205-10.


  529. Recurrent hepatitis C after liver transplantation
    Sheiner P, Rochon C. Mt Sinai J Med. 2012 Mar;79(2):190-8. doi: 10.1002/msj.21300.


  530. Recurrent diseases following liver transplantation: current concepts
    Petrovic LM. Curr Opin Organ Transplant. 2012 Apr 11. [Epub ahead of print]


  531. Steroid-free living donor liver transplantation for HCV - a multicenter prospective cohort study in Japan
    Marubashi S, Umeshita K, Asahara T, Fujiwara K, Haga H, Hashimoto T, Hatakeyama K, Ichida T, Kanematsu T, Kitajima M, Kiyosawa K, Makuuchi M, Miyagawa S, Satomi S, Soejima Y, Takada Y, Tanaka N, Teraoka S, Monden M. Clin Transplant. 2012 Apr 16. doi: 10.1111/j.1399-0012.2012.01627.x. [Epub ahead of print]


  532. Comparison of hepatitis C virus treatment between incarcerated and community patients
    Rice JP, Burnett D, Tsotsis H, Lindstrom MJ, Cornett DD, Voermans P, Sawyer J, Striker R, Lucey MR. Hepatology. 2012 Apr 13. doi: 10.1002/hep.25770. [Epub ahead of print]


  533. Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C
    Petta S, Ferraro D, Cammà C, Cabibi D, Di Cristina A, Di Marco V, Di Stefano R, Grimaudo S, Mazzola A, Levrero M, Scazzone C, Craxì A. Antivir Ther. 2012 Apr 13. doi: 10.3851/IMP2100. [Epub ahead of print]


  534. Immediate versus delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis
    Deuffic-Burban S, Castel H, Wiegand J, Manns MP, Wedemeyer H, Mathurin P, Yazdanpanah Y. J Hepatol. 2012 Apr 17. [Epub ahead of print]


  535. Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in taiwan
    Liao SF, Yang HI, Lee MH, Chen CJ, Lee WC. PLoS One. 2012;7(4):e34779. Epub 2012 Apr 10.


  536. The H63D Mutation of the Hemochromatosis Gene is Associated with Sustained Virological Response in Chronic Hepatitis C Patients Treated with Interferon-Based Therapy: A Meta-Analysis
    Li SH, Zhao H, Ren YY, Liu YZ, Song G, Ding P, Ding YP, Wang GQ. Tohoku J Exp Med. 2012;226(4):293-9.


  537. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C
    Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J. J Viral Hepat. 2012 May;19 Suppl 2:1-26. doi: 10.1111/j.1365-2893.2012.01590.x.


  538. Prevalence of fibromyalgia among patients with chronic hepatitis C infection: relationship to viral characteristics and quality of life
    Mohammad A, Carey JJ, Storan E, Scarry M, Coughlan RJ, Lee JM. J Clin Gastroenterol. 2012 May;46(5):407-12.


  539. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials
    Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G. PLoS One. 2012;7(4):e34372. Epub 2012 Apr 12.


  540. Hepatitis C virus cryoglobulinemia and non-hodgkin lymphoma
    Jadali Z. Hepat Mon. 2012 Feb;12(2):85-91. Epub 2012 Feb 29.


  541. Antiviral treatment for cirrhosis due to hepatitis C: a review
    Somasundaram A, Venkataraman J. Singapore Med J. 2012 Apr;53(4):231-5.


  542. Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels
    Uto H, Mawatari S, Kumagai K, Ido A, Tsubouchi H. Hepat Mon. 2012 Feb;12(2):77-84. Epub 2012 Feb 29.


  543. National patterns and predictors of liver biopsy use for management of hepatitis C
    Groessl EJ, Liu L, Ho SB, Kanwal F, Gifford AL, Asch SM. J Hepatol. 2012 Apr 17. [Epub ahead of print]


  544. Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office
    Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A. Am J Gastroenterol. 2012 Apr 24. doi: 10.1038/ajg.2012.48. [Epub ahead of print]


  545. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection
    Clark BT, Garcia-Tsao G, Fraenkel L. Patient Prefer Adherence. 2012;6:285-95. Epub 2012 Apr 4.


  546. Noninvasive methods to assess liver disease in patients with hepatitis B or C
    Castera L. Gastroenterology. 2012 May;142(6):1293-1302.e4.


  547. Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C
    Neuman MG, Schmilovitz-Weiss H, Hilzenrat N, Bourliere M, Marcellin P, Trepo C, Mazulli T, Moussa G, Patel A, Baig AA, Cohen L. Int J Hepatol. 2012;2012:231210. Epub 2012 Feb 22.


  548. Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients
    Saito H, Ito K, Sugiyama M, Matsui T, Aoki Y, Imamura M, Murata K, Masaki N, Nomura H, Adachi H, Hige S, Enomoto N, Sakamoto N, Kurosaki M, Mizokami M, Watanabe S. Hepatol Res. 2012 Mar 29. doi: 10.1111/j.1872-034X.2012.01013.x. [Epub ahead of print]


  549. Development of new IL28B genotyping method using Invader Plus assay
    Kani S, Tanaka Y, Matsuura K, Watanabe T, Yatsuhashi H, Orito E, Inose K, Motojuku N, Wakimoto Y, Mizokami M. Microbiol Immunol. 2012 May;56(5):318-23. doi: 10.1111/j.1348-0421.2012.00439.x.


  550. Fish to meat intake ratio and cooking oils are associated with hepatitis C virus carriers with persistently normal alanine aminotransferase levels
    Otsuka M, Uchida Y, Kawaguchi T, Taniguchi E, Kawaguchi A, Kitani S, Itou M, Oriishi T, Kakuma T, Tanaka S, Yagi M, Sata M. Hepatol Res. 2012 Mar 29. doi: 10.1111/j.1872-034X.2012.01014.x. [Epub ahead of print]


  551. Epidemiology of viral hepatitis and hepatocellular carcinoma
    El-Serag HB. Gastroenterology. 2012 May;142(6):1264-1273.e1.


  552. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
    Welsch C, Jesudian A, Zeuzem S, Jacobson I. Gut. 2012 May;61 Suppl 1:i36-i46.


  553. Management of non-infectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey
    Terrier B, Krastinova E, Marie I, Launay D, Lacraz A, Belenotti P, de Saint-Martin L, Quemeneur T, Huart A, Bonnet F, Le Guenno G, Kahn JE, Hinschberger O, Rullier P, Diot E, Lazaro E, Bridoux F, Zénone T, Carrat F, Hermine O, Léger JM, Mariette X, Senet P, Plaisier E, Cacoub P. Blood. 2012 Apr 3. [Epub ahead of print]


  554. HCV infection, B-cell non-Hodgkin's lymphoma and immunochemotherapy: Evidence and open questions
    Cox MC, Aloe-Spiriti MA, Cavalieri E, Alma E, Gigante E, Begini P, Rebecchini C, Delle Fave G, Marignani M. World J Gastrointest Oncol. 2012 Mar 15;4(3):46-53.


  555. Vaniprevir with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C - a randomized phase 2 study
    Manns MP, Gane E, Rodriguez-Torres M, Stoehr A, Yeh CT, Marcellin P, Wiedmann RT, Hwang PM, Caro L, Barnard RJ, Lee AW; for the MK-7009 Protocol 007 Study Group*.Hepatology. 2012 Apr 2. doi: 10.1002/hep.25743. [Epub ahead of print]


  556. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy
    Giannini EG, Marenco S, Fazio V, Pieri G, Savarino V, Picciotto A. Liver Int. 2012 Apr 4. doi: 10.1111/j.1478-3231.2012.02798.x. [Epub ahead of print]


  557. The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C
    Brennan BJ, Morcos PN, Wang K, Blotner SD, Morrison R, Hagedorn CH, Marbury TC, Sulkowski M, Grippo JF. Aliment Pharmacol Ther. 2012 Apr 3. doi: 10.1111/j.1365-2036.2012.05079.x. [Epub ahead of print]


  558. Metabolic syndrome in patients with chronic hepatitis C virus genotype 1 infection who do not have obesity or type 2 diabetes
    Oliveira LP, Jesus RP, Boulhosa RS, Mendes CM, Lyra AC, Lyra LG. Clinics (Sao Paulo). 2012;67(3):219-23.


  559. Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors
    Reddy MB, Morcos PN, Le Pogam S, Ou Y, Frank K, Lave T, Smith P. Antimicrob Agents Chemother. 2012 Apr 2. [Epub ahead of print]


  560. Managing Viral Hepatitis C: HCV: New Opportunities, High CostTwo new biologics establish a higher standard of care. Managing these agents, however, will be highly complex
    Cawood J. Biotechnol Healthc. 2011 Fall;8(3):26-8.


  561. Response-guided peginterferon-alpha-2b plus ribavirin therapy for chronic hepatitis C patients with genotype 2 and high viral loads
    Sato K, Hashizume H, Yamazaki Y, Horiguchi N, Kakizaki S, Takagi H, Mori M; the Gunma Liver Study Group. Hepatol Res. 2012 Mar 8. doi: 10.1111/j.1872-034X.2012.00997.x. [Epub ahead of print]


  562. Coping strategies used by patients infected with hepatitis C virus who are facing medication costs
    Sanyal C, Ingram EL, Sketris IS, Peltekian KM, Kirkland S. Can J Hosp Pharm. 2011 Mar;64(2):131-40.


  563. Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies
    Saxena V, Terrault N. Curr Opin Organ Transplant. 2012 Apr 3. [Epub ahead of print]


  564. Hepatitis C therapy update
    Casey LC, Lee WM. Curr Opin Gastroenterol. 2012 May;28(3):188-92.


  565. Preemptive antiviral treatment for hepatitis C virus after living donor liver transplantation
    Sugawara Y, Tamura S, Yamashiki N, Kaneko J, Aoki T, Sakamoto Y, Hasegawa K, Kokudo N. Transplant Proc. 2012 Apr;44(3):791-3.


  566. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis
    Druyts E, Mills EJ, Nachega J, O'Regan C, Cooper CL. Clin Exp Gastroenterol. 2012;5:11-21. Epub 2012 Feb 14.


  567. Follow-up of mild alanine aminotransferase elevation identifies hidden hepatitis C in primary care
    Helsper C, van Essen G, Frijling BD, de Wit NJ. Br J Gen Pract. 2012 Mar;62(596):212-6.


  568. Detection of hepatitis C virus RNA in dried blood spots
    Bennett S, Gunson RN, McAllister GE, Hutchinson SJ, Goldberg DJ, Cameron SO, Carman WF. J Clin Virol. 2012 Mar 12. [Epub ahead of print]


  569. The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases
    Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Colletta C, Vandelli C, Cmet S, Ceriani E, Smirne C, Toniutto P, Pirisi M. J Med Virol. 2012 May;84(5):747-55. doi: 10.1002/jmv.23259.


  570. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials
    Lee LY, Tong CY, Wong T, Wilkinson M. Int J Clin Pract. 2012 Apr;66(4):342-55. doi: 10.1111/j.1742-1241.2012.02895.x.


  571. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
    Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O'Regan C, Mills EJ. Ther Clin Risk Manag. 2012;8:105-30. Epub 2012 Mar 9.


  572. Economic Burden of Hepatitis C-Associated Diseases: Europe, Asia Pacific, and The Americas
    El Khoury AC, Wallace C, Klimack WK, Razavi H. J Med Econ. 2012 Mar 30. [Epub ahead of print]


  573. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
    Cammà C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, Cicchetti A, Colombo GL, Di Marco V, Gasbarrini A, Craxì A; on behalf of the WEF Study Group.. Hepatology. 2012 Mar 27. doi: 10.1002/hep.25734. [Epub ahead of print]


  574. IL28B SNP of donors and recipients can predict virological response to PEGIFN/RBV therapy in patients with recurrent hepatitis C after living donor liver transplantation
    Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H, Chayama K. J Gastroenterol Hepatol. 2012 Mar 20. doi: 10.1111/j.1440-1746.2012.07129.x. [Epub ahead of print]


  575. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus
    Kobayashi M, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Hosaka T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Miyakawa Y, Kumada H. J Gastroenterol. 2012 Mar 23. [Epub ahead of print]


  576. Association of hepatitis C virus with insulin resistance: evidences from animal studies and clinical studies
    Badar S, Khubaib B, Idrees M, Hussain A, Awan Z, Butt S, Afzal S, Akram M, Fatima Z, Aftab M, Saleem S, Munir S, Rauff B, Naudhani M, Ali L, Ali M, Rehman I. Hepat Mon. 2012 Jan;12(1):11-5. Epub 2012 Jan 20.


  577. New and Evolving Management Paradigms for Hepatitis C after Liver Transplantation
    Barritt AS 4th, Darling JM, Hayashi PH. Curr Hepat Rep. 2011 Sep;10(3):179-185.


  578. Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus
    Verna EC, Valadao R, Farrand E, Pichardo EM, Lai JC, Terrault NA, Brown RS Jr. Liver Transpl. 2012 Apr;18(4):461-7. doi: 10.1002/lt.23376.


  579. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C
    Perry CM. Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000.


  580. Hepatic Methionine-enkephalin may interfere with response to antiviral therapy in chronic hepatitis C
    Floreani A, Antoniazzi S, Mescoli C, Bergasa NV. Eur J Gastroenterol Hepatol. 2012 Apr;24(4):427-30.


  581. The interaction of metabolic factors with HCV infection: does it matter?
    Bugianesi E, Salamone F, Negro F. J Hepatol. 2012;56 Suppl 1:S56-65.


  582. Early viral load and recipient IL28B rs12979860 genotype are predictors for progression of hepatitis C after liver transplantation
    Graziadei IW, Zoller HM, Schloegl A, Nachbaur K, Pfeiffer KP, Mark W, Mikuz G, Pratschke J, Margreiter R, Vogel W. Liver Transpl. 2012 Feb 2. doi: 10.1002/lt.23402. [Epub ahead of print]


  583. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients
    Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. Ann Hepatol. 2012 Mar;11(2):179-85.


  584. Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity
    Welker MW, Reichert D, Susser S, Sarrazin C, Martinez Y, Herrmann E, Zeuzem S, Piiper A, Kronenberger B. PLoS One. 2012;7(2):e30796. Epub 2012 Feb 15.


  585. Natural History, Risk Factors And Management Of Hepatitis C After Liver Transplantation
    Mukherjee S. Inflamm Allergy Drug Targets. 2012 Feb 2. [Epub ahead of print]


  586. Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients
    Giannelli V, Giusto M, Farcomeni A, Ponziani FR, Pompili M, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Morelli MC, De Martin E, Miglioresi L, Di Paolo D, Fagiuoli S, Merli M; AISF RECOLT-C group study. Transpl Int. 2012 Feb 21. doi: 10.1111/j.1432-2277.2012.01440.x. [Epub ahead of print]


  587. The role of humoral innate immunity in hepatitis C virus infection
    Tarr AW, Urbanowicz RA, Ball JK. Viruses. 2012 Jan;4(1):1-27. Epub 2012 Jan 5.


  588. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients
    Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, Hyogo H, Kimura Y, Miki D, Hiraga N, Imamura M, Takahashi S, Ochi H, Hayes CN, Tanaka S, Arihiro K, Chayama K. J Gastroenterol. 2012 Feb 18. [Epub ahead of print]


  589. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk
    Litwin AH, Smith BD, Drainoni ML, McKee D, Gifford AL, Koppelman E, Christiansen CL, Weinbaum CM, Southern WN. Dig Liver Dis. 2012 Feb 17. [Epub ahead of print]


  590. Differential Antigen Specificity of Hepatitis C Virus-Specific Interleukin 17- and Interferon ?-Producing CD8+ T Cells During Chronic Infection
    Grafmueller S, Billerbeck E, Blum HE, Neumann-Haefelin C, Thimme R. J Infect Dis. 2012 Feb 20. [Epub ahead of print]


  591. Consumption of n-3 Fatty Acids and Fish Reduces Risk of Hepatocellular Carcinoma
    Sawada N, Inoue M, Iwasaki M, Sasazuki S, Shimazu T, Yamaji T, Takashi R, Tanaka Y, Mizokami M, Tsugane S; Japan Public Health Center-based Prospective StudyGroup.. Gastroenterology. 2012 Feb 16. [Epub ahead of print]


  592. Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon-? and Ribavirin Therapy in HCV/HIV-1 Coinfected Patients
    de Castellarnau M, Aparicio E, Parera M, Franco S, Tural C, Clotet B, Martínez MA. PLoS One. 2012;7(2):e31016. Epub 2012 Feb 6.


  593. Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus mediated liver disease post-transplantation
    Diamond DL, Krasnoselsky AL, Burnum KE, Monroe ME, Webb-Robertson BJ, McDermott JE, Yeh MM, Golib Dzib JF, Susnow N, Strom S, Proll SC, Belisle SE, Purdy DE, Rasmussen AL, Walters KA, Jacobs JM, Gritsenko MA, Camp DG, Bhattacharya R, Perkins JD, Carithers RL Jr, Liou IW, Larson AM, Benecke A, Waters KM, Smith RD, Katze MG. Hepatology. 2012 Feb 13. doi: 10.1002/hep.25649. [Epub ahead of print]


  594. Occupational transmission of hepatitis C in healthcare workers and factors associated with seroconversion: UK surveillance data
    Tomkins SE, Elford J, Nichols T, Aston J, Cliffe SJ, Roy K, Grime P, Ncube FM. J Viral Hepat. 2012 Mar;19(3):199-204. doi: 10.1111/j.1365-2893.2011.01543.x. Epub 2011 Oct 19.


  595. Outcomes of liver transplantation in HCV-HIV coinfected recipients
    Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, Ragni MV, Barin B, Simon D, Olthoff KM, Johnson L, Stosor V, Jayaweera D, Fung J, Sherman KE, Subramanian A, Michael Millis J, Slakey D, Berg CL, Carlson L, Ferrell L, Stablein DM, Odim J, Fox L, Stock PG; for the HIV-TR Investigators.. Liver Transpl. 2012 Feb 12. doi: 10.1002/lt.23411. [Epub ahead of print]


  596. Causes of Thrombocytopenia in Chronic Hepatitis C Viral Infection
    Osada M, Kaneko M, Sakamoto M, Endoh M, Takigawa K, Suzuki-Inoue K, Inoue O, Satoh K, Enomoto N, Yatomi Y, Ozaki Y. Clin Appl Thromb Hemost. 2012 Feb 12. [Epub ahead of print]


  597. Telaprevir for the treatment of hepatitis C
    Forestier N, Zeuzem S. Expert Opin Pharmacother. 2012 Mar;13(4):593-606. Epub 2012 Feb 15.


  598. Pegylated interferon-associated retinopathy is frequent in HCV patients with hypertension and justifies ophthalmologic screening
    Vujosevic S, Tempesta D, Noventa F, Midena E, Sebastiani G. Hepatology. 2012 Feb 13. doi: 10.1002/hep.25654. [Epub ahead of print]


  599. Review and management of drug interactions with boceprevir and telaprevir
    Kiser JJ, Burton JR, Anderson PL, Everson GT. Hepatology. 2012 Feb 13. doi: 10.1002/hep.25653. [Epub ahead of print]


  600. Pegylated interferon-? induced hypoferremia is associated with the immediate response to treatment in hepatitis C
    Ryan J, Altamura S, Devitt E, Mullins S, Lawless M, Muckenthaler M, Crowe J. Hepatology. 2012 Feb 15. doi: 10.1002/hep.25666. [Epub ahead of print]


  601. The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings
    David B. Rein, PhD; Bryce D. Smith, PhD; John S. Wittenborn, BS; Sarah B. Lesesne, BS; Laura D. Wagner, MPH; Douglas W. Roblin, PhD;Nita Patel, DrPH; John W. Ward, MD; and Cindy M. Weinbaum, MD, MPH. Ann Intern Med. 2012;156:263-270.


  602. New Protease Inhibitors for the Treatment of Chronic Hepatitis C A Cost-Effectiveness Analysis
    Shan Liu, SM; Lauren E. Cipriano, BSc, BA; Mark Holodniy, MD; Douglas K. Owens, MD, MS; and Jeremy D. Goldhaber-Fiebert, PhD. Ann Intern Med. 2012;156:279-290.


  603. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007
    Kathleen N. Ly, MPH; Jian Xing, PhD; R. Monina Klevens, DDS, MPH; Ruth B. Jiles, PhD, MPH; John W. Ward, MD; andScott D. Holmberg, MD, MPH. Ann Intern Med. 2012;156:271-278.


  604. Hepatitis C: The End of the Beginning and Possibly the Beginning of the End.
    Alter HJ, Liang TJ. Annals of Internal Medicine 2012, Feb21. Volume 156 • Number 4 317


  605. Economic burden of hepatitis C-associated diseases in the United States
    El Khoury AC, Klimack WK, Wallace C, Razavi H. J Viral Hepat. 2012 Mar;19(3):153-60. doi: 10.1111/j.1365-2893.2011.01563.x. Epub 2011 Dec 18.


  606. Depressive and anxiety disorders in chronic hepatitis C patients: Reliability and validity of the Patient Health Questionnaire
    Navinés R, Castellví P, Moreno-España J, Gimenez D, Udina M, Cañizares S, Diez-Quevedo C, Valdés M, Solà R, Martín-Santos R. J Affect Disord. 2012 Feb 10. [Epub ahead of print]


  607. Update on alisporivir in treatment of viral hepatitis C
    Flisiak R, Jaroszewicz J, Flisiak I, Lapi?ski T. Expert Opin Investig Drugs. 2012 Mar;21(3):375-82. Epub 2012 Feb 8.


  608. Serum IL-33 Levels Are Associated with Liver Damage in Patients with Chronic Hepatitis C
    Wang J, Zhao P, Guo H, Sun X, Jiang Z, Xu L, Feng J, Niu J, Jiang Y. Mediators Inflamm. 2012;2012:819636. Epub 2012 Jan 24.


  609. The Impact of IL28B Genotype on the Gene Expression Profile of Patients with Chronic Hepatitis C Treated with Pegylated Interferon Alpha and Ribavirin
    Younossi ZM, Birerdinc A, Estep M, Stepanova M, Afendy A, Baranova A. J Transl Med. 2012 Feb 7;10(1):25. [Epub ahead of print]


  610. A Predictive Model of Treatment Outcome in Patients with Chronic HCV Infection Using IL-28B and PD-1 Genotyping
    Ramón VC, Antonio LV, Rebeca AA, Antonio MG, Santiago M, Jesús P, Rosario LR, Paloma SC, Luis R, Rosa PL, Ramón PA, Carlos LL. J Hepatol. 2012 Feb 6. [Epub ahead of print]


  611. Continuous interferon-?2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients
    Roomer R, Bergmann JF, Boonstra A, Hansen BE, Haagmans BL, Kwadijk-de Gijsel S, van Vuuren AJ, de Knegt RJ, Janssen HL. Antivir Ther. 2011 Dec 13. doi: 10.3851/IMP2016. [Epub ahead of print]


  612. Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis
    Aizawa N, Enomoto H, Imanishi H, Saito M, Iwata Y, Tanaka H, Ikeda N, Sakai Y, Takashima T, Iwai T, Moriwaki E, Shimomura S, Iijima H, Nakamura H, Nishiguchi S. World J Hepatol. 2012 Jan 27;4(1):11-7.


  613. LD_HCV_TMC435
    Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, Lenz O, Peeters M, Sekar V, De Smedt G. J Hepatol. 2012 Feb 9. [Epub ahead of print]


  614. Antiviral strategies in hepatitis C virus infection
    Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. J Hepatol. 2012;56 Suppl:S88-S100.


  615. Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2
    Yamaguchi Y, Tamori A, Tanaka Y, Iwai S, Kobayashi S, Fujii H, Morikawa H, Hagihara A, Enomoto M, Kawada N. Hepatol Res. 2012 Feb 9. doi: 10.1111/j.1872-034X.2011.00956.x. [Epub ahead of print]


  616. A Phase 1, Randomized, Placebo-Controlled, Three-Day, Dose-Ranging Study of GS-5885, an NS5A Inhibitor, in Patients with Genotype 1 Hepatitis C
    Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM. J Hepatol. 2012 Feb 4. [Epub ahead of print]


  617. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, Jensen D. J Hepatol. 2012 Feb 4. [Epub ahead of print]


  618. Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection
    Cholongitas E, Theocharidou E, Goulis J, Tsochatzis E, Akriviadis E, Burroughs K. Aliment Pharmacol Ther. 2012 Mar;35(6):634-46. doi: 10.1111/j.1365-2036.2012.05000.x. Epub 2012 Feb 8.


  619. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients
    Baur K, Mertens JC, Schmitt J, Iwata R, Stieger B, Frei P, Seifert B, Ferrari HA, von Eckardstein A, Müllhaupt B, Geier A; the Swiss Hepatitis C Cohort Study Group. Antivir Ther. 2011 Dec 14. doi: 10.3851/IMP2018. [Epub ahead of print]


  620. GB virus C: the good boy virus?
    Bhattarai N, Stapleton JT. Trends Microbiol. 2012 Feb 8. [Epub ahead of print]


  621. Gambarin-Gelwan M, Jacobson IM. Curr Gastroenterol Rep. 2011 Dec 10. [Epub ahead of print]
    Source Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, 1305 York Ave, 4th floor, New York, NY, 10021, USA, mag2046@med.cornell.edu.


  622. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients
    Butt AA, Kanwal F. Clin Infect Dis. 2012 Jan;54(1):96-104. Epub 2011 Dec 7.


  623. Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons
    Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA. Clin Infect Dis. 2011 Dec 14. [Epub ahead of print]


  624. Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation
    Maharshak N, Halfon P, Deutsch V, Peretz H, Berliner S, Fishman S, Zelber-Sagi S, Rozovski U, Leshno M, Oren R. World J Gastroenterol. 2011 Dec 7;17(45):5007-13.


  625. Hepatic STAT1-Nuclear Translocation and Interleukin 28B Polymorphisms Predict Treatment Outcomes in Hepatitis C Virus Genotype 1-Infected Patients
    Miyamura T, Kanda T, Nakamoto S, Wu S, Fujiwara K, Imazeki F, Yokosuka O. PLoS One. 2011;6(12):e28617. Epub 2011 Dec 12.


  626. Neutralizing antibody response to hepatitis C virus
    Wang Y, Keck ZY, Foung SK. Viruses. 2011 Nov;3(11):2127-45. Epub 2011 Nov 2.


  627. Current Perspective of HCV NS5B Inhibitors: A Review
    Patil VM, Gupta SP, Samanta S, Masand N. Curr Med Chem. 2011 Dec 1;18(36):5564-97.


  628. Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons
    Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA. Clin Infect Dis. 2011 Dec 14. [Epub ahead of print]


  629. HCV and HCC: Clinical Update and a Review of HCC-Associated Viral Mutations in the Core Gene
    Ahmad J, Eng FJ, Branch AD. Semin Liver Dis. 2011 Nov;31(4):347-55. Epub 2011 Dec 21.


  630. Transmission of hepatitis C virus through transplanted organs and tissue - kentucky and massachusetts, 2011
    Centers for Disease Control and Prevention (CDC).AbstractMMWR Morb Mortal Wkly Rep. 2011 Dec 23;60:1697-700.


  631. Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B
    Dahari H, Guedj J, Perelson AS, Layden TJ. Curr Hepat Rep. 2011 Jul 2;10(3):214-227.


  632. Hepatitis C infection among recent initiates to injecting in England 2000-2008: Is a national hepatitis C action plan making a difference?
    Hope V, Parry JV, Marongui A, Ncube F. J Viral Hepat. 2012 Jan;19(1):55-64. doi: 10.1111/j.1365-2893.2010.01415.x. Epub 2011 Jan 7.


  633. The dependence of viral RNA replication on co-opted host factors
    Nagy PD, Pogany J. Nat Rev Microbiol. 2011 Dec 19. doi: 10.1038/nrmicro2692. [Epub ahead of print]


  634. Efficacy of splenectomy in preventing anemia in patients with recurrent hepatitis C following liver transplantation is not dependent on inosine triphosphate pyrophosphatase genotype
    Motomura T, Koga E, Taketomi A, Fukuhara T, Mano Y, Muto J, Konishi H, Toshima T, Uchiyama H, Yoshizumi T, Shirabe K, Maehara Y. Hepatol Res. 2011 Dec 19. doi: 10.1111/j.1872-034X.2011.00927.x. [Epub ahead of print]


  635. A summary of the 18th international symposium on hepatitis C virus and related viruses
    Polyak SJ, Morishima C, Scott JD, Cox A, de Araújo ES, Higgs MR, Loo YM, Golden-Mason L, Lindenbach BD, Baumert TF, Randall G, Gale M Jr. Gastroenterology. 2012 Jan;142(1):e1-5.


  636. Telaprevir: An oral protease inhibitor for hepatitis C virus infection
    Kim JJ, Culley CM, Mohammad RA. Am J Health Syst Pharm. 2012 Jan 1;69(1):19-33.


  637. HCV routes of transmission: what goes around comes around
    Alter MJ. Semin Liver Dis. 2011 Nov;31(4):340-6. Epub 2011 Dec 21.


  638. IL28B polymorphisms influence stage of the liver fibrosis and spontaneousor interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection
    Di Marco V, Bronte F, Calvaruso V, Capra M, Borsellino Z, Maggio A, Renda MC, Pitrolo L, Lo Pinto MC, Rizzo M, Fiorenza F, Gerardi C, Grimaudo S, Di Cristina A, Levrero M, Craxi' A. Haematologica. 2011 Dec 16. [Epub ahead of print]


  639. Association of Interleukin-28B and Hepatitis C Genotype 1 with a High Viral Load and Response to Pegylated Interferon plus Ribavirin Therapy
    Takita M, Hagiwara S, Arizumi T, Hayaishi S, Ueda T, Kitai S, Yada N, Inoue T, Minami Y, Chung H, Ueshima K, Sakurai T, Kudo M. Digestion. 2011;84 Suppl 1:56-61. Epub 2011 Dec 2.


  640. Interleukin28B and Inosine Triphosphatase Help to Personalize Hepatitis C Treatment
    Tanaka Y. Digestion. 2011;84 Suppl 1:50-5. Epub 2011 Dec 2.


  641. What is killing people with hepatitis C virus infection?
    Grebely J, Dore GJ. Semin Liver Dis. 2011 Nov;31(4):331-9. Epub 2011 Dec 21.


  642. Hepatitis C virus infection and genetic susceptibility to therapy
    Sibbing B, Nattermann J. J Gastrointestin Liver Dis. 2011 Dec;20(4):397-406.


  643. Determinants of Serum Alpha-Fetoprotein Levels in Hepatitis C Infected Patients
    Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB. Clin Gastroenterol Hepatol. 2011 Dec 6. [Epub ahead of print]


  644. Telaprevir: looking for a sustained virologic response in hepatitis C virus infection
    Nehra V, Rizza SA, Talwani R, Temesgen Z. Drugs Today (Barc). 2011 Nov;47(11):829-37.


  645. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients
    Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD. PLoS One. 2011;6(12):e26783. Epub 2011 Dec 2.


  646. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C-associated cryoglobulinemic vasculitis
    Sneller MC, Hu Z, Langford CA. Arthritis Rheum. 2011 Dec 6. doi: 10.1002/art.34322. [Epub ahead of print]


  647. Sperm DNA damage in patients with chronic viral C hepatitis
    La Vignera S, Condorelli RA, Vicari E, D'Agata R, Calogero AE. Eur J Intern Med. 2012 Jan;23(1):e19-24. Epub 2011 Sep 3.


  648. Telaprevir for the treatment of chronic hepatitis C infection. Expert Rev Anti Infect Ther.
    Muir AJ. Expert Rev Anti Infect Ther. 2011 Dec;9(12):1105-14.


  649. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C
    Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, Lok AS; for the HALT-C Trial Group. Liver Int. 2011 Nov 22. doi: 10.1111/j.1478-3231.2011.02686.x. [Epub ahead of print]


  650. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
    Nelson DR, Zeuzem S, Andreone P, Ferenci P, Herring R, Jensen DM, Marcellin P, Pockros PJ, Rodríguez-Torres M, Rossaro L, Rustgi VK, Sepe T, Sulkowski M, Thomason IR, Yoshida EM, Chan A, Hill G. Ann Hepatol. 2012 Jan;11(1):15-31.


  651. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus
    Patel K, Friedrich-Rust M, Lurie Y, Grigorescu M, Stanciu C, Lee CM, Schiff ER, Häussinger D, Manns MP, Gerken G, Colle I, Torbenson M, Pulkstenis E, Subramanian GM, McHutchison JG, Zeuzem S. World J Gastroenterol. 2011 Nov 7;17(41):4581-9.


  652. Specific Detection of Naturally Occurring Telaprevir and Boceprevir (Protease Inhibitors) HCV Resistant Mutants among Treatment Naive Infected Individuals
    Fonseca-Coronado S, Escobar-Gutiérrez A, Ruiz-Tovar K, Cruz-Rivera MY, Rivera-Osorio P, Vazquez-Pichardo M, Carpio-Pedroza JC, Ruíz-Pacheco JA, Cazares F, Vaughan G. J Clin Microbiol. 2011 Nov 23. [Epub ahead of print]


  653. Clinical significance of occult hepatitis B virus infection in chronic hepatitis C patients
    Jang JY, Jeong SW, Cheon SR, Lee SH, Kim SG, Cheon YK, Kim YS, Cho YD, Kim HS, Jin SY, Kim YS, Kim BS. Korean J Hepatol. 2011 Sep;17(3):206-12. doi: 10.3350/kjhep.2011.17.3.206.


  654. Interferon Free Hepatitis C Treatment Regimens: The Beginning of Another Era
    Poordad F, Chee GM. Curr Gastroenterol Rep. 2011 Nov 22. [Epub ahead of print]


  655. Female Sex and IL28B, a Synergism for Spontaneous Viral Clearance in Hepatitis C Virus (HCV) Seroconverters from a Community-Based Cohort
    van den Berg CH, Grady BP, Schinkel J, van de Laar T, Molenkamp R, van Houdt R, Coutinho RA, van Baarle D, Prins M. PLoS One. 2011;6(11):e27555. Epub 2011 Nov 15.


  656. Association between Chronic Viral Hepatitis Infection and Breast Cancer Risk: a Nationwide Population-based Case-control Study
    Su FH, Chang SN, Chen PC, Sung FC, Su CT, Yeh CC. BMC Cancer. 2011 Nov 24;11(1):495. [Epub ahead of print]


  657. Telaprevir for the treatment of chronic hepatitis C infection
    Muir AJ. Expert Rev Anti Infect Ther. 2011 Dec;9(12):1105-14.


  658. Absenteeism and productivity among employees being treated for hepatitis C
    Brook RA, Kleinman NL, Su J, Corey-Lisle PK, Iloeje UH. Am J Manag Care. 2011 Oct;17(10):657-64.


  659. The natural history of hepatitis C virus infection acquired during childhood
    Robinson JL, Doucette K. Liver Int. 2011 Sep 11. doi: 10.1111/j.1478-3231.2011.02633.x. [Epub ahead of print]


  660. Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade
    Lai M, Afdhal NH. Am J Gastroenterol. 2011 Dec;106(12):2121-2. doi: 10.1038/ajg.2011.343.


  661. Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and ?-fetoprotein levels
    Kajiwara E, Ooho A, Yamashita N. Hepatol Res. 2011 Dec 5. doi: 10.1111/j.1872-034X.2011.00916.x. [Epub ahead of print]


  662. Hepatitis C Virus Infects the Endothelial Cells of the Blood-Brain Barrier
    Fletcher NF, Wilson GK, Murray J, Hu K, Lewis A, Reynolds GM, Stamataki Z, Meredith LW, Rowe IA, Luo G, Lopez-Ramirez MA, Baumert TF, Weksler B, Couraud PO, Kim KS, Romero IA, Jopling C, Morgello S, Balfe P, McKeating JA. Gastroenterology. 2011 Nov 30. [Epub ahead of print]


  663. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent HCV after liver transplantation: Systematic review and meta-analysis
    Adebajo CO, Talwalkar JA, Poterucha JJ, Kim WR, Charlton MR. Liver Transpl. 2011 Dec 5. doi: 10.1002/lt.22460. [Epub ahead of print]


  664. A seven gene signature of the recipient predicts progression of fibrosis after liver transplantation for hepatitis C infection
    do O NT, Eurich D, Schmitz P, Schmeding M, Heidenhain C, Bahra M, Trautwein C, Neuhaus P, Neumann UP, Wasmuth HE. Liver Transpl. 2011 Dec 5. doi: 10.1002/lt.22475. [Epub ahead of print]


  665. Very Low Viral Load (VLVL) Relapse Following Treatment of Naïve Patients with Chronic Hepatitis C
    Hoefs JC, Aulakh VS, Ilagan BJ. Dig Dis Sci. 2011 Dec 4. [Epub ahead of print]


  666. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus
    Tungol A, Rademacher K, Schafer JA. J Manag Care Pharm. 2011 Nov;17(9):685-94.


  667. Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection
    Osaki R, Nishimura T, Shioya M, Takeuchi T, Okumura Y, Nakahara T, Bamba S, Nakajo S, Fujiyama Y, Andoh A. Mol Med Report. 2011 Nov 1. doi: 10.3892/mmr.2011.655. [Epub ahead of print]


  668. Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3
    Lee SS, Sherman M, Ramji A, Greenbloom S, Elkashab M, Pluta H, Hilzenrat N, Balshaw R, Usaty C, Myers RP. Aliment Pharmacol Ther. 2011 Nov 2. doi: 10.1111/j.1365-2036.2011.04911.x. [Epub ahead of print]


  669. Causes and evaluation of mildly elevated liver transaminase levels
    Oh RC, Hustead TR. Am Fam Physician. 2011 Nov 1;84(9):1003-8.


  670. The role of neutralising antibodies in hepatitis C virus infection
    Edwards V, Tarr AW, Urbanowicz R, Ball J. J Gen Virol. 2011 Nov 2. [Epub ahead of print]


  671. Novel Approach for Quantification of Hepatitis C Virus in Liver Cirrhosis Using Real-Time Reverse Transcriptase PCR
    Maudar KK, Gandhi P, Mishra PK, Varshney S, Punde R, Bhargav A. J Gastrointest Surg. 2011 Nov 3. [Epub ahead of print]


  672. Boceprevir
    Rizza SA, Talwani R, Nehra V, Temesgen Z. Drugs Today (Barc). 2011 Oct;47(10):743-51.


  673. Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
    Reddy KR, Belle SH, Fried MW, Afdhal NH, Navarro VJ, Hawke RL, Wahed AS, Doo E, Meyers CM. Clin Trials. 2011 Nov 4. [Epub ahead of print]


  674. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B
    Li S, Hu P, Zhang QQ, Liu YH, Hu HD, Zhang DZ, Ren H. Hepat Mon. 2011 Mar 1;11(3):163-172.


  675. Recombination in hepatitis C virus
    González-Candelas F, López-Labrador FX, Bracho MA. Viruses. 2011 Oct;3(10):2006-24. Epub 2011 Oct 24.


  676. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy
    Hung CH, Chen CH, Lu SN, Wang JH, Hu TH, Huang CM, Tsai MC, Lee CM. Antiviral Res. 2011 Oct 28. [Epub ahead of print]


  677. Implications of rapid virological response in hepatitis C therapy in the US veteran population
    Hwang EW, Thomas IC, Cheung R, Backus LI. Aliment Pharmacol Ther. 2011 Nov 7. doi: 10.1111/j.1365-2036.2011.04903.x. [Epub ahead of print]


  678. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
    Kwong AD, Kauffman RS, Hurter P, Mueller P. Nat Biotechnol. 2011 Nov 8;29(11):993-1003. doi: 10.1038/nbt.2020.


  679. Hepatitis C core Ag and its clinical applicability: Potential advantages and disadvantages for diagnosis and follow-up?
    Hosseini-Moghaddam S, Iran-Pour E, Rotstein C, Husain S, Lilly L, Renner E, Mazzulli T. Rev Med Virol. 2011 Nov 24. doi: 10.1002/rmv.717. [Epub ahead of print]


  680. Economic model of a birth cohort screening program for hepatitis C virus
    McGarry LJ, Pawar VS, Parekh HH, Rubin JL, Davis GL, Younossi ZM, Capretta JC, O'Grady MJ, Weinstein MC. Hepatology. 2011 Dec 2. doi: 10.1002/hep.25510. [Epub ahead of print]


  681. Role of LDL receptor in the hepatitis c virus life cycle
    Albecka A, Belouzard S, de Beeck AO, Descamps V, Goueslain L, Bertrand-Michel J, Tercé F, Duverlie G, Rouillé Y, Dubuisson J. Hepatology. 2011 Nov 26. doi: 10.1002/hep.25501. [Epub ahead of print]


  682. Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy
    Lötsch J, Hofmann WP, Schlecker C, Zeuzem S, Geisslinger G, Ultsch A, Doehring A. Pharmacogenomics. 2011 Dec;12(12):1729-40.


  683. Association between the epidermal growth factor rs4444903 G/G genotype and advanced fibrosis at a young age in chronic hepatitis C
    Falleti E, Cmet S, Fabris C, Bitetto D, Cussigh A, Fornasiere E, Bignulin E, Feruglio C, Mosanghini E, Fontanini E, Pirisi M, Toniutto P. Cytokine. 2011 Nov 26. [Epub ahead of print]


  684. Hepatitis C and non-Hodgkin lymphoma: The clinical perspective
    Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatology. 2011 Nov 26. doi: 10.1002/hep.25499. [Epub ahead of print]


  685. Diabetes Mellitus Following Liver Transplantation in Patients With Hepatitis C Virus: Risks and Consequences
    Gane EJ. Am J Transplant. 2011 Nov 28. doi: 10.1111/j.1600-6143.2011.03854.x. [Epub ahead of print]


  686. Toward the Establishment of a Prediction System for the Personalized Treatment of Chronic Hepatitis C
    Ochi H, Hayes CN, Abe H, Hayashida Y, Uchiyama T, Kamatani N, Nakamura Y, Chayama K. J Infect Dis. 2011 Nov 28. [Epub ahead of print]


  687. Improved hepatitis C treatment response in younger patients: findings from the UK HCV National Register cohort study
    Harris HE, Costella A, Amirthalingam G, Alexander G, Ramsay ME, Andrews N; the UK HCV National Register Collaborators. Epidemiol Infect. 2011 Nov 29:1-8. [Epub ahead of print]


  688. Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy
    Farinati F, Giacomin A, Vanin V, Sergio A, Burra P, Cillo U, Di Nolfo A, Del Poggio P, Benvegnu L, Zoli M, Borzio F, Giannini EG, Caturelli E, Cazzagon N, Rapaccini GL, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Eur J Gastroenterol Hepatol. 2011 Nov 18. [Epub ahead of print]


  689. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study
    Osaki Y, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, Nishikawa H, Saito S, Henmi S, Sakamoto A, Eso Y, Chiba T. J Gastroenterol. 2011 Nov 23. [Epub ahead of print]


  690. 65-gene-based risk score classifier predicts overall survival in hepatocellular carcinoma
    Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ, Kim DG, Kaseb A, Park YN, Wang XW, Thorgeirsson SS, Lee JS. Hepatology. 2011 Nov 22. doi: 10.1002/hep.24813. [Epub ahead of print]


  691. Are Patients with Child's A Cirrhosis and Hepatocellular Carcinoma Appropriate Candidates for Liver Transplantation?
    Berry K, Ioannou GN. Am J Transplant. 2011 Nov 28. doi: 10.1111/j.1600-6143.2011.03853.x. [Epub ahead of print]


  692. Subtle Hepatocellular Carcinoma: A Persisting Role for Alpha-Fetoprotein Monitoring in High-Risk Patients with Cirrhosis
    Schlansky B, Dobos N, Zaman A. Case Rep Gastroenterol. 2011 Sep;5(3):565-568. Epub 2011 Oct 1.


  693. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation
    He J, Zeng ZC, Fan J, Zhou J, Sun J, Chen B, Yang P, Wang BL, Zhang BH, Zhang JY. BMC Cancer. 2011 Nov 22;11(1):492. [Epub ahead of print]


  694. Genetic variants in HLA-DP/DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development
    Hu L, Zhai X, Liu J, Chu M, Pan S, Jiang J, Zhang Y, Wang H, Chen J, Shen H, Hu Z. Hepatology. 2011 Nov 22. doi: 10.1002/hep.24799. [Epub ahead of print]


  695. Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region
    Kawaoka T, Aikata H, Miyaki D, Murakami E, Azakami T, Takaki S, Nagaoki Y, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Tashiro H, Ohdan H, Chayama K. Hepatol Res. 2011 Nov;41(11):1126-31. doi: 10.1111/j.1872-034X.2011.00853.x.


  696. Genetic Variation of the IL-28B Promoter Affecting Gene Expression
    Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M. PLoS One. 2011;6(10):e26620. Epub 2011 Oct 25.


  697. Serum HCV RNA level is not associated with insulin resistance and metabolic syndrome in chronic hepatitis C patients with genotype 1 or 2 infection
    Huang HC, Chuang CS, Hsieh YY, Chang TS, Wei KL, Shen CH, Wu CS, Tung SY. Chang Gung Med J. 2011 Sep;34(5):487-95.


  698. Management of recurrent hepatitis C infection after liver transplantation
    Limaye AR, Firpi RJ. Clin Liver Dis. 2011 Nov;15(4):845-58.


  699. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C
    Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. Aliment Pharmacol Ther. 2011 Oct 28. doi: 10.1111/j.1365-2036.2011.04897.x. [Epub ahead of print]


  700. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response
    Muir AJ, Poordad FF, McHutchison JG, Shiffman ML, Berg T, Ferenci P, Heathcote EJ, Pawlotsky JM, Zeuzem S, Reesink HW, Dusheiko G, Martin EC, George S, Kauffman RS, Adda N. Hepatology. 2011 Nov;54(5):1538-46. doi: 10.1002/hep.24549.


  701. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care
    Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE, Dillon JF, Forrest E, Fraser A, Gillespie R, Goldberg DJ, Kennedy N, McDonald S, McLeod A, Mills PR, Morris J, Hayes P; on behalf of the Hepatitis C Clinical Database Monitoring Committee.. Hepatology. 2011 Nov;54(5):1547-1558. doi: 10.1002/hep.24561.


  702. An Italian study on health-related quality of life and fatigue in patients with chronic fatigue syndrome and patients with chronic HCV virus infection: similarities and differences
    Racciatti D, Gorgoretti V, Sepede G, Gambi F, Pizzigallo E. Int J Immunopathol Pharmacol. 2011 Jul-Sep;24(3):673-81.


  703. Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin
    Arends JE, Fransen JH, Hoepelman AI, van Baarle D. Int J Antimicrob Agents. 2011 Oct 3. [Epub ahead of print]


  704. Chronic viral hepatitis and risk of lymphoid malignancies: A retrospective twelve-year population-based cohort study in Côte d'Or, France
    Proby C, Minello A, Quantin C, Jooste V, Binquet C, Hägi M, Mounier M, Benzenine E, Hillon P, Maynadié M. Dig Liver Dis. 2011 Oct 3. [Epub ahead of print]


  705. Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C
    Park SH, Kim CH, Kim DJ, Suk KT, Park JH, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Park HY, Kim YB. Clin Biochem. 2011 Sep 28. [Epub ahead of print]


  706. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy
    Lee C. Arch Pharm Res. 2011 Sep;34(9):1403-7.


  707. The study of relationship between neutropenia and infection during treatment with peginterferon ? and ribavirin for chronic hepatitis C
    Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. Eur J Gastroenterol Hepatol. 2011 Oct 1. [Epub ahead of print]


  708. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C
    Golden-Mason L, Bambha KM, Cheng L, Howell CD, Taylor MW, Clark PJ, Afdhal N, Rosen HR; on behalf of the Virahep?C Study Group. Hepatology. 2011 Jul 11. doi: 10.1002/hep.24556. [Epub ahead of print]


  709. Body piercing and tattoos: a survey on young adults' knowledge of the risks and practices in body art
    Quaranta A, Napoli C, Fasano F, Montagna C, Caggiano G, Montagna MT. BMC Public Health. 2011 Oct 7;11(1):774. [Epub ahead of print]


  710. High Plasma Interleukin-18 Levels Mark the Acute Phase of Hepatitis C Virus Infection
    Chattergoon MA, Levine JS, Latanich R, Osburn WO, Thomas DL, Cox AL. J Infect Dis. 2011 Oct 7. [Epub ahead of print]


  711. Effect of Previous Interferon Treatment on Outcome After Curative Treatment for Hepatitis C Virus-Related Hepatocellular Carcinoma
    Miyatake H, Kobayashi Y, Iwasaki Y, Nakamura SI, Ohnishi H, Kuwaki K, Toshimori J, Hagihara H, Nouso K, Yamamoto K. Dig Dis Sci. 2011 Oct 12. [Epub ahead of print]


  712. Retrospective Chart Review to Assess the Relationship Between Depression and Sustained Virological Response From Interferon Treatment for Hepatitis C Virus
    Wackernah RC, Lou M, Park SH. Clin Ther. 2011 Oct 7. [Epub ahead of print]


  713. Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders
    Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H. Hepatology. 2011 Oct 10. doi: 10.1002/hep.24724. [Epub ahead of print]


  714. Association of coffee and caffeine consumption with fatty liver disease, non-alcoholic steatohepatitis, and degree of hepatic fibrosis
    Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Hepatology. 2011 Oct 10. doi: 10.1002/hep.24731. [Epub ahead of print]


  715. Upper limits of normal for alanine aminotransferase activity in the united states population
    Ruhl E, Everhart JE. Hepatology. 2011 Oct 10. doi: 10.1002/hep.24725. [Epub ahead of print]


  716. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview
    Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, Agresti M, Caraglia M, Sperlongano P. J Transl Med. 2011 Oct 10;9(1):171. [Epub ahead of print]


  717. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection
    Grebely J, Pham ST, Matthews GV, Petoumenos K, Bull RA, Yeung B, Rawlinson W, Kaldor J, Lloyd A, Hellard M, Dore GJ, White PA; On behalf of the ATAHC Study Group. Hepatology. 2011 Oct 26. doi: 10.1002/hep.24754. [Epub ahead of print]


  718. The COBAS(®) TaqMan(®) hepatitis C virus assays: automated systems for accurate and sensitive viral load quantification
    Colucci G, Knobel R. Expert Rev Mol Diagn. 2011 Nov;11(8):793-8.


  719. Notes from the field: risk factors for hepatitis C virus infections among young adults --- massachusetts, 2010
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 Oct 28;60:1457-8.


  720. Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-?2b plus ribavirin
    Ueyama M, Nakagawa M, Sakamoto N, Onozuka I, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Kitazume A, Murakawa M, Nishimura-Sakurai Y, Sekine-Osajima Y, Itsui Y, Azuma S, Kakinuma S, Watanabe M; the Ochanomizu-Liver Conference Study Group. Antivir Ther. 2011;16(7):1081-1091.


  721. Effects of Anti-Viral Therapy and HCV Clearance on Cerebral Metabolism and Cognition
    Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, Lenkinski R, Afdhal NH. J Hepatol. 2011 Oct 22. [Epub ahead of print]


  722. Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients
    Shindo H, Maekawa S, Komase K, Sueki R, Miura M, Kadokura M, Shindo K, Amemiya F, Kitamura T, Nakayama Y, Inoue T, Sakamoto M, Okada SI, Asahina Y, Izumi N, Honda M, Kaneko S, Enomoto N. Hepatol Int. 2011 Aug 18. [Epub ahead of print]


  723. Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection
    Wiegand J, Neumann K, Böhm S, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Sarrazin C, Berg T. Clin Infect Dis. 2011 Oct 21. [Epub ahead of print]


  724. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the HALT-C trial
    Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A, Wright EC; The HALT-C Trial Group. Hepatology. 2011 Oct 26. doi: 10.1002/hep.24752. [Epub ahead of print]


  725. Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C
    Miura M, Maekawa S, Kadokura M, Sueki R, Komase K, Shindo H, Ohmori T, Kanayama A, Shindo K, Amemiya F, Nakayama Y, Kitamura T, Uetake T, Inoue T, Sakamoto M, Okada S, Enomoto N. Hepatol Int. 2011 Aug 17. [Epub ahead of print]


  726. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma
    Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, Bartolozzi C, Ricci S. Cancer Chemother Pharmacol. 2011 Oct 28. [Epub ahead of print]


  727. Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C
    Klibanov OM, Williams SH, Smith LS, Olin JL, Vickery SB. Pharmacotherapy. 2011 Oct;31(10):951-74.


  728. Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2?weeks after therapy initiation
    Tamai H, Shingaki N, Shiraki T, Tukuda H, Mori Y, Moribata K, Enomoto S, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Yanaoka K, Oka M, Ichinose M. Hepatol Res. 2011 Sep 26. doi: 10.1111/j.1872-034X.2011.00879.x. [Epub ahead of print]


  729. Conclusion: Evaluation of viral reduction at week 2 after therapy initiation is useful for predicting SVR to low-dose PEG-IFN plus ribavirin therapy.
    Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Hepatology. 2011 Oct;54(4):1127-34. doi: 10.1002/hep.24503. Epub 2011 Aug 19.


  730. Adding to the toolbox: Receptor tyrosine kinases as potential targets in the treatment of hepatitis C
    Jilg N, Chung RT. J Hepatol. 2011 Jul 22. [Epub ahead of print]


  731. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C
    Asselah T, De Muynck S, Broët P, Masliah-Planchon J, Blanluet M, Bièche I, Lapalus M, Martinot-Peignoux M, Lada O, Estrabaud E, Zhang Q, Ray AE, Vidaud D, Ripault MP, Boyer N, Bedossa P, Valla D, Vidaud M, Marcellin P. J Hepatol. 2011 Sep 24. [Epub ahead of print]


  732. Histological Versus Clinical Cirrhosis in Chronic Hepatitis C: Does Race/Ethnicity Really Matter?
    Kohla M, Iwata S, Ea R, Keyhan S, Taylor R, Yu MC, Groshen S, Bonacini M. Dig Dis Sci. 2011 Sep 24. [Epub ahead of print]


  733. Level of α-Fetoprotein Predicts Mortality Among Patients With Hepatitis C-Related Hepatocellular Carcinoma
    Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Clin Gastroenterol Hepatol. 2011 Aug 4. [Epub ahead of print]


  734. Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD
    Boursier J, Chaigneau J, Roullier V, Lainé F, Sandrini J, Michalak S, Hubert I, Dib N, Oberti F, Bertrais S, Hunault G, Deugnier Y, Rousselet MC, Cavaro-Ménard C, Gallois Y, Aubé C, Calès P; the study group UNAM-METABOL. Eur J Gastroenterol Hepatol. 2011 Sep 7. [Epub ahead of print]


  735. Host genomics and HCV treatment response
    Clark PJ, Thompson AJ. J Gastroenterol Hepatol. 2011 Sep 14. doi: 10.1111/j.1440-1746.2011.06918.x. [Epub ahead of print]


  736. The Supplementation of Acetyl-l-Carnitine Decreases Fatigue and Increases Quality of Life in Patients with Hepatitis C Treated with Pegylated Interferon-? 2b Plus Ribavirin
    The Supplementation of Acetyl-l-Carnitine Decreases Fatigue and Increases Quality of Life in Patients with Hepatitis C Treated with Pegylated Interferon-? 2b Plus Ribavirin


  737. Rising burden of Hepatitis C Virus in Hemodialysis Patients
    Khan S, Attaullah S, Ali I, Ayaz S, Naseemullah, Khan SN, Siraj S, Khan J. Virol J. 2011 Sep 13;8(1):438. [Epub ahead of print]


  738. New therapies for hepatitis C virus infection
    Bacon BR, Khalid O. Mo Med. 2011 Jul-Aug;108(4):255-9.


  739. Interleukin 28B genotype determination using DNA from different sources: A simple and reliable tool for the epidemiological and clinical characterization of hepatitis C
    Cariani E, Critelli R, Rota C, Luongo M, Trenti T, Villa E. J Virol Methods. 2011 Aug 27. [Epub ahead of print]


  740. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma
    Kawaoka T, Aikata H, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Tashiro H, Ohdan H, Chayama K. J Viral Hepat. 2011 Oct;18(10):e550-60. doi: 10.1111/j.1365-2893.2011.01468.x. Epub 2011 May 23.


  741. Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response
    Floreani A, Cazzagon N, Boemo DG, Baldovin T, Baldo V, Egoue J, Antoniazzi S, Minola E. Eur J Gastroenterol Hepatol. 2011 Sep 12. [Epub ahead of print]


  742. A comparison of depression screening instruments in hepatitis C and the impact of depression on somatic symptoms
    Sockalingam S, Blank D, Al Jarad A, Alosaimi F, Hirschfield G, Abbey SE. Psychosomatics. 2011 Sep-Oct;52(5):433-40.


  743. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis
    Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, Ganne-Carrie N, Grando-Lemaire V, Trinchet JC, Gordien E, Vicaut E, Baghad I, Beaugrand M. J Viral Hepat. 2011 Oct;18(10):e516-22. doi: 10.1111/j.1365-2893.2011.01441.x.


  744. Use of HOMA-IR in hepatitis C
    Eslam M, Kawaguchi T, Del Campo JA, Sata M, Abo-Elneen Khattab M, Romero-Gomez M. J Viral Hepat. 2011 Oct;18(10):675-84. doi: 10.1111/j.1365-2893.2011.01474.x. Epub 2011 May 25.


  745. Psychosocial correlates of alcohol use and reduction for individuals with hepatitis C
    Perzynski AT, McCormick R, Webster NJ, Blixen CE, Kanuch S, Thomas CL, Mullen KD, Dawson NV. J Stud Alcohol Drugs. 2011 Sep;72(5):787-98.


  746. Future of hepatitis C therapy: development of direct-acting antivirals
    Dore GJ, Matthews GV, Rockstroh J. Curr Opin HIV AIDS. 2011 Sep 3. [Epub ahead of print]


  747. Comparison of 8 diagnostic algorithms for liver fibrosis in hepatitis C: New algorithms are more precise and entirely non-invasive
    Boursier J, de Ledinghen V, Zarski JP, Fouchard-Hubert I, Gallois Y, Oberti F, Calès P; Multicentric groups from SNIFF 32, VINDIAG 7, ANRS/HC/EP23 FIBROSTAR studies. Hepatology. 2011 Sep 2. doi: 10.1002/hep.24654. [Epub ahead of print]


  748. Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation
    Coto-Llerena M, Crespo G, González P, Koutsoudakis G, Miquel R, Navasa M, Forns X, Pérez-Del-Pulgar S. J Hepatol. 2011 Aug 31. [Epub ahead of print]


  749. Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response
    Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N, Hoshioka Y, Yasui Y, Katoh T, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nitta S, Sakamoto N, Izumi N. Hepatology. 2011 Aug 24. doi: 10.1002/hep.24623. [Epub ahead of print]


  750. Relative performances of FibroTest, Fibroscan and biopsy for assessing the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard
    Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Le Nahour G, Vaillant JC, Ratziu V, Charlotte F. J Hepatol. 2011 Aug 31. [Epub ahead of print]


  751. The impact of illicit drug use on spontaneous hepatitis C clearance: experience from a large cohort population study
    Poustchi H, Esmaili S, Mohamadkhani A, Nikmahzar A, Pourshams A, Sepanlou SG, Merat S, Malekzadeh R. PLoS One. 2011;6(8):e23830. Epub 2011 Aug 24.


  752. Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
    Kenneth E. Sherman, M.D., Ph.D., Steven L. Flamm, M.D., Nezam H. Afdhal, M.D., David R. Nelson, M.D., Mark S. Sulkowski, M.D., Gregory T. Everson, M.D., Michael W. Fried, M.D., Michael Adler, M.D., Ph.D., Hendrik W. Reesink, M.D., Ph.D., Marie Martin, Ph.D., Abdul J. Sankoh, Ph.D., Nathalie Adda, M.D., Robert S. Kauffman, M.D., Ph.D., Shelley George, M.D., Christopher I. Wright, M.D., Ph.D., and Fred Poordad, M.D. for the ILLUMINATE Study Team


  753. Staying Safe From Hepatitis C: Engaging With Multiple Priorities
    Harris M, Treloar C, Maher L. Qual Health Res. 2011 Aug 25. [Epub ahead of print]


  754. IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection
    Gonzalez SA, Keeffe EB. Gastroenterol Hepatol (N Y). 2011 Jun;7(6):366-73.


  755. The cryoglobulinaemias
    Ramos-Casals M, Stone JH, Cid MC, Bosch X. Lancet. 2011 Aug 23. [Epub ahead of print]


  756. T cell responses in hepatitis C: the good, the bad and the unconventional
    Klenerman P, Thimme R. Gut. 2011 Aug 28. [Epub ahead of print]


  757. A paradigm shift in the outpatient approach to liver function tests
    Senadhi V. South Med J. 2011 Jul;104(7):521-5.


  758. Neuropsychological alterations in hepatitis C infection: The role of inflammation
    Senzolo M, Schiff S, D'Aloiso CM, Crivellin C, Cholongitas E, Burra P, Montagnese S. World J Gastroenterol. 2011 Aug 7;17(29):3369-74.


  759. Viral hepatitis C, active component, U.S. Armed Forces, 2000-2010
    Armed Forces Health Surveillance Center (AFHSC). MSMR. 2011 Aug;18(8):10-4.


  760. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3
    Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S, Diago M, Arora S, Foster GR, Torbenson M, Benhamou Y, Nelson DR, Sulkowski MS, Zeuzem S, Pulkstenis E, Subramanian GM, McHutchison JG; for the ACHIEVE-1 and ACHIEVE-2/3 Study Teams. Gut. 2011 Aug 26. [Epub ahead of print]


  761. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy
    Coppola N, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, Sagnelli C, Ferrara MG, Sagnelli E. Dig Liver Dis. 2011 Aug 30. [Epub ahead of print]


  762. Boceprevir: A User's Guide
    Kwo PY, Zhao R. Clin Liver Dis. 2011 Aug;15(3):537-53.


  763. The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors
    Membreno FE, Lawitz EJ. Clin Liver Dis. 2011 Aug;15(3):611-26.


  764. Second-wave Protease Inhibitors: Choosing an Heir
    Ciesek S, von Hahn T, Manns MP. Clin Liver Dis. 2011 Aug;15(3):597-609. Epub 2011 Jun 25.


  765. Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations
    Khalid O, Bacon BR. Clin Liver Dis. 2011 Aug;15(3):573-83.


  766. Mixing and matching drugs: what makes sense?
    Welzel TM, Zeuzem S. Clin Liver Dis. 2011 Aug;15(3):657-64.


  767. Hepatitis C therapy: other players in the game
    Ahn J, Flamm SL. Clin Liver Dis. 2011 Aug;15(3):641-56.


  768. The NS5A Replication Complex Inhibitors: Difference Makers?
    Gish RG, Meanwell NA. Clin Liver Dis. 2011 Aug;15(3):627-39.


  769. Naives, nonresponders, relapsers: who is there left to treat?
    Desai AP, Reau N. Clin Liver Dis. 2011 Aug;15(3):483-95.


  770. Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus
    Hevezi PA, Tom E, Wilson K, Lambert P, Gutierrez-Reyes G, Kershenobich D, Zlotnik A. Autoimmunity. 2011 Aug 24. [Epub ahead of print]


  771. An overview of emerging therapies for the treatment of chronic hepatitis C
    Ilyas JA, Vierling JM. Clin Liver Dis. 2011 Aug;15(3):515-36.


  772. The impact of genetic variability on liver disease in the Hispanic/Latin-American population
    Lau-Corona D, Kershenobich D, Gutierrez-Reyes G. Autoimmunity. 2011 Aug 24. [Epub ahead of print]


  773. Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection
    Holmes JA, Desmond PV, Thompson AJ. Clin Liver Dis. 2011 Aug;15(3):497-513.


  774. An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation
    Hashemi N, Araya V, Tufail K, Thummalakunta L, Feyssa E, Azhar A, Niazi M, Ortiz J. World J Hepatol. 2011 Jul 27;3(7):198-204.


  775. IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection
    IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection


  776. Interferon-free regimens: the near future, the likely and the not so likely
    Shiffman ML. Clin Liver Dis. 2011 Aug;15(3):665-75. Epub 2011 Jun 25.


  777. 1990-2010: two decades of interferon-based therapy
    Buti M, Esteban R. Clin Liver Dis. 2011 Aug;15(3):473-82. Epub 2011 Jun 14.


  778. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective
    McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, I D. J Manag Care Pharm. 2011 Sep;17(7):531-46.


  779. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. J Hepatol. 2011 Aug 6. [Epub ahead of print]


  780. Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C (September)
    Foote BC, Spooner LM, Belliveau PP. Ann Pharmacother. 2011 Aug 9. [Epub ahead of print]


  781. Increased Risk of Severe Recurrence of Hepatitis C Virus in Liver Transplant Recipients of Donation After Cardiac Death Allografts
    Hernandez-Alejandro R, Croome KP, Quan D, Mawardi M, Chandok N, Dale C, McAlister V, Levstik MA, Wall W, Marotta P. Transplantation. 2011 Aug 9. [Epub ahead of print]


  782. Failure to achieve 2-log10 viral decrease in first four weeks of peg-IFNalpha-2b plus ribavirin therapy for chronic hepatitis C with genotype 1b and high viral titer is useful in predicting non-response: evaluation of response-guided therapy
    Ohkoshi S, Yamagiwa S, Yano M, Takahashi H, Aoki YH, Waguri N, Igarashi K, Sugitani S, Takahashi T, Ishikawa T, Kamimura T, Wakabayashi H, Watanabe T, Matsuda Y, Aoyagi Y. Hepatogastroenterology. 2011 May-Jun;58(107-108):965-70.


  783. Realize the advance in HCV treatment, but remain cautious
    Asselah T. J Hepatol. 2011 Aug 8. [Epub ahead of print]


  784. Impact of Hispanic or Asian Ethnicity on the Treatment Outcomes of Chronic Hepatitis C: Results From the WIN-R Trial
    Hu KQ, Freilich B, Brown RS, Brass C, Jacobson IM. J Clin Gastroenterol. 2011 Sep;45(8):720-6.


  785. Early effect of peginterferon alpha-2b plus ribavirin treatment on blood pressure and insulin resistance in patients with chronic hepatitis C
    Taskoparan M, Serin E, Gokturk HS, Icer MO, Abaci K, Ozer B, Zumrutdal A, Yilmaz U. Hepatogastroenterology. 2011 May-Jun;58(107-108):875-9.


  786. A cohort study to investigate hepatocellular carcinoma risk in hepatitis C patients
    Wang CH, Mo LR, Chang KK, Lin RC, Kuo JJ. Hepatogastroenterology. 2011 May-Jun;58(107-108):904-8.


  787. Hepatitis C virus and the skin
    Al-Ali J, Al-Mutari N, Ahmed el-SF. Hepatogastroenterology. 2011 May-Jun;58(107-108):880-6.


  788. Hepatorenal Syndrome: Are We Missing Some Prognostic Factors?
    Martinez MO, Sayles H, Vivekanandan R, D' Souza S, Florescu MC. Dig Dis Sci. 2011 Aug 18. [Epub ahead of print]


  789. Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study
    Hiramatsu N, Inoue Y, Oze T, Kurashige N, Yakushijin T, Mochizuki K, Miyagi T, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Hayashi N. J Gastroenterol. 2011 Aug 20. [Epub ahead of print]


  790. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection
    Valva P, Casciato P, Diaz Carrasco JM, Gadano A, Galdame O, Galoppo MC, Mullen E, De Matteo E, Preciado MV. PLoS One. 2011;6(8):e23218. Epub 2011 Aug 17.


  791. FibroTest(®) and Fibroscan(®) performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate
    Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Moussalli J, Lebray P, Thabut D, Ratziu V. Clin Res Hepatol Gastroenterol. 2011 Aug 16. [Epub ahead of print]


  792. Prevalence of HCV risk behaviors among prison inmates: tattooing and injection drug use
    Smith BD, Drobeniuc J, Jewett A, Branson BM, Garfein RS, Teshale E, Kamili S, Weinbaum CM. J Infect Dis. 2011 Sep;204(6):825-31.


  793. Prevalence of HCV risk behaviors among prison inmates: tattooing and injection drug use
    Peña-Orellana M, Hernández-Viver A, Caraballo-Correa G, Albizu-García CE. J Health Care Poor Underserved. 2011;22(3):962-82.


  794. Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy
    Andrade LJ, Atta AM, Atta ML, Mangabeira CN, Paraná R. Braz J Infect Dis. 2011 Aug;15(4):377-81.


  795. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males
    White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Hepatology. 2011 Aug 19. doi: 10.1002/hep.24618. [Epub ahead of print]


  796. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy
    D'Ambrosio R, Aghemo A, Rumi MG, Primignani M, Dell'era A, Lampertico P, Donato MF, De Nicola S, Prati GM, de Franchis R, Colombo M. Antivir Ther. 2011;16(5):677-84.


  797. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature
    Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, Tavoni A, Zignego AL, De Vita S. Autoimmun Rev. 2011 Jul 24. [Epub ahead of print]


  798. Changes in Depressive Symptoms and Impact on Treatment Course Among Hepatitis C Patients Undergoing Interferon-? and Ribavirin Therapy: A Prospective Evaluation
    Chapman J, Oser M, Hockemeyer J, Weitlauf J, Jones S, Cheung R. Am J Gastroenterol. 2011 Aug 9. doi: 10.1038/ajg.2011.252. [Epub ahead of print]


  799. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California
    Telles Dias P, Hahn JA, Delwart E, Edlin B, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP, Page K. BMC Infect Dis. 2011 Aug 2;11(1):208. [Epub ahead of print]


  800. New hepatitis C therapies in clinical development
    Vermehren J, Sarrazin C. Eur J Med Res. 2011 Jul 25;16(7):303-14.


  801. Progress toward development of a hepatitis C vaccine with broad shoulders
    Ray R. Sci Transl Med. 2011 Aug 3;3(94):94ps33.


  802. Chronic hepatitis C
    Jang JY, Chung RT. Gut Liver. 2011 Jun;5(2):117-32. Epub 2011 Jun 24.


  803. Emerging therapeutic options in hepatitis c virus infection
    Poordad F, Khungar V. Am J Manag Care. 2011 Mar;17(4 Suppl):S123-30.


  804. Role of the nurse practitioner in the management of patients with chronic hepatitis C
    Olson M, Jacobson IM. J Am Acad Nurse Pract. 2011 Aug;23(8):410-20. doi: 10.1111/j.1745-7599.2011.00603.x. Epub 2011 Mar 31.


  805. Comparative Analysis of Hepatitis C Recurrence and Fibrosis Progression Between Deceased-Donor and Living-Donor Liver Transplantation: 8-Year Longitudinal Follow-Up
    Jain A, Singhal A, Kashyap R, Safadjou S, Ryan CK, Orloff MS. Transplantation. 2011 Jul 27. [Epub ahead of print]


  806. Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment
    Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. Int J Infect Dis. 2011 Jul 29. [Epub ahead of print]


  807. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews
    Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Lancet. 2011 Jul 27. [Epub ahead of print]


  808. Multi-center evaluation of the Abbott RealTime HCV Assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C
    Vermehren J, Yu ML, Monto A, Yao JD, Anderson C, Bertuzis R, Schneider G, Sarrazin C. J Clin Virol. 2011 Jul 29. [Epub ahead of print]


  809. Pregnancy outcomes associated with viral hepatitis
    Reddick KL, Jhaveri R, Gandhi M, James AH, Swamy GK. J Viral Hepat. 2011 Jul;18(7):e394-8. doi: 10.1111/j.1365-2893.2011.01436.x. Epub 2011 Feb 8.


  810. Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy
    Deltenre P, Moreno C, Tran A, Ollivier I, Provôt F, Stanke F, Lazrek M, Castel H, Canva V, Louvet A, Colin M, Glowacki F, Dharancy S, Henrion J, Hazzan M, Noel C, Mathurin P. Aliment Pharmacol Ther. 2011 Jun 20. doi: 10.1111/j.1365-2036.2011.04741.x. [Epub ahead of print]


  811. Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse
    Shoeb D, Rowe IA, Freshwater D, Mutimer D, Brown A, Moreea S, Sood R, Marley R, Sabin CA, Foster GR. Eur J Gastroenterol Hepatol. 2011 Jun 17. [Epub ahead of print]


  812. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data
    Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K, Han KH, Wallace CM, Zeuzem S, Negro F. Liver Int. 2011 Jul;31 Suppl 2:4-17. doi: 10.1111/j.1478-3231.2011.02535.x.


  813. Education by a Nurse Increases Response of Patients With Chronic Hepatitis C to Therapy With Peginterferon-alfa2a and Ribavirin
    Larrey D, Salse A, Ribard D, Boutet O, Hyrailles-Blanc V, Niang B, Pageaux GP, Vaucher E, Arpurt JP, Boulay G, Karlova N, Daures JP; Hepatitis C Network of Languedoc Roussillon (France). Clin Gastroenterol Hepatol. 2011 Jun 6. [Epub ahead of print]


  814. Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance
    Watanabe T, Konishi I, Shigematsu S, Uesugi K, Joko K, Seike H, Okada S, Miyaoka H, Nakanishi S, Abe M, Matsuura B, Michitaka K, Horiike N, Hiasa Y, Onji M. Hepatol Res. 2011 Jun 17. doi: 10.1111/j.1872-034X.2011.00816.x. [Epub ahead of print]


  815. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review
    Brunasso AM, Puntoni M, Gulia A, Massone C. Rheumatology (Oxford). 2011 Jun 20. [Epub ahead of print]


  816. Health Utilities and Psychometric Quality of Life in Patients With Early- and Late-Stage Hepatitis C Virus Infection
    Hsu PC, Federico CA, Krajden M, Yoshida EM, Bremner KE, Anderson FH, Weiss AA, Krahn MD. J Gastroenterol Hepatol. 2011 Jun 16. doi: 10.1111/j.1440-1746.2011.06813.x. [Epub ahead of print]


  817. Cholesterol and chronic hepatitis C virus infection
    Honda A, Matsuzaki Y. Hepatol Res. 2011 Jun 17. doi: 10.1111/j.1872-034X.2011.00838.x. [Epub ahead of print]


  818. Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis
    Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Sugauchi F, Tamori A, Kakinnuma S, Matsuura K, Izumi N. J Gastroenterol. 2011 Jun 17. [Epub ahead of print]


  819. Telaprevir for previously untreated chronic hepatitis C virus infection
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. N Engl J Med. 2011 Jun 23;364(25):2405-16.


  820. Telaprevir for retreatment of HCV infection
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. N Engl J Med. 2011 Jun 23;364(25):2417-28.


  821. Viral hepatitis: Impact of adherence to combination therapy for hepatitis C
    Arase Y. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):248-9.


  822. Telaprevir Alone or with Peginterferon and Ribavirin Reduces HCV RNA in Patients with Chronic Genotype 2 but Not 3 Infections
    Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M. Gastroenterology. 2011 May 31. [Epub ahead of print]


  823. Clarification of interspousal hepatitis C virus infection in acute hepatitis C patients by molecular evolutionary analyses: Consideration on sexual and non-sexual transmission between spouses
    Nakamura I, Tanaka Y, Ochiai K, Moriyasu F, Mizokami M, Imawari M. Hepatol Res. 2011 Jun 23. doi: 10.1111/j.1872-034X.2011.00843.x. [Epub ahead of print]


  824. Acute hepatitis C infection lowers serum lipid levels
    Corey KE, Mendez-Navarro J, Barlow LL, Patwardhan V, Zheng H, Kim AY, Lauer GM, Chung RT. J Viral Hepat. 2011 Jul;18(7):e366-71. doi: 10.1111/j.1365-2893.2011.01434.x. Epub 2011 Feb 8.


  825. TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1
    Petta S, Di Marco V, Di Stefano R, Cabibi D, Cammà C, Marchesini G, Craxì A. J Viral Hepat. 2011 Jul;18(7):e372-80. doi: 10.1111/j.1365-2893.2011.01439.x. Epub 2011 Feb 22.


  826. Managing patients with hepatitis B-related or hepatitis C-related decompensated cirrhosis
    Fink SA, Jacobson IM. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):285-95.


  827. Improving surveillance for acute hepatitis C
    Deacon RM, Wand H, Stelzer-Braid S, Treloar C, Maher L. Commun Dis Intell. 2011 Mar;35(1):16-20.


  828. The Risk of Incident Coronary Heart Disease Among Veterans With and Without HIV and Hepatitis C
    Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Goetz MB, Butt AA, Rodriguez Barradas MC, Gibert C, Leaf D, Brown ST, Samet J, Kazis L, Bryant K, Justice AC; for the Veterans Aging Cohort Study. Circ Cardiovasc Qual Outcomes. 2011 Jun 28. [Epub ahead of print]


  829. Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial
    Maieron A, Metz-Gercek S, Scherzer TM, Laferl H, Fischer G, Bischof M, Gschwantler M, Ferenci P. BMC Res Notes. 2011 Jun 29;4(1):220. [Epub ahead of print]


  830. Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C
    Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A, Dhiman RK, Das A, Chawla YK. Dig Dis Sci. 2011 Jun 25. [Epub ahead of print]


  831. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin
    Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, Kuo HT, Dai CY, Yu ML. J Hepatol. 2011 May 19. [Epub ahead of print]


  832. Genetic variation in IL28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection
    Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Hepatology. 2011 Jun 30. doi: 10.1002/hep.24503. [Epub ahead of print]


  833. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C
    Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, Thompson A, Clark PJ, Gardner SD, McHutchison JG, McCarthy JJ. J Hepatol. 2011 Apr 14. [Epub ahead of print]


  834. Ophthalmological complications in hepatitis C virus infection: Side effect of interferon therapy or a direct role of HCV?
    Pazienza V. Biomed Pharmacother. 2011 May 30. [Epub ahead of print]


  835. Oral combination therapy: Future hepatitis C virus treatment?
    Hézode C. J Hepatol. 2011 May 19. [Epub ahead of print]


  836. Efficacy and Safety of Pegylated Interferon in Children and adolescents Infected with Chronic Hepatitis C: A Preliminary Study
    Abdel-Aziz DH, Sabry NA, El-Sayed MH, El-Gazayerly ON. J Pharm Pract. 2011 Apr;24(2):203-10. Epub 2010 Apr 2.


  837. A sprint to increase response to HCV treatment: expectancies but caution
    Asselah T. J Hepatol. 2011 Jun 30. [Epub ahead of print]


  838. The tasks of self-managing hepatitis C: The significance of disclosure
    Fry M, Bates G. Psychol Health. 2011 Jul 7. [Epub ahead of print]


  839. Vitamin A deficiency in patients with hepatitis C virus-related chronic liver disease
    Peres WA, Chaves GV, Gonçalves JC, Ramalho A, Coelho HS. Br J Nutr. 2011 Jun 8:1-8. [Epub ahead of print]


  840. Hepatitis C Reactivation in Patients Who Have Diffuse Large B-Cell Lymphoma Treated With Rituximab: A Case Report and Review of Literature
    Nooka A, Shenoy PJ, Sinha R, Lonial S, Flowers CR. Clin Lymphoma Myeloma Leuk. 2011 May 12. [Epub ahead of print]


  841. Spontaneous clearance of hepatitis C virus in vertically infected children
    Farmand S, Wirth S, Löffler H, Woltering T, Kenzel S, Lainka E, Henneke P. Eur J Pediatr. 2011 Jul 7. [Epub ahead of print]


  842. Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes
    Pattullo V, McAndrews MP, Damyanovich A, Heathcote EJ. Liver Int. 2011 Aug;31(7):1028-38. doi: 10.1111/j.1478-3231.2011.02549.x. Epub 2011 May 25.


  843. Predicting response to therapy in chronic hepatitis C: an approach combining IL28B gene polymorphisms and clinical data
    Ladero JM, Martin EG, Fernández C, Carballo M, Devesa MJ, Martínez C, Suárez A, Díaz-Rubio M, Agúndez JA. J Gastroenterol Hepatol. 2011 Jul 1. doi: 10.1111/j.1440-1746.2011.06834.x. [Epub ahead of print]


  844. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene
    Toyoda H, Kumada T, Hayashi K, Honda T, Katano Y, Goto H, Kawaguchi T, Murakami Y, Matsuda F. J Med Virol. 2011 Sep;83(9):1559-64. doi: 10.1002/jmv.22145.


  845. Insulin resistance and chronic liver disease
    Kawaguchi T, Taniguchi E, Itou M, Sakata M, Sumie S, Sata M. World J Hepatol. 2011 May 27;3(5):99-107.


  846. Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes
    Connell LE, Salihu HM, Salemi JL, August EM, Weldeselasse H, Mbah AK. Liver Int. 2011 Jun 7. doi: 10.1111/j.1478-3231.2011.02556.x. [Epub ahead of print]


  847. Hepatitis C virus infection in USA: an estimate of true prevalence
    Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Liver Int. 2011 Mar 16. doi: 10.1111/j.1478-3231.2011.02494.x. [Epub ahead of print]


  848. An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C
    O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM; and the HALT-C Trial Group. PLoS One. 2011;6(7):e20904. Epub 2011 Jul 8.


  849. Gaps in the Achievement of Effectiveness of HCV Treatment in National VA Practice
    Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag H, Kramerer JR. J Hepatol. 2011 Jul 11. [Epub ahead of print]


  850. Diagnosing and treating hepatitis c virus infection
    Schiff ER. Am J Manag Care. 2011 Mar;17(4 Suppl):S108-15.


  851. Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C
    Burgueño-Montañés C, Pérez-Álvarez R. Arch Soc Esp Oftalmol. 2011 Jun;86(6):193-195. Epub 2011 Apr 29.


  852. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse
    Lan CL, Guillygomarc'h A, Danielou H, Dréau GL, Lainé F, Védeilhié C, Deugnier Y, Brissot P, Guyader D, Moirand R. J Hepatol. 2011 Jul 11. [Epub ahead of print]


  853. Improved Responses to Pegylated Interferon alfa-2b and Ribavirin by Individualizing Treatment for 24-72 Weeks
    Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T. Gastroenterology. 2011 Jul 21. [Epub ahead of print]


  854. Peginterferon Maintenance Therapy in Patients with Advanced Hepatitis C to Prevent Hepatocellular Carcinoma: The Plot Thickens
    Aghemo A, Colombo M. J Hepatol. 2011 Jul 20. [Epub ahead of print]


  855. Current understanding of insulin resistance in hepatitis C
    Kaddai V, Negro F. Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):503-16.


  856. Mechanisms of non-response to antiviral treatment in chronic hepatitis C
    Chevaliez S, Asselah T. Clin Res Hepatol Gastroenterol. 2011 Jun;35 Suppl 1:S31-41.


  857. Hepatic steatosis at one year is an additional predictor of subsequent fibrosis severity in liver transplantation recipients with recurrent hepatitis C virus
    Brandman D, Pingitore A, Lai J, Roberts J, Ferrell L, Bass N, Terrault N. Liver Transpl. 2011 Jul 18. doi: 10.1002/lt.22389. [Epub ahead of print]


  858. Liver stiffness diminishes with antiviral response in chronic hepatitis C
    Hézode C, Castéra L, Roudot-Thoraval F, Bouvier-Alias M, Rosa I, Roulot D, Leroy V, Mallat A, Pawlotsky JM. Aliment Pharmacol Ther. 2011 Jul 13. doi: 10.1111/j.1365-2036.2011.04765.x. [Epub ahead of print]


  859. Effects of Hepatitis C virus on cardiovascular risk in infected patients: A comparative study
    Oliveira CP, Kappel CR, Siqueira ER, Lima VM, Stefano JT, Michalczuk MT, Marini SS, Barbeiro HV, Soriano FG, Carrilho FJ, Pereira LM, Alvares-da-Silva MR. Int J Cardiol. 2011 Jul 22. [Epub ahead of print]


  860. Hyporesponsiveness to pegifn?2b plus ribavirin in patients with hepatitis C-related advanced fibrosis
    Prati GM, Aghemo A, Rumi MG, D'Ambrosio R, Nicola SD, Donato MF, Degasperi E, Colombo M. J Hepatol. 2011 Jul 11. [Epub ahead of print]


  861. A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C Treatment
    Evon DM, Simpson K, Kixmiller S, Galanko J, Dougherty K, Golin C, Fried MW. Am J Gastroenterol. 2011 Jul 19. doi: 10.1038/ajg.2011.219. [Epub ahead of print]


  862. Pregnancy outcomes associated with viral hepatitis
    Reddick KL, Jhaveri R, Gandhi M, James AH, Swamy GK. J Viral Hepat. 2011 Jul;18(7):e394-8. doi: 10.1111/j.1365-2893.2011.01436.x. Epub 2011 Feb 8.


  863. Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy
    Deltenre P, Moreno C, Tran A, Ollivier I, Provôt F, Stanke F, Lazrek M, Castel H, Canva V, Louvet A, Colin M, Glowacki F, Dharancy S, Henrion J, Hazzan M, Noel C, Mathurin P. Aliment Pharmacol Ther. 2011 Jun 20. doi: 10.1111/j.1365-2036.2011.04741.x. [Epub ahead of print]


  864. Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse
    Shoeb D, Rowe IA, Freshwater D, Mutimer D, Brown A, Moreea S, Sood R, Marley R, Sabin CA, Foster GR. Eur J Gastroenterol Hepatol. 2011 Jun 17. [Epub ahead of print]


  865. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data
    Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K, Han KH, Wallace CM, Zeuzem S, Negro F. Liver Int. 2011 Jul;31 Suppl 2:4-17. doi: 10.1111/j.1478-3231.2011.02535.x.


  866. Education by a Nurse Increases Response of Patients With Chronic Hepatitis C to Therapy With Peginterferon-alfa2a and Ribavirin
    Larrey D, Salse A, Ribard D, Boutet O, Hyrailles-Blanc V, Niang B, Pageaux GP, Vaucher E, Arpurt JP, Boulay G, Karlova N, Daures JP; Hepatitis C Network of Languedoc Roussillon (France). Clin Gastroenterol Hepatol. 2011 Jun 6. [Epub ahead of print]


  867. Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance
    Watanabe T, Konishi I, Shigematsu S, Uesugi K, Joko K, Seike H, Okada S, Miyaoka H, Nakanishi S, Abe M, Matsuura B, Michitaka K, Horiike N, Hiasa Y, Onji M. Hepatol Res. 2011 Jun 17. doi: 10.1111/j.1872-034X.2011.00816.x. [Epub ahead of print]


  868. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review
    Brunasso AM, Puntoni M, Gulia A, Massone C. Rheumatology (Oxford). 2011 Jun 20. [Epub ahead of print]


  869. Health Utilities and Psychometric Quality of Life in Patients With Early- and Late-Stage Hepatitis C Virus Infection
    Hsu PC, Federico CA, Krajden M, Yoshida EM, Bremner KE, Anderson FH, Weiss AA, Krahn MD. J Gastroenterol Hepatol. 2011 Jun 16. doi: 10.1111/j.1440-1746.2011.06813.x. [Epub ahead of print]


  870. Cholesterol and chronic hepatitis C virus infection
    Honda A, Matsuzaki Y. Hepatol Res. 2011 Jun 17. doi: 10.1111/j.1872-034X.2011.00838.x. [Epub ahead of print]


  871. Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis
    Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Sugauchi F, Tamori A, Kakinnuma S, Matsuura K, Izumi N. J Gastroenterol. 2011 Jun 17. [Epub ahead of print]


  872. Telaprevir for previously untreated chronic hepatitis C virus infection
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. N Engl J Med. 2011 Jun 23;364(25):2405-16.


  873. Telaprevir for retreatment of HCV infection
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. N Engl J Med. 2011 Jun 23;364(25):2417-28.


  874. Viral hepatitis: Impact of adherence to combination therapy for hepatitis C
    Arase Y. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):248-9.


  875. Telaprevir Alone or with Peginterferon and Ribavirin Reduces HCV RNA in Patients with Chronic Genotype 2 but Not 3 Infections
    Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M. Gastroenterology. 2011 May 31. [Epub ahead of print]


  876. Clarification of interspousal hepatitis C virus infection in acute hepatitis C patients by molecular evolutionary analyses: Consideration on sexual and non-sexual transmission between spouses
    Nakamura I, Tanaka Y, Ochiai K, Moriyasu F, Mizokami M, Imawari M. Hepatol Res. 2011 Jun 23. doi: 10.1111/j.1872-034X.2011.00843.x. [Epub ahead of print]


  877. Acute hepatitis C infection lowers serum lipid levels
    Corey KE, Mendez-Navarro J, Barlow LL, Patwardhan V, Zheng H, Kim AY, Lauer GM, Chung RT. J Viral Hepat. 2011 Jul;18(7):e366-71. doi: 10.1111/j.1365-2893.2011.01434.x. Epub 2011 Feb 8.


  878. TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1
    Petta S, Di Marco V, Di Stefano R, Cabibi D, Cammà C, Marchesini G, Craxì A. J Viral Hepat. 2011 Jul;18(7):e372-80. doi: 10.1111/j.1365-2893.2011.01439.x. Epub 2011 Feb 22.


  879. Managing patients with hepatitis B-related or hepatitis C-related decompensated cirrhosis
    Fink SA, Jacobson IM. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):285-95.


  880. Improving surveillance for acute hepatitis C
    Deacon RM, Wand H, Stelzer-Braid S, Treloar C, Maher L. Commun Dis Intell. 2011 Mar;35(1):16-20.


  881. The Risk of Incident Coronary Heart Disease Among Veterans With and Without HIV and Hepatitis C
    Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Goetz MB, Butt AA, Rodriguez Barradas MC, Gibert C, Leaf D, Brown ST, Samet J, Kazis L, Bryant K, Justice AC; for the Veterans Aging Cohort Study. Circ Cardiovasc Qual Outcomes. 2011 Jun 28. [Epub ahead of print]


  882. Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial
    Maieron A, Metz-Gercek S, Scherzer TM, Laferl H, Fischer G, Bischof M, Gschwantler M, Ferenci P. BMC Res Notes. 2011 Jun 29;4(1):220. [Epub ahead of print]


  883. Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C
    Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A, Dhiman RK, Das A, Chawla YK. Dig Dis Sci. 2011 Jun 25. [Epub ahead of print]


  884. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin
    Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, Kuo HT, Dai CY, Yu ML. J Hepatol. 2011 May 19. [Epub ahead of print]


  885. Genetic variation in IL28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection
    Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Hepatology. 2011 Jun 30. doi: 10.1002/hep.24503. [Epub ahead of print]


  886. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C
    Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, Thompson A, Clark PJ, Gardner SD, McHutchison JG, McCarthy JJ. J Hepatol. 2011 Apr 14. [Epub ahead of print]


  887. Ophthalmological complications in hepatitis C virus infection: Side effect of interferon therapy or a direct role of HCV?
    Pazienza V. Biomed Pharmacother. 2011 May 30. [Epub ahead of print]


  888. Oral combination therapy: Future hepatitis C virus treatment?
    Hézode C. J Hepatol. 2011 May 19. [Epub ahead of print]


  889. Efficacy and Safety of Pegylated Interferon in Children and adolescents Infected with Chronic Hepatitis C: A Preliminary Study
    Abdel-Aziz DH, Sabry NA, El-Sayed MH, El-Gazayerly ON. J Pharm Pract. 2011 Apr;24(2):203-10. Epub 2010 Apr 2.


  890. Risk factors for the development of depression in patients with hepatitis C taking interferon-?
    Smith KJ, Norris S, O'Farrelly C, O'Mara SM. Neuropsychiatr Dis Treat. 2011;7:275-92. Epub 2011 May 15.


  891. Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Patients With HCV Genotype 3.
    Shah SR, Patel K, Marcellin P, Foster GR, Manns M, Kottilil S, Healey L, Pulkstenis E, Subramanian GM, McHutchison JG, Sulkowski MS, Zeuzem S, Nelson DR. Clin Gastroenterol Hepatol. 2011 May 13. [Epub ahead of print]


  892. All-Cause, Liver-Related, and Non-Liver-Related Mortality Among HCV-Infected Individuals in the General US Population
    El-Kamary SS, Jhaveri R, Shardell MD. Clin Infect Dis. 2011 Jun 10. [Epub ahead of print]


  893. Response-guided Peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized controlled trials and implications for the future
    Di Martino V, Richou C, Cervoni JP, Sanchez-Tapias JM, Jensen DM, Mangia A, Buti M, Sheppard F, Ferenci P, Thévenot T. Hepatology. 2011 Jun 14. doi: 10.1002/hep.24480. [Epub ahead of print]


  894. Importance of Host Genetic Factors HLA and IL28B as Predictors of Response to Pegylated Interferon and Ribavirin
    de Rueda PM, López-Nevot MA, Sáenz-López P, Casado J, Martín-Casares A, Palomares P, Quiles R, Gila A, Romero-Gómez M, Pavón EJ, Muñoz JA, Carazo A, Sanz-Cameno P, Moreno-Otero R, Diago M, León J, Ruiz-Extremera A, Salmerón J. Am J Gastroenterol. 2011 Jun 14. doi: 10.1038/ajg.2011.82. [Epub ahead of print]


  895. Is pre-treatment liver biopsy necessary for all hepatitis C genotypes?
    Peltekian KM, Bain VG, Lee SS, Sherman M, Cooper CL, Yoshida EM, Marotta PJ, Krajden M, Balshaw R, Deschênes M. Ann Hepatol. 2011 Jun 1;10(3):260-9.


  896. Cyclosporine A-Based Immunosuppression Reduces Relapse Rate After Antiviral Therapy in Transplanted Patients With Hepatitis C Virus Infection: A Large Multicenter Cohort Study
    ReViS-TC Study Group. Transplantation. 2011 Jun 8. [Epub ahead of print]


  897. Predictive value of the fibrosis scores in patients with chronic hepatitis C associated with liver fibrosis and metabolic syndrome
    Miyaaki H, Ichikawa T, Taura N, Miuma S, Shibata H, Isomoto H, Takeshima F, Nakao K. Intern Med. 2011;50(11):1137-41. Epub 2011 Jun 1.


  898. IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C
    Chayama K, Hayes CN, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y, Kamatani N, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H. J Infect Dis. 2011 Jul;204(1):84-93.


  899. Meta-analysis: insulin resistance and sustained virological response in hepatitis C
    Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Aliment Pharmacol Ther. 2011 May 29. doi: 10.1111/j.1365-2036.2011.04716.x. [Epub ahead of print]


  900. Unmet needs among people reported with hepatitis C, new york city
    Bornschlegel K, Crotty KJ, Sahl S, Balter S. J Public Health Manag Pract. 2011 Jul-Aug;17(4):E9-E17.


  901. Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers
    Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, Parish B, Burke T, Pak W, Dunkelberg J, Kistin M, Brown J, Jenkusky S, Komaromy M, Qualls C. N Engl J Med. 2011 Jun 1. [Epub ahead of print]


  902. Retreatment of Hepatitis C with Consensus Interferon and Ribavirin After Nonresponse or Relapse to Pegylated Interferon and Ribavirin: A National VA Clinical Practice Study
    Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, Cunningham F, Monto A. Dig Dis Sci. 2011 Jun 2. [Epub ahead of print]


  903. Dyspnoea in patients with chronic hepatitis C treated with pegylated interferon and ribavirin
    Garib JR, Garcia GF, Teixeira R, Lima E Silva FD. Scand J Infect Dis. 2011 May 2. [Epub ahead of print]


  904. Host-based ribavirin resistance influences hepatitis C virus replication and treatment response
    Ibarra KD, Jain MK, Pfeiffer JK. J Virol. 2011 May 4. [Epub ahead of print]


  905. Hepatitis C virus infected females have a higher risk of advanced fibrosis and graft loss after liver transplantation than males
    Lai JC, Verna EC, Brown RS Jr, O'Leary JG, Trotter JF, Forman LM, Duman JD, Foster RG, Stravitz RT, Terrault NA; for the ConsoRtiUm to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Hepatology. 2011 Apr 28. doi: 10.1002/hep.24390. [Epub ahead of print]


  906. Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection
    Corbetta S, Redaelli A, Pozzi M, Bovo G, Ratti L, Redaelli E, Pellegrini C, Beck-Peccoz P, Spada A. Eur J Clin Invest. 2011 Mar 9. doi: 10.1111/j.1365-2362.2011.02498.x. [Epub ahead of print]


  907. Understanding the host genetics of chronic hepatitis B and C
    Thursz M, Yee L, Khakoo S. Semin Liver Dis. 2011 May;31(2):115-27. Epub 2011 May 2.


  908. Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: A vicious circle of clinical significance?
    Franceschini L, Realdon S, Marcolongo M, Mirandola S, Bortoletto G, Alberti A. Hepatology. 2011 Apr 29. doi: 10.1002/hep.24394. [Epub ahead of print]


  909. Hepatitis C virus infection among adolescents and young adults --- massachusetts, 2002--2009
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 May 6;60(17):537-41.


  910. Hepatitis C-related cirrhosis with sustained prevention of hepatocellular carcinoma recurrence by long-term administration of super-low-dose peginterferon-alpha 2b
    Mamori S, Mamori H. Case Rep Gastroenterol. 2011 Jan 19;5(1):56-62.


  911. Racial differences in hepatitis C treatment eligibility
    Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS; on behalf of the IDEAL Study Team. Hepatology. 2011 Apr 12. doi: 10.1002/hep.24358. [Epub ahead of print]


  912. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C (HEP-10-2210)
    Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; for the HALT-C Trial Group. Hepatology. 2011 Apr 21. doi: 10.1002/hep.24370.


  913. Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C
    Yoneda S, Umemura T, Joshita S, Ichijo T, Matsumoto A, Yoshizawa K, Katsuyama Y, Ota M, Tanaka E; and the Nagano Interferon Treatment Research Group. Hepatol Res. 2011 Apr 19. doi: 10.1111/j.1872-034X.2011.00802.x. [Epub ahead of print]


  914. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus
    Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR; for the PHOENIX Study Group. Liver Transpl. 2011 May;17(5):528-538. doi: 10.1002/lt.22271.


  915. Hepatic Akt expression correlates with advanced fibrosis in patients with chronic hepatitis C infection
    Huang JF, Chuang YH, Dai CY, Yu ML, Huang CF, Hsiao PJ, Hsieh MY, Huang CI, Yeh ML, Yang JF, Lin ZY, Chen SC, Chuang WL. Hepatol Res. 2011 Apr 19. doi: 10.1111/j.1872-034X.2011.00786.x. [Epub ahead of print]


  916. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin
    Rallón NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, McHutchison J, Benito JM. AIDS. 2011 Apr 18. [Epub ahead of print]


  917. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination
    Ohara T, Oteki T, Suzuki T, Suzuki M, Matsuzaki Y. Hepatogastroenterology. 2011 Jan-Feb;58(105):133-6.


  918. The dissociation between the diabetes and both Child-Pugh score and in-hospital mortality in cirrhotic patients due to hepatitis B, hepatitis C, or alcoholic
    Chen YW, Chen HH, Wang TE, Chang CW, Chang CW, Chen WC, Wu CJ. Hepatol Int. 2011 Apr 21. [Epub ahead of print]


  919. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy
    Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K. J Med Virol. 2011 Jun;83(6):1048-57. doi: 10.1002/jmv.22069.


  920. IL28B SNP rs12979860 Is a Critical Predictor for On-Treatment and Sustained Virologic Response in Patients with Hepatitis C Virus Genotype-1 Infection
    Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, Chang SW, Sheen IS. PLoS One. 2011 Mar 30;6(3):e18322.


  921. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191)
    Imhof I, Simmonds P. Hepatology. 2011 Apr;53(4):1090-9. doi: 10.1002/hep.24172.


  922. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon
    Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG; for the HALT-C Trial Group. Hepatology. 2011 Apr;53(4):1100-1108. doi: 10.1002/hep.24169.


  923. Should Ribavirin Be Used to Treat Hepatitis C in Dialysis Patients?
    Carrion AF, Fabrizi F, Martin P. Semin Dial. 2011 Apr 11. doi: 10.1111/j.1525-139X.2011.00851.x. [Epub ahead of print]


  924. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1
    Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, Weltman M, Rawlinson W, Rizkalla B, Depamphilis JK, Roberts SK; on behalf of the CHARIOT Study Group. Hepatology. 2011 Apr;53(4):1109-1117. doi: 10.1002/hep.24180.


  925. Frequency of HCV infection in renal cell carcinoma patients
    Budako?lu B, Aksoy S, Arslan C, Uyetürk U, Babacan NA, Ozcan MF, Y?ld?z R, Oven BB, Ozdemir NY, Dizdar O, Büyükberber S, Ak?nc? MB, Türker I, Oksüzo?lu B, Altundag K, Zengin N. Med Oncol. 2011 Apr 3. [Epub ahead of print]


  926. Zinc: A complementary factor in the treatment of chronic hepatitis C? (Review)
    Grüngreiff K, Reinhold D. Mol Med Report. 2010 May-Jun;3(3):371-5. doi: 10.3892/mmr_00000267.


  927. A new standard of care for the treatment of chronic HCV infection
    Hofmann WP, Zeuzem S. Nat Rev Gastroenterol Hepatol. 2011 Apr 5. [Epub ahead of print]


  928. Hepatitis C virus NS3/4A protease quasispecies complexity and catalytic efficiency influence responsiveness to peginterferon plus ribavirin treatment in HCV/HIV-co-infected patients
    Aparicio E, Franco S, Parera M, Andrés C, Tural C, Clotet B, Martínez MA. J Virol. 2011 Apr 6. [Epub ahead of print]


  929. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus
    Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, Moradpour D. J Viral Hepat. 2011 May;18(5):305-15. doi: 10.1111/j.1365-2893.2011.01451.x. Epub 2011 Mar 23


  930. A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C
    Boursier J, de Ledinghen V, Zarski JP, Rousselet MC, Sturm N, Foucher J, Leroy V, Fouchard-Hubert I, Bertrais S, Gallois Y, Oberti F, Dib N, Calès P. Am J Gastroenterol. 2011 Apr 5. [Epub ahead of print]


  931. Donor and Recipient IL28B Polymorphisms in HCV-Infected Patients Undergoing Antiviral Therapy before and after Liver Transplantation
    Coto-Llerena M, Pérez-Del-Pulgar S, Crespo G, Carrión JA, Martínez SM, Sánchez-Tapias JM, Martorell J, Navasa M, Forns X. Am J Transplant. 2011 Apr 5. doi: 10.1111/j.1600-6143.2011.03491.x. [Epub ahead of print]


  932. Differences in circulating MMP-9 levels with regard to viral load and AST:ALT ratio between chronic hepatitis B and C patients
    Helaly GF. Br J Biomed Sci. 2011;68(1):38-42.


  933. Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes
    Fernandez-Rodriguez CM, Gutierrez ML, Lledó JL, Casas ML. World J Gastroenterol. 2011 Mar 28;17(12):1558-62.


  934. Occult hepatitis B virus infection: A complex entity with relevant clinical implications
    Larrubia JR. World J Gastroenterol. 2011 Mar 28;17(12):1529-30.


  935. Host genetics in immune-mediated hepatitis C virus clearance
    Schmidt J, Thimme R, Neumann-Haefelin C. Biomark Med. 2011 Apr;5(2):155-69.


  936. Prevalence of hepatitis C virus infection among health-care workers: A 10-year survey
    Marconi A, Candido S, Talamini R, Libra M, Nicoletti F, Spandidos DA, Stivala F, Proietti L. Mol Med Report. 2010 Jul-Aug;3(4):561-4. doi: 10.3892/mmr_00000297.


  937. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
    Hartwell D, Jones J, Baxter L, Shepherd J. Health Technol Assess. 2011 Apr;15(17):1-210.


  938. Clinical significance of occult hepatitis B virus infection
    Romero M, Madejón A, Fernández-Rodríguez C, García-Samaniego J. World J Gastroenterol. 2011 Mar 28;17(12):1549-52.


  939. Malnutrion Impairs Interferon Signaling through mTOR and FoxO pathways in Patients with Chronic Hepatitis C
    Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S; Hokuriku Liver Study Group. Gastroenterology. 2011 Mar 30. [Epub ahead of print]


  940. Genetics in liver disease: new concepts
    Zimmer V, Lammert F. Curr Opin Gastroenterol. 2011 Mar 30. [Epub ahead of print]


  941. A new era of hepatitis C therapy begins
    Jensen DM. N Engl J Med. 2011 Mar 31;364(13):1272-4.


  942. Hepatitis C Treatment Completion in Individuals With Psychiatric Comorbidity and Depression
    Gardenier D, Wisnivesky J, McGinn LK, Kronish IM, McGinn TG. Gastroenterol Nurs. 2011 March/April;34(2):102-106.


  943. Acoustic Liver Biopsy in Patients with Hepatitis C and Advanced Liver Fibrosis Using Endoscopic Ultrasound
    Vegesna A, Nazir A, Chung CY, Kane S, Thomas R, Miller L. Dig Dis Sci. 2011 Apr 1. [Epub ahead of print]


  944. Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis
    Chen JJ, Yu CB, Du WB, Li LJ. Hepatobiliary Pancreat Dis Int. 2011 Apr;10(2):122-7.


  945. Delayed viral clearance of chronic hepatitis C in patients after treatment failure
    Cho SH, Lee SW, Choi SR, Han SY, Roh MH, Lee JH, Jang JS, Baek YH, Kim SY. Gut Liver. 2011 Mar;5(1):110-4. Epub 2011 Mar 16.


  946. IL28B single nucleotide polymorphisms in the treatment of hepatitis C
    Lange CM, Zeuzem S. J Hepatol. 2011 Mar 24. [Epub ahead of print]


  947. Antiviral therapy in patients after treatment for hepatitis C-related hepatocellular carcinoma
    Shin SR, Paik SW, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC. Gut Liver. 2011 Mar;5(1):77-81. Epub 2011 Mar 16.


  948. High-Dose Pegylated Interferon Alfa and Ribavirin in Non-responder Hepatitis C Patients and Relationship with IL28B Genotype (SYREN Trial)
    Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM. Gastroenterology. 2011 Mar 23. [Epub ahead of print]


  949. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C
    Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; on behalf of the ITAHEC Study Group. Aliment Pharmacol Ther. 2011 Mar 28. doi: 10.1111/j.1365-2036.2011.04635.x. [Epub ahead of print]


  950. HCV-genotypes: a review on their origin, global status, assay system, pathogenecity and response to treatment
    Irshad M, Ansari MA, Singh A, Nag P, Raghvendra L, Singh S, Badhal SS. Hepatogastroenterology. 2010 Nov-Dec;57(104):1529-38.


  951. Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States from 1988-2008
    Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Clin Gastroenterol Hepatol. 2011 Mar 24. [Epub ahead of print]


  952. Hepatic encephalopathy: A central neuroinflammatory disorder?
    Butterworth RF. Hepatology. 2011 Apr;53(4):1372-6. doi: 10.1002/hep.24228.


  953. Increased risk of parkinsonism among patients with cirrhosis: a 7-year follow-up study
    Kang JH, Tsai MC, Lin CC, Lin HL, Lin HC. Liver Int. 2011 May;31(5):685-691. doi: 10.1111/j.1478-3231.2010.02432.x. Epub 2011 Jan 11.


  954. Validation of the Psychometric Hepatic Encephalopathy Score (PHES) for Identifying Patients with Minimal Hepatic Encephalopathy
    Duarte-Rojo A, Estradas J, Hernández-Ramos R, Ponce-de-León S, Córdoba J, Torre A. Dig Dis Sci. 2011 Apr 3. [Epub ahead of print]


  955. Regional variations in the concentrations of ketone bodies in cirrhosis and hepatic encephalopathy: a study in patients with TIPSS
    Dabos KJ, Houghton BJ, Pyleris E, Redhead DN, Hayes PC, Salder IH, Plevris JN. Liver Int. 2011 May;31(5):707-11. doi: 10.1111/j.1478-3231.2011.02483.x. Epub 2011 Mar 6.


  956. Microglia activation in hepatic encephalopathy
    Zemtsova I, Görg B, Keitel V, Bidmon HJ, Schrör K, Häussinger D. Hepatology. 2011 Mar 30. doi: 10.1002/hep.24326. [Epub ahead of print]


  957. Complications and outcomes in chronic liver disease
    Rahimi RS, Rockey DC. Curr Opin Gastroenterol. 2011 Mar 30. [Epub ahead of print]


  958. Low-protein diets for hepatic encephalopathy debunked: let them eat steak
    Cabral CM, Burns DL. Nutr Clin Pract. 2011 Apr;26(2):155-9.


  959. Management of Hepatitis C Antiviral Therapy Adverse Effects
    Sung H, Chang M, Saab S. Curr Hepat Rep. 2011 Mar;10(1):33-40. Epub 2010 Dec 24.


  960. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more
    Pearlman BL, Traub N. Clin Infect Dis. 2011 Apr;52(7):889-900.


  961. Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?
    Vezali E, Aghemo A, Lampertico P, Colombo M. Clin Res Hepatol Gastroenterol. 2011 Mar 22. [Epub ahead of print]


  962. Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C
    Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, Berg T, Poo JL, Mello CB, Guenther R, Niederau C, Terg R, Bedossa P, Boparai N, Griffel LH, Burroughs M, Brass CA, Albrecht JK; EPIC(3) Study Group. Gastroenterology. 2011 Mar 16. [Epub ahead of print]


  963. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease
    Gisbert JP, Chaparro M, Esteve M. Aliment Pharmacol Ther. 2011 Mar;33(6):619-33.


  964. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection
    Nguyen LH, Ko S, Wong SS, Tran PS, Trinh HN, Garcia RT, Ahmed A, Lutchman GA, Keeffe EB, Nguyen MH. Hepatology. 2011 Mar 21. doi: 10.1002/hep.24308. [Epub ahead of print]


  965. Boceprevir for Untreated Chronic HCV Genotype 1 Infection
    Fred Poordad, M.D., Jonathan McCone, Jr., M.D., Bruce R. Bacon, M.D., Savino Bruno, M.D., Michael P. Manns, M.D., Mark S. Sulkowski, M.D., Ira M. Jacobson, M.D., K. Rajender Reddy, M.D., Zachary D. Goodman, M.D., Ph.D., Navdeep Boparai, M.S., Mark J. DiNubile, M.D., Vilma Sniukiene, M.D., Clifford A. Brass, M.D., Ph.D., Janice K. Albrecht, Ph.D., and Jean-Pierre Bronowicki, M.D., Ph.D. for the SPRINT-2 Investigators. N Engl J Med 2011; 364:1195-1206March 31, 2011


  966. Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States from 1988-2008
    Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Clin Gastroenterol Hepatol. 2011 Mar 24. [Epub ahead of print]


  967. Gastroenterology. 2011 Mar 24. [Epub ahead of print]
    A Functional Polymorphism in the Epidermal Growth Factor Gene is Associated with Risk for Hepatocellular Carcinoma.


  968. High-Dose Pegylated Interferon Alfa and Ribavirin in Non-responder Hepatitis C Patients and Relationship with IL28B Genotype (SYREN Trial)
    Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM. Gastroenterology. 2011 Mar 23. [Epub ahead of print]


  969. Antiviral therapy in patients after treatment for hepatitis C-related hepatocellular carcinoma
    Shin SR, Paik SW, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC. Gut Liver. 2011 Mar;5(1):77-81. Epub 2011 Mar 16.


  970. IL28B single nucleotide polymorphisms in the treatment of hepatitis C
    Lange CM, Zeuzem S. J Hepatol. 2011 Mar 24. [Epub ahead of print]


  971. Delayed viral clearance of chronic hepatitis C in patients after treatment failure
    Cho SH, Lee SW, Choi SR, Han SY, Roh MH, Lee JH, Jang JS, Baek YH, Kim SY. Gut Liver. 2011 Mar;5(1):110-4. Epub 2011 Mar 16.


  972. Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis
    Chen JJ, Yu CB, Du WB, Li LJ. Hepatobiliary Pancreat Dis Int. 2011 Apr;10(2):122-7.


  973. Acoustic Liver Biopsy in Patients with Hepatitis C and Advanced Liver Fibrosis Using Endoscopic Ultrasound
    Vegesna A, Nazir A, Chung CY, Kane S, Thomas R, Miller L. Dig Dis Sci. 2011 Apr 1. [Epub ahead of print]


  974. Hepatitis C Treatment Completion in Individuals With Psychiatric Comorbidity and Depression
    Gardenier D, Wisnivesky J, McGinn LK, Kronish IM, McGinn TG. Gastroenterol Nurs. 2011 March/April;34(2):102-106.


  975. A new era of hepatitis C therapy begins
    Jensen DM. N Engl J Med. 2011 Mar 31;364(13):1272-4.


  976. Genetics in liver disease: new concepts
    Zimmer V, Lammert F. Curr Opin Gastroenterol. 2011 Mar 30. [Epub ahead of print]


  977. Malnutrion Impairs Interferon Signaling through mTOR and FoxO pathways in Patients with Chronic Hepatitis C
    Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S; Hokuriku Liver Study Group. Gastroenterology. 2011 Mar 30. [Epub ahead of print]


  978. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection
    Nguyen LH, Ko S, Wong SS, Tran PS, Trinh HN, Garcia RT, Ahmed A, Lutchman GA, Keeffe EB, Nguyen MH. Hepatology. 2011 Mar 21. doi: 10.1002/hep.24308. [Epub ahead of print]


  979. Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: A meta-analysis of two large prospective clinical trials
    D'Heygere F, George C, Van Vlierberghe H, Decaestecker J, Nakad A, Adler M, Delwaide J, Laureys A, Nevens F. J Med Virol. 2011 May;83(5):815-9. doi: 10.1002/jmv.22049.


  980. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection
    Petta S, Cammà C, Marco VD, Macaluso FS, Maida M, Pizzolanti G, Belmonte B, Cabibi D, Stefano RD, Ferraro D, Guarnotta C, Venezia G, Craxì A. Liver Int. 2011 Apr;31(4):507-15.


  981. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment
    Romero-Gomez M, Eslam M, Ruiz A, Maraver M. Liver Int. 2011 Apr;31(4):443-60.


  982. Hepatitis C virus in primary care: survey of nurses' attitudes to caring
    Frazer K, Glacken M, Coughlan B, Staines A, Daly L. J Adv Nurs. 2011 Mar;67(3):598-608.


  983. Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis
    Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Dig Dis Sci. 2011 Mar 5. [Epub ahead of print]


  984. Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C?
    Blacklaws H, Gardner A, Usher K. J Clin Nurs. 2011 Mar 3.. [Epub ahead of print]


  985. Treatment failure and resistance with direct acting antiviral drugs against hepatitis C virus
    Pawlotsky JM. Hepatology. 2011 Mar 3. doi: 10.1002/hep.24262. [Epub ahead of print]


  986. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
    Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O. Hepatology. 2011 Mar;53(3):746-54. doi: 10.1002/hep.24154.


  987. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
    Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Nat Rev Gastroenterol Hepatol. 2011 Mar 8. [Epub ahead of print]


  988. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities
    Dibonaventura MD, Wagner JS, Yuan Y, L'italien G, Langley P, Ray Kim W. J Med Econ. 2011 Mar 9. [Epub ahead of print]


  989. Second phase HCV RNA decline during telaprevir based therapy increases with drug effectiveness: Implications for treatment duration
    Guedj J, Perelson AS. Hepatology. 2011 Mar 7. [Epub ahead of print]


  990. Coffee Consumption is Associated with Response to Peginterferon and Ribavirin Therapy in Patients with Chronic Hepatitis C
    Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE; HALT-C Trial Group. Gastroenterology. 2011 Mar 1. [Epub ahead of print]


  991. Depression in patients with nonalcoholic Fatty liver disease and chronic viral hepatitis B and C
    Weinstein AA, Kallman Price J, Stepanova M, Poms LW, Fang Y, Moon J, Nader F, Younossi ZM. Psychosomatics. 2011 Mar-Apr;52(2):127-32.


  992. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation
    Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, Neuhaus R, Neuhaus P, Neumann UP, Bahra M. Liver Transpl. 2011 Mar;17(3):289-98.


  993. IL-32: A new proinflammatory cytokine involved in HCV-related liver inflammation and fibrosis
    Moschen AR, Fritz T, Clouston AD, Rebhan I, Bauhofer O, Barrie HD, Powell EE, Kim SH, Dinarello CA, Bartenschlager R, Jonsson JR, Tilg H. Hepatology. 2011 Mar 4. doi: 10.1002/hep.24285. [Epub ahead of print]


  994. Survival After Liver Transplantation Using Hepatitis C Virus-Positive Donor Allografts: Case-Controlled Analysis of the UNOS Database
    Burr AT, Li Y, Tseng JF, Saidi RF, Bozorgzadeh A, Shah SA. World J Surg. 2011 Mar 8. [Epub ahead of print]


  995. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype
    Neukam K, Nattermann J, Rallón N, Rivero A, Caruz A, Macías J, Vogel M, Benito J, Camacho A, Mira J, Schwarze-Zander C, Barreiro P, Martínez A, Rockstroh J, Soriano V, Pineda J. HIV Med. 2011 Mar 6. [Epub ahead of print]


  996. HCV RNA decline in the first 24hours exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin
    Laufer N, Bolcic F, Rolón M, Martinez A, Reynoso R, Pérez H, Salomón H, Cahn P, Quarleri J. Antiviral Res. 2011 Mar 1. [Epub ahead of print]


  997. A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients with Hepatitis C
    Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. Clin Gastroenterol Hepatol. 2011 Mar 10. [Epub ahead of print]


  998. Non-Invasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients with Chronic Hepatitis C
    Vergniol J, Foucher J, Terrebonne E, Bernard PH, Le Bail B, Merrouche W, Couzigou P, de Lédinghen V. Gastroenterology. 2011 Mar 1. [Epub ahead of print]


  999. High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients
    Patel K, Lucas J, Thompson J, Dubois L, Tillmann H, Thompson A, Uzarski D, Califf R, Moseley M, Ginsburg G, McHutchison J, McCarthy J; for MURDOCK Horizon 1 Study Team. Hepatology. 2011 Mar 4. [Epub ahead of print]


  1000. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients
    Labarga P, Soriano V, Caruz A, Poveda E, Di Lello F, Hernandez-Quero J, Moreno S, Bernal E, Miró JM, Leal M, Gutierrez F, Portilla J, Pineda JA; on behalf of CoRIS. AIDS. 2011 Mar 3. [Epub ahead of print]


  1001. Insulin Resistance is Independently Associated with Significant Hepatic Fibrosis in Asian Chronic Hepatitis C Genotype 2 or 3 Patients
    Patel K, Thompson A, Chuang W, Lee C, Peng C, Shanmuganathan G, Thongsawat S, Tanwandee T, Mahachai V, Pramoolsinsap C, Cho M, Han K, Shah S, Foster G, Clark P, Pulkstenis E, Subramanian M, McHutchison J. J Gastroenterol Hepatol. 2011 Mar 16. doi: 10.1111/j.1440-1746.2011.06722.x. [Epub ahead of print]


  1002. Genetic variation in IL28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV infected children
    Ruiz-Extremera A, Muñoz-Gámez J, Salmerón-Ruiz MA, de Rueda PM, Quiles-Pérez R, Gila-Medina A, Casado J, Martín AB, Sanjuan-Nuñez L, Carazo A, Pavón EJ, Ocete-Hita E, León J, Salmerón J. Hepatology. 2011 Mar 16. [Epub ahead of print]


  1003. Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort
    Cooper C, Kanters S, Klein M, Chaudhury P, Marotta P, Wong P, Kneteman N, Mills EJ. AIDS. 2011 Mar 27;25(6):777-86.


  1004. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study
    Marcellin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Varastet M, Lang JP, Melin P, Cacoub P; for the CheObs Study Group. Liver Int. 2011 Apr;31(4):516-524.Epub 2011 Feb 15.


  1005. Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in Patients With Genotype 2 and 3 Chronic Hepatitis C
    Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rössle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Müller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H. J Hepatol. 2011 Jan 12. [Epub ahead of print]


  1006. New direct-acting antivirals' combination for the treatment of chronic hepatitis C
    Asselah T, Marcellin P. Liver Int. 2011 Jan;31 Suppl 1:68-77.


  1007. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C
    Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H. J Gastroenterol. 2011 Jan 19. [Epub ahead of print]


  1008. Impact of a sustained virological response on the long-term outcome of hepatitis C
    Alberti A. Liver Int. 2011 Jan;31 Suppl 1:18-22.


  1009. Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients
    Akiyama T, Mizuta T, Kawazoe S, Eguchi Y, Kawaguchi Y, Takahashi H, Ozaki I, Fujimoto K. World J Gastroenterol. 2011 Feb 21;17(7):914-21.


  1010. Hepatitis C virus infection during pregnancy and the newborn period - are they opportunities for treatment?
    Arshad M, El-Kamary SS, Jhaveri R. J Viral Hepat. 2011 Apr;18(4):229-36. doi: 10.1111/j.1365-2893.2010.01413.x. Epub 2011 Jan 7.


  1011. How to use virological tools for the optimal management of chronic hepatitis C
    de Leuw P, Sarrazin C, Zeuzem S. Liver Int. 2011 Jan;31 Suppl 1:3-12.


  1012. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?
    Castera L, Bedossa P. Liver Int. 2011 Jan;31 Suppl 1:13-7.


  1013. Future hepatitis C virus treatment: interferon-sparing combinations
    Gane E. Liver Int. 2011 Jan;31 Suppl 1:62-7.


  1014. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care
    McHutchison JG. Liver Int. 2011 Jan;31 Suppl 1:29-35.


  1015. Optimal therapy in hepatitis C virus genotypes 2 and 3 patients
    Petta S, Craxì A. Liver Int. 2011 Jan;31 Suppl 1:36-44.


  1016. Viral Genotype-Specific Role of PNPLA3, PPARG, MTTP and IL28B in Hepatitis C Virus-Associated Steatosis
    Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Moradpour D, Cerny A, Malinverni R, Kaddai V, Bochud M, Negro F, Bochud PY; On Behalf Of The Swiss Hepatitis C Cohort Study Group. J Hepatol. 2011 Jan 11. [Epub ahead of print]


  1017. Sustained virologic response among Latino veterans; does it represent the cure of chronic hepatitis C infection?
    De Jesús J, Nieves-Santiago P, Rodríguez-Pérez F, Toro DH. P R Health Sci J. 2010 Dec;29(4):397-401.


  1018. Immunological/virological peripheral blood biomarkers and distinct patterns of sleeping quality in chronic Hepatitis C patients
    de Almeida CM, de Lima TA, Castro DB, Torres KL, da Silva Braga W, Peruhype-Magalhães V, Teixeira-Carvalho A, Martins-Filho OA, Malheiro A. Scand J Immunol. 2011 Jan 13. [Epub ahead of print]


  1019. Treatment of hepatitis C virus infection in patients with end-stage renal disease
    Liu CH, Kao JH. J Gastroenterol Hepatol. 2011 Feb;26(2):228-39.


  1020. Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony
    Jamma S, Hussain G, Lau DT. Curr Hepat Rep. 2010;9(4):260-269.


  1021. Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads
    Itoh Y, Nishimura T, Hashimoto H, Yamaguchi K, Niimi T, Yokomizo C, Fujii H, Minami M, Yasui K, Mitsuyoshi H, Okanoue T, Takehara T, Hiasa Y, Onji M, Yoshikawa T. Hepatol Res. 2011 Feb;41(2):126-32.


  1022. Incidence of Hepatitis-C among HIV infected men who have sex with men (MSM) attending a sexual health service: a cohort study
    Gamage DG, Read TR, Bradshaw CS, Hocking JS, Howley K, Chen MY, Fairley CK. BMC Infect Dis. 2011 Feb 3;11(1):39. [Epub ahead of print]


  1023. Hepatitis C virus Resistance to Protease Inhibitors
    Halfon P, Locarnini S. J Hepatol. 2011 Jan 29. [Epub ahead of print]


  1024. Diagnosis of Depression in Former Injection Drug Users With Chronic Hepatitis C
    Scott JD, Wang CC, Coppel E, Lau A, Veitengruber J, Roy-Byrne P. J Clin Gastroenterol. 2011 Feb 2. [Epub ahead of print]


  1025. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin
    Trapero-Marugán M, Mendoza J, Chaparro M, González-Moreno L, Moreno-Monteagudo JA, Borque MJ, Moreno-Otero R. World J Gastroenterol. 2011 Jan 28;17(4):493-8.


  1026. Interferon lambdas: the next cytokine storm
    Kelly C, Klenerman P, Barnes E. Gut. 2011 Feb 8. [Epub ahead of print]


  1027. Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease
    Durante-Mangoni E, Iossa D, Pinto D, De Vincentiis L, Ragone E, Utili R. Dig Liver Dis. 2011 Feb 8. [Epub ahead of print]


  1028. Epidemic of Sexually Transmitted Hepatitis C Virus Infection Among HIV-Infected Men
    Fierer DS. Curr Infect Dis Rep. 2010 Mar;12(2):118-25.


  1029. Recommendations for the management of mixed Cryoglobulinemia syndrome in Hepatitis C virus-infected patients
    Pietrogrande M, Devita S, Zignego A, et al. Autoimmun Rev. 2011 Feb 5. [Epub ahead of print]


  1030. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy
    Krishnan SM, Dixit NM. PLoS Comput Biol. 2011 Feb 3;7(2)


  1031. Pegylated-interferon-?(2a) in clinical practice: how to manage patients suffering from side effects
    Calvaruso V, Mazza M, Almasio PL. Expert Opin Drug Saf. 2011 Feb 16. [Epub ahead of print]


  1032. Dendritic cells in hepatitis C infection: can they (help) win the battle?
    Dolganiuc A, Szabo G. J Gastroenterol. 2011 Feb 17. [Epub ahead of print]


  1033. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy
    Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, Niu WF, Jeng J, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS. Proc Natl Acad Sci U S A. 2011 Feb 14. [Epub ahead of print]


  1034. High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis
    Petta S, Tripodo C, Grimaudo S, Cabibi D, Cammà C, Di Cristina A, Di Marco V, Di Vita G, Ingrao S, Mazzola A, Marchesini G, Pipitone R, Craxì A. Dig Liver Dis. 2011 Feb 14. [Epub ahead of print]


  1035. Psychiatrists' knowledge and practices in screening and assessment of Hepatitis C for inpatients with severe mental illness
    Lagios K, Deane F. Australas Psychiatry. 2011 Feb 25. [Epub ahead of print]


  1036. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia
    Poordad F, Theodore D, Sullivan J, Grotzinger K. J Med Econ. 2011 Feb 25. [Epub ahead of print]


  1037. Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics
    Tavis JE, Donlin MJ, Aurora R, Fan X, Di Bisceglie AM. Genome Med. 2011 Feb 8;3(2):8. [Epub ahead of print]


  1038. Novel Findings for the Development of Drug Therapy for Various Liver Diseases:Genetic Variation in IL-28B Is Associated With Response to the Therapy for Chronic Hepatitis C
    Sugiyama M, Tanaka Y, Nakanishi M, Mizokami M. J Pharmacol Sci. 2011 Feb 22. [Epub ahead of print]


  1039. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children
    Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, Murray KF, Narkewicz MR, Rosenthal P, Smith LJ, Lobritto SJ, Schwarz KB, Robuck PR, Barton B, González-Peralta RP. Hepatology. 2011 Feb 23. [Epub ahead of print]


  1040. Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature
    López V, Molina I, Monteagudo C, Jordá E. Int J Dermatol. 2011 Mar;50(3):287-91.


  1041. Assessment of fibrosis and cirrhosis in liver biopsies: an update
    Germani G, Hytiroglou P, Fotiadu A, Burroughs AK, Dhillon AP. Semin Liver Dis. 2011 Feb;31(1):82-90. Epub 2011 Feb 22.


  1042. Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future
    Ferenci P. Expert Opin Drug Saf. 2011 Feb 23. [Epub ahead of print]


  1043. Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
    Gaglio PJ, Moss N, McGaw C, Reinus J. Dig Dis Sci. 2011 Feb 19. [Epub ahead of print]


  1044. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-? plus ribavirin therapy in Taiwanese chronic HCV infection
    Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, Chang SW, Wu J, Sheen IS. Genes Immun. 2011 Feb 24. [Epub ahead of print]


  1045. Prevention of virus hepatitis A to E.
    Cornberg M, Manns MP. Internist (Berl). 2011 Feb 23. [Epub ahead of print]


  1046. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in us patients with chronic hepatitis C
    Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; the HALT-C Trial Group. Hepatology. 2011 Mar 3. [Epub ahead of print]


  1047. 'Easy to Treat' genotypes were not created equal. Can rapid virological response (RVR) level the playing field?
    Duarte-Rojo A, Heathcote EJ, Feld JJ. J Hepatol. 2011 Feb 17. [Epub ahead of print]


  1048. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C
    Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, Missale G, Zeuzem S, Pawlotsky JM, Schalm S, Hellstrand K, Neumann AU, Lagging M; the DITTO-HCV study group. J Hepatol. 2011 Feb 24. [Epub ahead of print]


  1049. Mechanism of action of Ribavirin in a novel hepatitis C virus replication cell system
    Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N. Virus Res. 2011 Feb 11. [Epub ahead of print]


  1050. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b
    Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M; the Ochanomizu-Liver Conference Study Group. J Med Virol. 2011 Feb 25. doi: 10 [Epub ahead of print]


  1051. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006
    Williams IT, Bell BP, Kuhnert W, Alter MJ. Arch Intern Med. 2011 Feb 14;171(3):242-8.


  1052. U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for
    Ho SB, Aqel B, Dieperink E, Liu S, Tetrick L, Falck-Ytter Y, Decomarmond C, Smith CI, McKee DP, Boyd W, Kulig CC, Bini EJ, Pedrosa MC. Dig Dis Sci. 2011 Jan 11. [Epub ahead of print]


  1053. HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies
    Operskalski EA, Kovacs A. Curr HIV/AIDS Rep. 2011 Jan 11. [Epub ahead of print]


  1054. The natural history of interferon-alpha induced thyroiditis in chronic hepatitis C patients: A long term study
    Tran HA, Jones TL, Ianna EA, Reeves GE. Thyroid Res. 2011 Jan 8;4(1):2. [Epub ahead of print]


  1055. Hepatic steatosis and hepatitis C: Still unhappy bedfellows?
    Hwang SJ, Lee SD. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:96-101.


  1056. Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1
    Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, Eugen-Olsen J, Weis N. Eur J Clin Microbiol Infect Dis. 2011 Jan 13. [Epub ahead of print]


  1057. IL-28B predicts response to chronic hepatitis C therapy -fine-mapping and replication study in Asian populations
    Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Imamura M, Hiraga N, Kawakami Y, Aimitsu S, Kao JH, Kubo M, Tsunoda T, Kumada H, Nakamura Y, Hayes CN, Chayama K. J Gen Virol. 2011 Jan 12. [Epub ahead of print]


  1058. The natural history of interferon-alpha induced thyroiditis in chronic hepatitis C patients: A long term study
    Tran HA, Jones TL, Ianna EA, Reeves GE. Thyroid Res. 2011 Jan 8;4(1):2. [Epub ahead of print]


  1059. Hepatic steatosis and hepatitis C: Still unhappy bedfellows?
    Hwang SJ, Lee SD. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:96-101.


  1060. Hepatitis C virus: How genetic variability affects pathobiology of disease
    Chayama K, Hayes CN. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:83-95.


  1061. Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1
    Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, Eugen-Olsen J, Weis N. Eur J Clin Microbiol Infect Dis. 2011 Jan 13. [Epub ahead of print]


  1062. IL-28B predicts response to chronic hepatitis C therapy -fine-mapping and replication study in Asian populations
    Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Imamura M, Hiraga N, Kawakami Y, Aimitsu S, Kao JH, Kubo M, Tsunoda T, Kumada H, Nakamura Y, Hayes CN, Chayama K. J Gen Virol. 2011 Jan 12. [Epub ahead of print]


  1063. New direct-acting antivirals' combination for the treatment of chronic hepatitis C
    Asselah T, Marcellin P. Liver Int. 2011 Jan;31 Suppl 1:68-77.


  1064. Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in Patients With Genotype 2 and 3 Chronic Hepatitis C
    Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rössle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Müller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H. J Hepatol. 2011 Jan 12. [Epub ahead of print]


  1065. How to use virological tools for the optimal management of chronic hepatitis C
    de Leuw P, Sarrazin C, Zeuzem S. Liver Int. 2011 Jan;31 Suppl 1:3-12.


  1066. Impact of a sustained virological response on the long-term outcome of hepatitis C
    Alberti A. Liver Int. 2011 Jan;31 Suppl 1:18-22.


  1067. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C
    Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H. J Gastroenterol. 2011 Jan 19. [Epub ahead of print]


  1068. Optimal therapy in hepatitis C virus genotypes 2 and 3 patients
    Petta S, Craxì A. Liver Int. 2011 Jan;31 Suppl 1:36-44.


  1069. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care
    McHutchison JG. Liver Int. 2011 Jan;31 Suppl 1:29-35.


  1070. Future hepatitis C virus treatment: interferon-sparing combinations
    Gane E. Liver Int. 2011 Jan;31 Suppl 1:62-7.


  1071. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?
    Castera L, Bedossa P. Liver Int. 2011 Jan;31 Suppl 1:13-7.


  1072. Immunological/virological peripheral blood biomarkers and distinct patterns of sleeping quality in chronic Hepatitis C patients
    de Almeida CM, de Lima TA, Castro DB, Torres KL, da Silva Braga W, Peruhype-Magalhães V, Teixeira-Carvalho A, Martins-Filho OA, Malheiro A. Scand J Immunol. 2011 Jan 13. [Epub ahead of print]


  1073. Sustained virologic response among Latino veterans; does it represent the cure of chronic hepatitis C infection?
    De Jesús J, Nieves-Santiago P, Rodríguez-Pérez F, Toro DH. P R Health Sci J. 2010 Dec;29(4):397-401.


  1074. Viral Genotype-Specific Role of PNPLA3, PPARG, MTTP and IL28B in Hepatitis C Virus-Associated Steatosis
    Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Moradpour D, Cerny A, Malinverni R, Kaddai V, Bochud M, Negro F, Bochud PY; On Behalf Of The Swiss Hepatitis C Cohort Study Group. J Hepatol. 2011 Jan 11. [Epub ahead of print]


  1075. Treatment of hepatitis C virus infection in patients with end-stage renal disease
    Liu CH, Kao JH. J Gastroenterol Hepatol. 2011 Feb;26(2):228-39.


  1076. Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony
    Jamma S, Hussain G, Lau DT. Curr Hepat Rep. 2010;9(4):260-269.


  1077. Hepatitis C virus Resistance to Protease Inhibitors
    Halfon P, Locarnini S. J Hepatol. 2011 Jan 29. [Epub ahead of print]


  1078. Incidence of Hepatitis-C among HIV infected men who have sex with men (MSM) attending a sexual health service: a cohort study
    Gamage DG, Read TR, Bradshaw CS, Hocking JS, Howley K, Chen MY, Fairley CK. BMC Infect Dis. 2011 Feb 3;11(1):39. [Epub ahead of print]


  1079. Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads
    Itoh Y, Nishimura T, Hashimoto H, Yamaguchi K, Niimi T, Yokomizo C, Fujii H, Minami M, Yasui K, Mitsuyoshi H, Okanoue T, Takehara T, Hiasa Y, Onji M, Yoshikawa T. Hepatol Res. 2011 Feb;41(2):126-32.


  1080. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin
    Trapero-Marugán M, Mendoza J, Chaparro M, González-Moreno L, Moreno-Monteagudo JA, Borque MJ, Moreno-Otero R. World J Gastroenterol. 2011 Jan 28;17(4):493-8.


  1081. Diagnosis of Depression in Former Injection Drug Users With Chronic Hepatitis C
    Scott JD, Wang CC, Coppel E, Lau A, Veitengruber J, Roy-Byrne P. J Clin Gastroenterol. 2011 Feb 2. [Epub ahead of print]


  1082. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C
    Pattullo V, Heathcote EJ, Wong DK. Hepatol Int. 2010 Aug 8;4(4):723-31.


  1083. Hepatitis C virus in primary care: survey of nurses' attitudes to caring
    Frazer K, Glacken M, Coughlan B, Staines A, Daly L. J Adv Nurs. 2011 Mar;67(3):598-608.


  1084. Interferon lambdas: the next cytokine storm
    Kelly C, Klenerman P, Barnes E. Gut. 2011 Feb 8. [Epub ahead of print]


  1085. Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease
    Durante-Mangoni E, Iossa D, Pinto D, De Vincentiis L, Ragone E, Utili R. Dig Liver Dis. 2011 Feb 8. [Epub ahead of print]


  1086. Epidemic of Sexually Transmitted Hepatitis C Virus Infection Among HIV-Infected Men
    Fierer DS. Curr Infect Dis Rep. 2010 Mar;12(2):118-25.


  1087. Recommendations for the management of mixed Cryoglobulinemia syndrome in Hepatitis C virus-infected patients
    Pietrogrande M, Devita S, Zignego A, et al. Autoimmun Rev. 2011 Feb 5. [Epub ahead of print]


  1088. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy
    Krishnan SM, Dixit NM. PLoS Comput Biol. 2011 Feb 3;7(2)


  1089. Pegylated-interferon-?(2a) in clinical practice: how to manage patients suffering from side effects
    Calvaruso V, Mazza M, Almasio PL. Expert Opin Drug Saf. 2011 Feb 16. [Epub ahead of print]


  1090. High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis
    Petta S, Tripodo C, Grimaudo S, Cabibi D, Cammà C, Di Cristina A, Di Marco V, Di Vita G, Ingrao S, Mazzola A, Marchesini G, Pipitone R, Craxì A. Dig Liver Dis. 2011 Feb 14. [Epub ahead of print]


  1091. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006
    Williams IT, Bell BP, Kuhnert W, Alter MJ. Arch Intern Med. 2011 Feb 14;171(3):242-8.


  1092. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy
    Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, Niu WF, Jeng J, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS. Proc Natl Acad Sci U S A. 2011 Feb 14. [Epub ahead of print]


  1093. Dendritic cells in hepatitis C infection: can they (help) win the battle?
    Dolganiuc A, Szabo G. J Gastroenterol. 2011 Feb 17. [Epub ahead of print]


  1094. Psychiatrists' knowledge and practices in screening and assessment of Hepatitis C for inpatients with severe mental illness
    Lagios K, Deane F. Australas Psychiatry. 2011 Feb 25. [Epub ahead of print]


  1095. Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics
    Tavis JE, Donlin MJ, Aurora R, Fan X, Di Bisceglie AM. Genome Med. 2011 Feb 8;3(2):8. [Epub ahead of print]


  1096. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia
    Poordad F, Theodore D, Sullivan J, Grotzinger K. J Med Econ. 2011 Feb 25. [Epub ahead of print]


  1097. Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature
    López V, Molina I, Monteagudo C, Jordá E. Int J Dermatol. 2011 Mar;50(3):287-91.


  1098. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children
    Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, Murray KF, Narkewicz MR, Rosenthal P, Smith LJ, Lobritto SJ, Schwarz KB, Robuck PR, Barton B, González-Peralta RP. Hepatology. 2011 Feb 23. [Epub ahead of print]


  1099. Novel Findings for the Development of Drug Therapy for Various Liver Diseases:Genetic Variation in IL-28B Is Associated With Response to the Therapy for Chronic Hepatitis C
    Sugiyama M, Tanaka Y, Nakanishi M, Mizokami M. J Pharmacol Sci. 2011 Feb 22. [Epub ahead of print]


  1100. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-? plus ribavirin therapy in Taiwanese chronic HCV infection
    Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, Chang SW, Wu J, Sheen IS. Genes Immun. 2011 Feb 24. [Epub ahead of print]


  1101. Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
    Gaglio PJ, Moss N, McGaw C, Reinus J. Dig Dis Sci. 2011 Feb 19. [Epub ahead of print]


  1102. Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future
    Ferenci P. Expert Opin Drug Saf. 2011 Feb 23. [Epub ahead of print]


  1103. Assessment of fibrosis and cirrhosis in liver biopsies: an update
    Germani G, Hytiroglou P, Fotiadu A, Burroughs AK, Dhillon AP. Semin Liver Dis. 2011 Feb;31(1):82-90. Epub 2011 Feb 22.


  1104. Prevention of virus hepatitis A to E.
    Cornberg M, Manns MP. Internist (Berl). 2011 Feb 23. [Epub ahead of print]


  1105. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in us patients with chronic hepatitis C
    Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; the HALT-C Trial Group. Hepatology. 2011 Mar 3. [Epub ahead of print]


  1106. Mechanism of action of Ribavirin in a novel hepatitis C virus replication cell system
    Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N. Virus Res. 2011 Feb 11. [Epub ahead of print]


  1107. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C
    Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, Missale G, Zeuzem S, Pawlotsky JM, Schalm S, Hellstrand K, Neumann AU, Lagging M; the DITTO-HCV study group. J Hepatol. 2011 Feb 24. [Epub ahead of print]


  1108. 'Easy to Treat' genotypes were not created equal. Can rapid virological response (RVR) level the playing field?
    Duarte-Rojo A, Heathcote EJ, Feld JJ. J Hepatol. 2011 Feb 17. [Epub ahead of print]


  1109. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b
    Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M; the Ochanomizu-Liver Conference Study Group. J Med Virol. 2011 Feb 25. doi: 10 [Epub ahead of print]


  1110. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006
    Williams IT, Bell BP, Kuhnert W, Alter MJ. Arch Intern Med. 2011 Feb 14;171(3):242-8.


  1111. Treatment failure and resistance with direct acting antiviral drugs against hepatitis C virus
    Pawlotsky JM. Hepatology. 2011 Mar 3. doi: 10.1002/hep.24262. [Epub ahead of print]


  1112. Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C?
    Blacklaws H, Gardner A, Usher K. J Clin Nurs. 2011 Mar 3.. [Epub ahead of print]


  1113. Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis
    Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Dig Dis Sci. 2011 Mar 5. [Epub ahead of print]


  1114. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
    Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O. Hepatology. 2011 Mar;53(3):746-54. doi: 10.1002/hep.24154.


  1115. The natural history of interferon-alpha induced thyroiditis in chronic hepatitis C patients: A long term study
    Tran HA, Jones TL, Ianna EA, Reeves GE. Thyroid Res. 2011 Jan 8;4(1):2. [Epub ahead of print]


  1116. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses
    Houghton M. Immunol Rev. 2011 Jan;239(1):99-108.


  1117. Chronic viral hepatitis: epidemiology, molecular biology, and antiviral therapy
    Gonzalez SA, Keeffe EB. Front Biosci. 2011 Jan 1;16:225-50.


  1118. Hepatitis C virus replication and potential targets for direct-acting agents
    O'Leary JG, Davis GL. Therap Adv Gastroenterol. 2010 Jan;3(1):43-53


  1119. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients
    Burney T, Dusheiko G. Expert Rev Anti Infect Ther. 2010 Dec 14


  1120. Evaluation of a New; Rapid Test for Detecting HCV Infection; Suitable for Use with Blood or Oral Fluid
    Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, Tatum HA, Friel TJ, Demicco MP, Lee WM, Eder SE, Monto A, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Unangst JL, Kriebel L, Feiss G, Roehler M. J Virol Methods. 2010 Dec 20


  1121. Dietary History and Physical Activity and Risk of Advanced Liver Disease in Veterans with Chronic Hepatitis C Infection
    White DL, Richardson PA, Al-Saadi M, Fitzgerald SJ, Green L, Amaratunge C, Anand M, El-Serag HB. Dig Dis Sci. 2010 Dec 28.


  1122. Thrombocytopenia in chronic hepatitis C
    Olariu M, Olariu C, Olteanu D. J Gastrointestin Liver Dis. 2010 Dec;19(4):381-5.


  1123. Current therapies for chronic hepatitis C
    Ferguson MC. Pharmacotherapy. 2011 Jan;31(1):92-111.


  1124. Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-?-2a and ribavirin in HIV/HCV co-infected patients
    Vachon Marie-Louise C; Factor Stephanie H; Branch Andrea D; Fiel Maria-Isabel; Rodriguez-Torres Maribel; Bräu Norbert; Sterling Richard K; Slim Jihad; Talal Andrew H; Dieterich Douglas T; Sulkowski Mark S. Journal of hepatology 2011;54(1):41-7. 2. 2010.


  1125. NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C
    Asselah T. J Hepatol. 2010 Dec 15.


  1126. Lymphocytosis as a predictor of poor response to treatment of hepatitis C
    Martinez-Camacho A, Khaoustov VI, Adam E, Lewis DE, Tavakoli-Tabasi S, Yoffe B. Gastroenterol Clin Biol. 2010 Dec 22.


  1127. Comparable performance of TMA and Real-Time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy
    Bortoletto G, Campagnolo D, Mirandola S, Comastri G, Severini L, Pulvirenti FR, Alberti A. J Clin Virol. 2010 Dec 29. [Epub ahead of print]


  1128. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes
    Loomba R, Rivera MM, McBurney R, Park Y, Haynes-Williams V, Rehermann B, Alter HJ, Herrine SK, Liang TJ, Hoofnagle JH, Heller T. Aliment Pharmacol Ther. 2010 Dec 29. [Epub ahead of print]


  1129. Impact of hepatitis C in mortality in patients on hemodialysis
    Rabanal CP, Zevallos JC, Cusato RC. J Bras Nefrol. 2010 Dec;32(4):337-341.


  1130. Hepatitis C virus: Up to the minute
    Roche B, Samuel D. Liver Transpl. 2010 Oct;16(S2):S26-S35.


  1131. Transfusion-transmissible viral infections among US military recipients of whole blood and platelets during Operation Enduring Freedom and Operation Iraqi Freedom
    Hakre S, Peel SA, O'Connell RJ, Sanders-Buell EE, Jagodzinski LL, Eggleston JC, Myles O, Waterman PE, McBride RH, Eader SA, Davis KW, Rentas FJ, Sateren WB, Naito NA, Tobler SK, Tovanabutra S, Petruccelli BP, McCutchan FE, Michael NL, Cersovsky SB, Scott PT. Transfusion. 2010 Oct 7. [Epub ahead of print]


  1132. Seizures During Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C: Observations From the WIN-R Trial
    Ahmed F, Jacobson IM, Herrera JL, Brand M, Wasserman RB, Fixelle AM, Rustgi VK, Albert C, Brown R, Brass C; for the WIN-R Study Group. J Clin Gastroenterol. 2010 Oct 6. [Epub ahead of print]


  1133. Antiviral therapy for hepatitis C is associated with improved clinical outcomes in patients with advanced fibrosis
    Russo MW. Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):535-9.


  1134. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C
    Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N. Hepatology. 2010 Aug 20. [Epub ahead of print]


  1135. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C
    Comai S, Cavalletto L, Chemello L, Bernardinello E, Ragazzi E, Costa CV, Bertazzo A. Pharmacol Res. 2010 Oct 9. [Epub ahead of print]


  1136. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients
    de Bruijne J, Bergmann JF, Reesink HW, Weegink CJ, Molenkamp R, Schinkel J, Tong X, Li J, Treitel MA, Hughes EA, van Lier JJ, van Vliet AA, Janssen HL, de Knegt RJ. Hepatology. 2010 Aug 19. [Epub ahead of print]


  1137. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy
    Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS. Aliment Pharmacol Ther. 2010 Oct;32(8):969-83. . Epub 2010 Aug 15.


  1138. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C
    Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Hepatology. 2010 Jul 29. [Epub ahead of print]


  1139. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
    Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. BMC Gastroenterol. 2010 Sep 9;10(1):103. [Epub ahead of print]


  1140. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy
    Tuma P, Medrano J, Resino S, Vispo E, Madejón A, Sánchez-Piedra C, Rivas P, Labarga P, Martín-Carbonero L, Barreiro P, Soriano V. Antivir Ther. 2010;15(6):881-6.


  1141. Use of Statins in Patients with Chronic Hepatitis C
    Andrus MR, East J. South Med J. 2010 Sep 2. [Epub ahead of print]


  1142. Patient-to-patient transmission of hepatitis C virus (HCV) during colonoscopy diagnosis
    Gonzalez-Candelas F, Guiral S, Carbo R, Valero A, Vanaclocha H, Gonzalez F, Bracho MA. Virol J. 2010 Sep 8;7(1):217. [Epub ahead of print


  1143. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France
    Larsen C, Bousquet V, Delarocque-Astagneau E, Pioche C, Roudot-Thoraval F; the HCV surveillance steering committee, the HCV surveillance group and Jean-Claude Desenclos. J Med Virol. 2010 Oct;82(10):1647-1654.


  1144. Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy
    François C, Descamps V, Brochot E, Bernard I, Canva V, Mathurin P, Castelain S, Duverlie G. J Med Virol. 2010 Oct;82(10):1640-6.


  1145. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis
    Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Yatsuhashi H, Izumi N. J Gastroenterol. 2010 Sep 10. [Epub ahead of print]


  1146. The impact of smoking on incident type 2 diabetes in a cohort with hepatitis B but not hepatitis C infection
    Wang CS, Chang TT, Yao WJ, Wang ST, Chou P. Viral Hepat. 2010 Aug 31. [Epub ahead of print]


  1147. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial
    Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P. Psychosomatics. 2010 Sep;51(5):401-8.


  1148. von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4
    Pramhas S, Homoncik M, Ferenci P, Ferlitsch A, Scherzer T, Gangl A, Peck-Radosavljevic M. Antivir Ther. 2010;15(6):831-9.


  1149. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C
    Rao GA, Pandya PK. Gastroenterology. 2010 Sep 9. [Epub ahead of print]


  1150. Candidate hepatitis C vaccine trials and people who inject drugs: Challenges and opportunities
    Maher L, White B, Hellard M, Madden A, Prins M, Kerr T, Page K. Vaccine. 2010 Sep 7. [Epub ahead of print]


  1151. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics
    Guedj J, Neumann AU. J Theor Biol. 2010 Sep 10. [Epub ahead of print]


  1152. Intensified peginterferon alfa-2a/ribavirin therapy for patients with HCV genotype 1, weight >/=85 kg and high viral load: randomized trial
    Reddy KR, Shiffman ML, Rodriguez-Torres M, Cheinquer H, Abdurakhmanov D, Bakulin I, Morozov V, Silva GF, Geyvandova N, Stanciu C, Rabbia M, McKenna M, Thommes JA, Harrison SA; PROGRESS Study Investigators. Gastroenterology. 2010 Sep 2. [Epub ahead of print]


  1153. A Multidisciplinary Therapeutic Approach for Reducing the Risk of Psychiatric Side Effects in Patients With Chronic Hepatitis C Treated With Pegylated Interferon ? and Ribavirin
    Neri S, Bertino G, Petralia A, Giancarlo C, Rizzotto A, Calvagno GS, Mauceri B, Abate G, Boemi P, Di Pino A, Ignaccolo L, Vadalà G, Misseri M, Maiorca D, Mastrosimone G, Judica A, Palermo F. J Clin Gastroenterol. 2010 Sep 8. [Epub ahead of print]


  1154. Hepatitis C virus infection: A "liaison a trois" amongst the virus, the host, and chronic low-level inflammation for human survival
    Barnaba V. J Hepatol. 2010 Jun 25. [Epub ahead of print]


  1155. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C
    Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL; the HALT-C Trial Group. Gut. 2010 Jul 30. [Epub ahead of print]


  1156. Impact of Interferon-Ribavirin Treatment on Hepatitis C Virus (HCV) Protease Quasispecies Diversity in HIV- and HCV-Coinfected Patients
    Chary A, Winters MA, Kottilil S, Murphy AA, Polis MA, Holodniy M. J Infect Dis. 2010 Aug 2. [Epub ahead of print]


  1157. Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression
    Maluf DG, Archer KJ, Villamil F, Stravitz RT, Mas V. Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):445-58.


  1158. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis
    Jafari S, Copes R, Baharlou S, Etminan M, Buxton J. Int J Infect Dis. 2010 Jul 31. [Epub ahead of print]


  1159. Comparison of Immune Restoration in Early versus Late Interferon Alpha Therapy against Hepatitis C Virus
    Abdel-Hakeem MS, Bédard N, Badr G, Ostrowski M, Sékaly RP, Bruneau J, Willems B, Heathcote EJ, Shoukry NH. J Virol. 2010 Jul 28. [Epub ahead of print]


  1160. Acute Hepatitis C: Diagnosis and Management
    McLean OR, Herrera JL. PRACTICAL GASTROENTEROLOGY • SEPTEMBER 2007;31:66-77.


  1161. Management of Hepatitis C Virus Infection
    Tran LC, Woods AR, Herrera JL. Drug Benefit Trends 2004;16:266-276.


  1162. Hepatitis C: Who should be treated?
    Smith JR, Herrera JL. PRACTICAL GASTROENTEROLOGY • SEPTEMBER 2002;26:14-21.


  1163. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C
    Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK; International Hepatitis Interventional Therapy Group. Am J Gastroenterol. 2003 Nov;98(11):2354-62.


  1164. Increased prevalence of depression in hepatitis C infection patients
    Hjerrild S, Renvillard SG, Leutscher PD, Videbech P. Ugeskr Laeger. 2010 Jun 21;172(25):1889-1893.


  1165. Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros
    Masuzaki R, Yoshida H, Omata M. Dig Liver Dis. 2010 Jul;42 Suppl 3:S281-6.


  1166. New Frontiers of HCV Therapy in HIV/HCV Co-infection
    Amorosa VK. Curr HIV/AIDS Rep. 2010 Jun 20. [Epub ahead of print]


  1167. Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy
    Hofer H, Aydin I, Neumueller-Guber S, Mueller C, Scherzer TM, Staufer K, Steindl-Munda P, Wrba F, Ferenci P. J Viral Hepat. 2010 Jun 21. [Epub ahead of print]


  1168. Gender influence on treatment of chronic hepatitis C genotype 1
    Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, Sampaio JP, Batah PN, Barbosa DV, Ferraz ML, Silva AE. Rev Soc Bras Med Trop. 2010 Jun;43(3):217-23.


  1169. Treatment options for HCV nonresponders and relapse patients
    Pearlman BL, Sjogren MH. Gastroenterol Hepatol (N Y). 2010 Mar;6(3 Suppl 6):1-12.


  1170. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection
    Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Carlos Lopez-Talavera J, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Hepatology. 2010 May 14. [Epub ahead of print]


  1171. Treatment of Hepatitis C in Renal Transplantation Candidates: A Single-Center Experience
    Werner T, Aqel B, Balan V, Byrne T, Carey E, Douglas D, Heilman RL, Jorge. Transplantation. 2010 Jun 22. [Epub ahead of print]


  1172. Evidence for separation of HCV subtype 1a into two distinct clades
    Pickett BE, Striker R, Lefkowitz EJ. J Viral Hepat. 2010 Jun 21. [Epub ahead of print]


  1173. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy
    Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, Torres DM, Koury K, Goteti VS, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS. Hepatology. 2010 Jun 1. [Epub ahead of print]


  1174. Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS; and the HALT?C Trial Group. Hepatology. 2010 May 14. [Epub ahead of print]
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare
providers only. Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.